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A. van Steenpaal 
Multidrug resistance is a phenomenon first observed when drugs were tested to 
treat cancer. The cancer cells developed resistance against the tested drug and at 
the same time also against other, structurally-unrelated drugs. This catalyzed the 
search for the molecular mechanism, resulting in the identification of a substrate 
transport protein that is able to export a wide variety of drugs out of cancer cells, 
the P-glycoprotein or multidrug resistance protein 1 (MDR1 ). Soon after, similar 
solute transporters were identified that showed comparable characteristics and 
were called multidrug resistance-associated proteins (MRPs). MDR1 and MRPs are 
also expressed in healthy tissue, but their physiological role was unclear for a long 
time. MDR1 and MRPs are particularly present in barrier forming cells, such as in 
the liver (blood-bile), intestine (blood-gut lumen) and brain (blood-brain). This thesis 
describes the function and regulation of the Multidrug resistance-associated protein 
1 in intestinal and liver diseases. First, an overview will be given of the function and 
cellular architecture of the intestine and liver, followed by a description of relevant 
diseases of these organs, e.g. inflammatory bowel diseases and liver regeneration. 
Next, the superfamily of ATP-binding cassette (ABC)-transporters will be introduced 
with specific emphasis on MRP1, a member of the ABC subclass C. Finally, the 
present knowledge of the function and regulation of MRP1 during pathological 
conditions will be summarized, followed by the scope of this thesis. 
1. The intestine 
1.1 Intestinal function and architecture 
The intestine performs the important task of uptake of nutrients from ingested foods. 
It consists of several morphologically different sections, which can be roughly divided 
into the small intestine and the large intestine (colon). In the small intestine food is 
mixed with fat-solubilizing bile and digestive enzymes that make nutrients accessible 
for absorption. In the colon, electrolytes and water are reabsorbed from the bowel 
content. To maximize the absorption surface, both the small and large intestinal 
surface is heavily folded forming crypts and villi. 
The intestinal wall can be roughly divided into 4 sections; the mucosa, submucosa, 
muscularis externa and serosa (Figure 1 A). The serosa is the outer, protective 
layer of connective tissue, the muscularis externa is the layer of smooth muscle 
that controls the bowel movement (both constricting as well as longitudinal). The 
submucosa is a layer of connective tissue that contains nerves that connect to the 
muscularis mucosa and a matrix of blood vessels that run in to the mucosa. The 





















Figure 1. Architecture and cell types of the intestine. (A) Schematic representation of a cross section 
of the intestinal wall. Four (4) functional layers of tissue can be discriminated. The outer layer is the 
serosa, which is a protective layer of connective tissue. Next, the muscularis mucosa is a layer of 
muscle, responsible for bowel movement. The submucosa contains blood vessels and elastic fiber 
with collagen that maintains the shape of the intestine. Moreover, it contains nerves that connect to 
the muscularis mucosa. The most inner layer is the mucosa. In this layer, uptake of nutrients takes 
place. (B) Schematic representation of a crypt and two villi in the mucosa of the intestine. The intestinal 
progenitor cell compartment is located at the base of the crypt. Intestinal progenitor cells proliferate 
continuously both towards the top of the villus as well as the base of the crypt. The newly formed cells 
that migrate into the villus differentiate into mature intestinal epithelial cells. 
The mucosa consists of another 3 sublayers, the muscularis mucosa, the lamina 
propria and the mucosa (or epithelium). The muscularis mucosa is a thin layer of 
smooth muscle that maintains the folded surface area in the intestine. Above the 
muscularis mucosa, the lamina propria is a layer of connective tissue that contains 
many lymph nodes harboring immune cells for protection against pathogens residing 
in the intestine. Finally, the layer that is in direct contact with the bowel content 
is the epithelium. The epithelium contains several different cell types with highly 
specialized functions; e.g. the production of mucin (by Goblet cells), secretion of 
antibacterial enzymes (by Paneth cells), secretion of hormones (enteroendocrine 
cells) or the absorption of nutrients (enterocytes) (1 ). On top of the epithelium, a non­
cellular barrier is present in the form of a thick mucin layer, completing the protective 
layer of the intestinal wall. 
The intestine contains billions of resident bacteria, which aid in the digestion of food. 
The intestinal mucosa prevents bacteria from penetrating into the underlying tissue 
or the circulation by forming a tight barrier of epithelial cells. In addition, the lamina 
propria provides large amounts of immune cells to remove bacteria that do penetrate 
the mucosa. To maintain the epithelial cell barrier, the intestine is continuously 
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renewing the epithelial cell layer by proliferation and differentiation of intestinal stem 
cells, located in the base of the crypts (Figure 1 B) (reviewed in (2), (3)). Although their 
exact location in the crypt is still a matter of debate (reviewed in (4 )) it is known that 
these stem cells differentiate into mature epithelial cells as they move up towards the 
villus tip. There, they are lost by controlled cell death (apoptosis) and/or shedding. 
In this way, the intestinal epithelium is completely renewed every 2-5 days (5). The 
intestinal progenitor cells can differentiate into all different epithelial cell types e.g. 
enterocytes, Paneth cells, Goblet cells and enteroendocrine cells. 
1.2 Inflammatory bowel disease 
One of the most prevalent intestinal diseases in the Western world is inflammatory 
bowel disease (IBD), with an estimated 2.2 million patients in Europe and 1-1.4 
million patients in the US. IBD include Crohn's disease (CD) and ulcerative colitis 
(UC) (6). Both diseases are characterized by a dysregulated immune response to 
the endogenous microflora, resulting in continuous inflammation and ulceration of 
the intestinal mucosa (7). Characteristic symptoms are abdominal pain, (bloody) 
diarrhea and loss of appetite. Although CD and UC share common symptoms, they 
also show highly specific characteristics. Inflammation can be found throughout the 
entire gastrointestinal tract (from mouth to anus) in CD, but generally starts in the 
terminal ileum and spreads into the colon. In contrast, inflammation in UC starts from 
the anus, from which it spreads into the colon. The ileum, however, is never affected 
in UC. Furthermore, CD displays a "patchy" pattern of ulceration, which can penetrate 
into all layers of the intestinal wall, while UC shows a continuous inflammation which 
is restricted to the outer layer of the colon mucosa. It is evident that both CD and 
UC are caused by abnormal immune responses against the endogenous gut flora. 
This is indicated by the fact that animals kept in germ free conditions do not develop 
intestinal inflammation (8) and that antibiotics and probiotics can decrease the 
inflammation in IBD patients (reviewed in (9)). 
A genetic predisposition has been demonstrated for both CD and UC, but this appears 
more pronounced in CD. One of the first genes in which mutations were found 
to be associated with CD was located in the previously discovered susceptibility 
region (IBD1) of chromosome 16 (10), CARD15/NOD2 (caspase recruitment 
domain family, member 15 / nucleotide-binding oligomerization domain containing 
2) (11 ). NOD2 encodes a protein that senses the bacterial wall product muramyl 
dipeptide, suggesting that impaired sensing of penetrated bacteria into the intestinal 
mucosa is involved in the development of CD. Next, OCTN, encoding an organic 
cation transporter, and DLG5, encoding a protein involved in epithelial integrity, 
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were identified to be associated with CD (both OCTN and GLD5) (12, 13) and UC 
(GLD5) (13). Therefore, decreased epithelial integrity seems to be involved in the 
development of both CD and UC. 
The past 2 years have revealed an enormous network of genes that are associated 
with CD and UC. This is the result of genome-wide association studies (GWASs) 
that analyzed high numbers of genomic single nucleotide polymorphisms (SNPs) in 
large cohorts of 180 patients compared to controls (reviewed in (14, 15). Currently, 
approximately 80 alleles have been shown to be associated with CD, while the 
number is now approximately 30 for UC. These GWAS allow the detection of specific 
cellular mechanism that predispose for the development of IBD and much research 
is now being performed in analyzing the functions of these genes and the relevance 
for intestinal inflammation. However, it should be noted that IBD develops as a result 
of genetic predisposition and environmental factors, where the latter appears to be 
the most relevant for the development of disease. 
2. The liver 
2.1 Liver function 
The liver is one of the largest organs in the human body. It is an omnipotent organ that 
serves several important functions. Toxic compounds are metabolized in the liver, so 
that they can be excreted from the body. This occurs mainly by conjugation of these 
compounds to glutathione, glucuronide or sulphate to produce more hydrophilic 
metabolites, which can be excreted via the kidneys into urine. In addition, toxic 
compounds are excreted via the bile into the intestine. The liver produces bile salts 
that are required for the excretion of hydrophobic compounds from the liver, as well 
as for the uptake of essential lipid-soluble fats and vitamins from the intestine. Other 
important functions of the liver are sensing and elimination of pathogens, regulation 
of blood glucose levels and storage of vitamins, amino acids and glycogen. 
2.2 Liver architecture 
Before returning to the heart, blood from (nearly) all organs is transported to the 
liver via the upper or lower portal vein. The venous blood carries nutrients from 
the intestine as well as waste products from other organs. Oxygenated blood is 
delivered to the liver via the hepatic artery. Venous and arterial blood is channeled 
into small blood vessels (sinusoids), which are lined by endothelial cells (Figure 2A). 
Beneath the endothelial cell layer lies a string of the functional and most dominant 
cell type in the liver, the hepatocytes. Here, compounds are taken up from the blood 
through the basolateral membrane (facing the blood), metabolized or stored and 
13 
A � Kupffer cell sinusoidal lumen 
endothelial c- • --::::.c • >c::- • ==- c • =,C::• > c • =-c • 
:> 
:::�::::e 
cell layer e e 
B 





:> c:::- �. -� - �.--:::::,
c • 
:> 
canal of Hering 
� 
cholangiocytes PC hepatocytes 
Figure 2: Cell types in the liver. (A) Sinusoids are lined by endothelial cells. Kupffer cells (liver-specific 
macrophages) are located in the sinusoids. Ste/late cells reside in the space of Disse that separates 
the endothelial cells and hepatocytes. Strings of hepatocytes are lined between the portal vein and 
central vein. Hepatocytes transport bile salts, cholesterol and waste products into the bile cana/icu/i. 
Bile then moves to the gall bladder via the bile ducts. (B) The progenitor cell compartment in the liver 
is located in the canals of Hering (the interphase of hepatocytes and cholangiocytes). 
excreted again when necessary. Hepatocytes export bile salts, phospholipids and 
cholesterol via the apical (or canalicular) membrane into the bile canaliculi, through 
which these bile components flow via the bile ducts into the gallbladder for storage. 
Upon food intake, bile is released from the gallbladder into the gut. It mixes with the 
bowel content, thereby solubilizing the fat-soluble nutrients. At the end of the ileum 
(small bowel) the bile acids and nutrients are taken up by enterocytes returned to 
the liver via the portal vein. Bile salts are re-used in this so-called enterohepatic 
circulation. 
2.3 Liver diseases 
Liver diseases are very common and can have numerous causes, such as (viral) 
infections like hepatitis B or C, autoimmune disorders, metabolic syndrome, 
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fungal toxins, drug and alcohol abuse. Liver diseases can be subdivided in acute 
and chronic forms. Acute liver disease, for example resulting from de nova viral 
infections or drug-intoxication, lead to a very rapid loss of functional liver tissue 
(particularly hepatocytes) and requires curative treatment within days to prevent 
liver failure. Chronic liver diseases develop over many years to decades. This is 
typically seen in patients with persistent viral infection, autoimmune disorders, 
metabolic syndrome and drug/alcohol abuse. Functional liver tissue is replaced by 
activated and proliferating hepatic stellate cells that produce excessive amounts of 
extracellular matrix proteins like collagens, a process that is well known as fibrosis 
(reviewed in (16)). The rigid extracellular matrix materials eventually encapsulates 
the liver lobules and progresses to cirrhosis and as a result, blood and bile flow 
in the liver become obstructed. Cirrhosis eventually leads to liver failure, with the 
only treatment option being liver transplantation. Chronic liver disease can develop 
unnoticed because the normal liver has a significant overcapacity. Symptoms may 
not become apparent until the liver function is reduced to below 30% of its original 
capacity. Common symptoms of liver disease are inflammation, jaundice (yellowing 
of the skin), darkened urine and light-colored stools, generalized itching, fatigue and 
abdominal pain in the upper right part of the stomach. 
The liver plays an important role in sensing pathogens and hosts the largest 
population of resident tissue macrophages (Kupffer cells) (Figure 2A) as well as 
T lymphocytes, natural killer (NK) cells and natural killer T (NKT) cells (reviewed 
in (17)). The innate immune response plays an important role in hepatic damage 
after liver injury. For instance, absence of functional Toll like receptor 4 (TLR4 ), the 
endogenous sensor of the bacteria-derived endotoxin lipopolysaccharide (LPS), 
protect mice from alcohol-induced liver inflammation and damage (18). Furthermore, 
decreased recruitment of neutrophils decreases hepatic necrosis and improves 
survival in mice after acetaminophen-induced liver injury (19,20). 
2.4 Modes of cell death during liver disease 
Liver injury is associated with loss of function and/or viability of hepatocytes. 
Hepatocytes die, but different modes of cell death can be distinguished, e.g. necrosis 
and apoptosis (or programmed cell death). Necrosis is a passive, degenerative 
process. When cells are suddenly exposed to high levels of toxic compounds or 
different environmental conditions (e.g. extremely high or low temperatures or 
oxidative stress (21 )), the integrity of the cell membrane collapses and the cell 
content is released into the environment. In vivo, this provokes an inflammatory 
reaction, often leading to even more tissue damage. In contrast, apoptosis is a tightly 
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regulated process. In short, apoptosis is initiated by extracellular or intracellular 
signals that cause an ATP-driven activation of proteases (caspases) that leads to cell 
shrinkage, chromatin condensation, mitochondrial dysfunction and cell fragmentation 
into apoptotic bodies. The apoptotic bodies remain membrane-surrounded and 
are removed by phagocytosis. In contrast to necrosis, apoptosis does not lead to 
massive release of cellular components into the circulation, 
There are two major pathways of apoptosis depending on the origin of the apoptotic 
trigger, the extrinsic pathway and the intrinsic pathway (Figure 3) (reviewed in (22)). 
The extrinsic pathway requires activation and oligomerization of membrane-bound 
"death" receptors (e.g. Fas, TNF/TRAIL-receptors) by their corresponding agonists 
(Fas-Ligand, Tumor Necrosis Factor alpha, TRAIL). Extracellular activation of 
these death receptors results in the intracellular recruitment of adaptor proteins 
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Figure 3: Apoptosis pathways. Internal signals (e.g. oxidative stress) initiate the intrinsic pathway. 
The mitochondrial membrane destabilizes leading to leakage of cyochrome C. Cytochrome C in 
combination with procaspase-9 and APAF-1 form the apoptosome, thereby activating caspase-9. 
Caspase-9 activates caspase-3 and -7, leading to apoptosis. 
The extrinsic pathway is activated by binding of specific ligands to membrane-bound receptors. 
Activation leads to the intracellular recruitment of adaptor proteins, which activate caspase-8. 
Caspase-8 directly activates caspase-3 or -7 and leads to cytochrome C leakage from mitochondria. 
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and ultimately in the recruitment and cleavage of caspase-8. Cleaved and active 
caspase-8 is the initiator of the intracellular apoptotic cascade. Caspase-8 cleaves 
the protein BID (BH3-interacting domain death agonist) and activates the effector 
caspases, caspase-3 and -7. Truncated Bid translocates to mitochondria, where 
it induces pore formation in the mitochondrial membrane, resulting in leakage of 
cytochrome C into the cytoplasm. Cytochrome C than interacts with caspase-9 
and the apoptotic protease-activating factor 1 (APAF1) to form the apoptosome. 
Subsequently, caspase-9 is activated and cleaves and activates caspases-3 and 
-7. The effector caspases 3 and 7 are proteases that attack and destroy numerous 
proteins, which will lead to the characteristic apoptotic cell death. 
The intrinsic pathway is activated by intracellular signals. The main trigger for 
apoptosis is cellular stress (oxidative stress, protein misfolding, DNA damage). It 
typically activates one or more members of the BH3-only family (e.g. BID, BAD). 
When the amount of activated BH3-only members exceeds a certain threshold 
"organelle-damage"-specific caspases are activated ( e.g. caspase-9 for mitochondria 
and caspase-12 for the endoplasmic reticulum) that lead to the activation of the 
downstream effector caspases (caspase-9, caspase-7). The execution phase of both 
intrinsic and extrinsic pathways of apoptosis are similar, as both pathways converge 
in activation of the effector caspases 3 and 7. 
2.5 Liver regeneration 
The liver possesses the remarkable ability to regenerate after injury. This process 
is very rapid, e.g. after surgical removal of 70% of the liver in mice, the organ grows 
back to it's original volume in only a few days (23). 
Liver regeneration depends largely on proliferation of hepatocytes ( reviewed in (24) ). 
However, this is only true when there are no other confounding factors that affect their 
function and viability. In the healthy liver, only 1 in 20.000 to 40.000 hepatocytes is 
dividing. When liver tissue is lost, hepatocytes quickly respond and start to proliferate 
to restore the original liver mass. The capacity of hepatocytes to divide and restore 
liver mass is nicely illustrated by experiments in which a small amount of mature 
rat hepatocytes were transplanted into rats who were partially hepatectomized and 
previously treated with a chemical to block proliferation of resident hepatocytes. 
After 2 months, liver mass and function were back to normal and was composed 
predominantly of donor hepatocytes (25,26). In most liver diseases, however, 
hepatocyte proliferation is (partly) inhibited, e.g. due to viral infections, high levels 
of cytokines, bile salts, oxidative stress or chemical inhibition/drug intoxication. In 
these conditions, liver regeneration depends on the activation and differentiation 
of liver-specific stem cells and/or the recruitment of bone marrow stem cells. The 
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liver-specific stem cell compartment (also called hepatic progenitor cells) is located 
at the interface of the hepatocytes and the bile duct epithelial cells (cholangiocytes), 
also known as the canal of Hering (Figure 2 8). The hepatic progenitor cells are 
pluripotent and can differentiate into several liver-specific cell types, including the 
2 main functional cell types, hepatocytes and cholangiocytes (27). Based on their 
morphological appearance, hepatic progenitor cells are also called oval cells . 
Previous studies have shown that several ATP-binding cassette (ABC) transporters 
are induced in hepatic progenitor cells concomitant with the activation process. 
This was observed both in liver disease models in rats (28) and in severe liver 
disease in humans (29), suggesting an important function of these transporters in 
hepatic progenitor cells. In the following section, first a general overview of the ABC­
transporter family is presented, followed by detailed information about MRP1. 
3. ATP Binding Cassette transporters 
The first ATP-binding cassette (ABC) transporter was identified in the beginning of 
the 1980's in research aimed at resolving the molecular mechanism that makes 
cancer cells resistant to chemotherapeutic drugs ((30-32), reviewed in (33)). The 
development of (multi)drug resistance is a common problem in the treatment of 
cancer. A protein was identified that is responsible for exporting the anti-cancer 
drug out of the cancer cell. This protein was called P-glycoprotein (P-gp ), or the 
multidrug resistance protein 1 (MDR1 ). Soon after the first identification of MDR1, 
a structural homologue was found that shared many of its features and was named 
multidrug resistance-associated protein 1 (MRP1 ). MDR1 and MRP1 are now known 
as the founders of the ABC-transporter superfamily. Although MDRs and MRPs are 
particularly know for generating multidrug resistance in cancer cells, they are also 
expressed in normal human cells. 
Many compounds are transported in, out and through cells, crossing cellular and 
organellar membranes. The family of ABC transporters play a key role in these 
processes, in particular in transporting potentially toxic compounds. The ABC 
transporter superfamily consists of 49 members divided into 7 subgroups (A-G) 
(reviewed in (34)). MDR1 is the prototypical ABC transporter and contains two 
transmembrane domains {TMD) connected by two intracellular nucleotide binding 
domains (NBD). The NBDs of the ABC transporters contain highly conserved 
amino acid sequences, the so called Walker A and B motifs and the ABC signature 
sequence (or C motif) that resides in between the Walker A and B motifs (Figure 
4A). The A, B and C motifs are involved in binding and hydrolyzing ATP that drives 
the unidirectional substrate transport of ABC transporters . Proteins belonging to the 
ABC transporter superfamily are divided into subfamilies based on their structural 
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homology. Although most ABC transporters comply to the MDR1-type structure, 
there are variations to this. First of all, there are ABC-transporters that contain only 
one TMD and one NBD, e.g. ABCG5, GB and ABCD1 to 4 (Figure 4B). These "half' 
transporters need to dimerize to form a fully functional transporter and is structurally 
similar to MDR1. Secondly, several of the MRP-type ABC-transporters of subfamily 
C contain a third transmembrane domain {TMDO) upstream of the core TMD1-
NBD1-TMD2-NBD2, e.g. ABCC1/Multidrug resistance protein 1 (MRP1 ), ABCC2/ 
MRP2 and ABCC3/MRP3) (Figure 4C). 
3.1 The ABCC subfamily and Multidrug Resistance-associated proteins 
With 13 members, the ABCC subfamily is the largest subfamily of ABC transporters. It 
contains MRP1 to 10 (ABCC1-6, ABCC10-13), CFTR (cystic fibrosis transmembrane 





Figure 4. Typical structures of ABC transporters. (A) standard structure of ABC transporters, 
containing 2 membrane spanning domains with an intracellular amino and carboxylic terminal domain. 
Two intracellular nucleotide binding domains are present. (BJ Structure of ABC half-transporters. 
These transporters consist of one TMD, one NBD and intracellular amino and carboxylic terminal 
domains. (C) Structure of "long" ABC transporters from the ABCC subfamily. These transporters 
contain an additional TMD at the amino terminal side of the protein. The amino terminal domain is 
located extracellularly. 
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and B (ABCC9) (reviewed in (35)). All MRPs, have a distinctly different structural 
element compared to other ABC transporters. All MRPs show different spacing 
between the Walker A and the ABC signature motif in the NH2-proximal NBD (NBD1) 
compared to the COOH-proximal NBD (NBD2). Moreover, members of the ABCC 
subfamily contain a highly conserved single amino acid substitution (glutamate to 
aspartate) in the NBD1, just following the Walker B motif, that differentiates them 
from other ABC transporters (36,37). This substitution strongly affects the catalytic 
properties of NBD1. A glutamate residue at that position, as found in other ABC 
transporters, enhances the ATPase activity of this NBD. However, the substrate 
transport activity of MRP1 is severely impaired when the glutamate is introduced by 
site directed mutagenesis (36). In ABCC transporters, ATP hydrolysis takes place 
mainly at NBD2, whereas NBD1 is responsible for ATP binding. In contrast, NBD1 
and NBD2 in other ABC transporters are involved in both ATP binding and hydrolysis. 
CFTR, SUR1 and SUR2 are ion channels (chloride and potassium, respectively), 
whereas the MRP1-MRP8 genes all encode transporters responsible for transport of 
bulky compounds. The functions of MRP9 and MRP10 are still a matter of debate. 
In fact, it is unclear whether the human ABCC13 gene (encoding MRP10) produces 
a functional protein (38). 
The ABCC subfamily can be further subdivided into two groups, the long and 
short ABCC proteins. CFTR, MRP4, MRP5, MRP8 and MRP10 have a "standard" 
structure consisting of two TMD's and two NBDs. MRP1-3, MRP6, MRP7, SUR1 and 
SUR2 contain the extra TMD0 at the NH2 terminus (reviewed in (35)). MRP9 is an 
exception, as the gene encodes two proteins, the first consists of 8 transmembrane 
domains and lacks the second NBD. The second smaller protein is expected to 
encode for only the second NBD (39). 
MRP1 and MRP3 are the closest relatives based on the amino acid sequence and 
share 58% amino acid identity. MRP1 shares 45% and 43% amino acid identity with 
MRP2 and MRP6, respectively (reviewed in (35)). 
3.2 ABC transporters in the intestinal epithelium. 
Many ABC transporters are expressed in the enterocytes of the intestinal epithelium. 
On the one hand they provide protection against potentially toxic compounds in the 
gut lumen. On the other hand, they are involved in the efficient absorption of nutrients 
and transport to the circulation. Particularly MDR1 and MRP3 are expressed at high 
levels in the intestinal epithelium. MDR1 is located at the apical membrane of the 
enterocyte and transports neutral and positively charged amphiphatic compounds 
towards the gut lumen. It is an important factor in the intestinal epithelium that 
protects the organism from these toxic compounds in the gut. Like hepatocytes, 
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enterocytes are also involved in the detoxification of toxins. MRP3 is (one of) the 
most dominant MRP-type transporter in enterocytes and is involved in the export of 
conjugated metabolites to the blood, so they can be excreted via the kidneys (40-
42). M RP1, MRP4, MRP5 and MRP6 are also present in enterocytes in the healthy 
intestine and may aid in the secretion of such compounds (reviewed in (35)). The 
ABCG5/ABCG8 heterodimer resides in the apical membrane of enterocytes and the 
hepatocytes and exports plant sterols to the gut lumen or the bile thereby preventing 
their accumulation in blood (43,44). 
3.3 ABC transporters in hepatocytes 
ABC transporters that play a crucial role in the physiological function of the liver 
are the bile salt export pump (BSEP, ABCB 11 ), the multidrug resistance protein 3 
(MDR3/ABCB4; Mdr2 in rodents) and MRP2 (ABCC2). These three proteins reside 
in the canalicular membrane of hepatocytes and transport substrates to the bile 
(reviewed in (34 )). BSEP and MDR3 act together in the formation of bile. BSEP is the 
main transporter for bile salts, while MDR3 transports phospholipids. Bile salts and 
phospholipids form mixed micelles in bile and are the carriers for fatty compounds 
that need to be excreted or absorbed in the intestine. MRP2 is the transporter 
for bilirubin (45), the breakdown product of blood hemoglobin. In addition, MRP2 
excretes divalent sulphated or glucuronidated bile acids that may accumulate 
during liver disease (46). MRP1, M RP3 and M RP4 are also expressed in the liver, 
however, at considerably lower levels compared to BSEP, MDR3 and MRP2. They 
reside in the basolateral membrane. Expression of MRP3 and MRP4 is induced in 
hepatocytes during cholestatic liver disease and transport bile acids into the blood. 
This is considered a rescue mechanism that comes into play to protect hepatocytes 
from bile salt-induced cell damage. M RP1 levels are low in the healthy liver, but are 
induced during liver disease and is particularly present in the hepatic progenitor cell 
compartment (29). 
3.4 MRP substrates 
MRPs transport a wide variety of substrates, but the individual substrate specificity 
varies greatly. MRP1 and M RP2 share a considerable substrate overlap, transporting 
predominantly organic anions such as glucuronide- or sulphate-conjugates (phase 
2 metabolites). Examples of well known MRP1/MRP2 substrates are leukotriene 
C4, steroids, bile salt-metabolites and estrogen conjugates. In contrast, MRP3 
transports unconjugated bile salts as well as a wide variety of glucuronide conjugates. 
Substrates for M RP4 and MRP5 are nucleoside and nucleotide analogs and cyclic 
nucleotides. Furthermore, MRP4 and MRP6 have recently been shown to transport 
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leukotriene C4 with equal specificity as MRP1 (47,48). 
3.5 MRP cellular location 
MRPs are ubiquitously expressed in the healthy body. However, a distinct difference 
is observed in the abundance of specific MRPs in specific tissues. MRP1 expression 
is high in lung, testis, kidney, placenta, skeletal and cardiac muscle (36,49,50) and 
low in the liver and intestine. MRP2 is expressed in liver, kidney, small intestine, 
colon, gall bladder, placenta, and lung while MRP3 is expressed mainly in the adrenal 
gland, pancreas, gut, gall bladder, and placenta. Tissue distribution of all MRP-type 
transporters are shown in Table 1. 
MRP-type transporters are all efflux transporters. However, the direction of transport 
towards specific body fluids varies depending on their cellular location. Generally, 
MRPs are located on the cell membrane transporting compounds from the cytosol 
into the cell environment. However, most cells found in the body are embedded in 
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Table 1 :  Tissue distribution, subcel/ular location and endogenous substra­
tes for MRP type ABC transporters (reviewed in (34,51)) 
MRP Organ Membrane Substrates 
location 
MRP1/ABCC1 ubiquitous; high Basolateral L TC4, glutathione-, 
in lung, brain, sulphate- and 
heart, testis glucuronide conjugates, 
glutathione 
MRP2/ABCC2 liver, kidney Apical L TC4, estradiol 
glucuronide, bilirubin 
glucuronide 
MRP3/ABCC3 Liver Basolateral L TC4, estradiol 
glucuronide, glutathione 
MRP4/ABCC4 Brain, brain Basolateral conjugated steroids, 
capillary cAMP, cGMP, bile salts, 
endothelium prostaglandins 
MRP5/ABCC5 Basolateral conjugated steroids, 
cAMP, cGMP, bile salts 
MRP6/ABCC6 liver , kidney Basolateral Glutathione conjugates, 
LTC4 
MRP7/ABCC1 0 ubiquitous; high Unknown estradiol glucuronide 
in pancreas 
MRP8/ABCC1 1 foetal tissue, apical cyclic nucleotides, 
central and (predicted) steroid su lphates 
peripheral 
nervous system 
MRP9/ABCC 1 2  Ubiquitous; endoplasmic Unknown 
mainly testis, reticulum 
brain, ovary, 
prostate 
MRP1 0/ABCC1 3 Pseudogene; encodes a non-functional ABC transporter 
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organs facing two different environments. These cells are polarized and developed 
two different subdomains in the plasmamembrane. The plasmamembrane facing the 
blood is called the basolateral membrane, membranes facing away from the blood 
are called apical (or canalicular in the liver) membranes. In these polarized cells, 
MRPs are differentially distributed across the cellular membrane. MRP1, MRP3 
and MRP4 are located at the basolateral membrane, whereas MRP2 is exclusively 
located at the apical membrane. 
4 MRP1 function in (patho)physiological conditions 
4.1 Discovery of MRP1 
MRP1 was first described in 1992 (36). The ABCC1 gene that encodes MRP1 was 
cloned and sequenced from a doxorubicin resistant human lung cancer cell l ine. 
The substrate specificity of MRP1 has been extensively studied. MRP1 transports a 
wide variety of (metabolites of) chemotherapeutic drugs, thereby limiting the efficacy 
of drug-based cancer therapy (reviewed in (52-55)). These drugs include Vinka 
alkaloids, anthracyclines and platinum-based drugs. 
4.2 Endogenous substrates and their role in inflammation of the gut and 
liver. 
MRP1 has a high specificity for glucuronide-, sulphate- and glutathione-conjugates 
that are generated in the cellular detoxifying machinery (also known as phase-2 
metabolites) (56-58). This function is in fact much l ike its role in multidrug resistance 
in cancer cells, but now protecting cells in normal tissue. MRP1 transports reduced 
and oxidized glutathione ((59), reviewed in (60)). Glutathione is involved in the 
cellular protection against oxidative stress and export of oxidized glutathione provides 
cellular against cell death. MRP1 also transports the pro-inflammatory cytokine 
leukotriene C4 (58,61 )(Figure 5), suggesting a possible role of MRP1 in inflammatory 
reactions. MRP1 is present in several inflammatory cell types in peripheral blood (62-
64 ). Mrp1 expression is induced in activated Th-lymphocytes (62,65). In addition, 
blocking Mrp1 function inhibits Th-lymphocyte activation and significantly alters the 
cytokine release profile (63). This observation is supported by the fact that Mrp1-
deficient mice show a disturbed response to inflammatory stimuli (66). Moreover, 
Mrp1-deficient mice are more susceptible to develop colitis compared to wild type 
animals (67). Thus, MRP1 may be an important factor in the intestinal epithelium that 
protects against the development of Inflammatory Bowel Disease. 
Specific induction of MRP1 was also detected in human inflammatory l iver diseases 
l ike primary biliary cirrhosis and chronic hepatitis C infection. While MRP1 expression 















Figure 5. Main physiological 
substrates of MRP 1.  MRP1 has 
a high affinity for the pro-inflam­
matory cytokine leukotriene C4, 
glutathione and phase 2 meta­
bolites of xenobiotics and endo­
genous toxins. 
ductules in the inflamed liver. Upregulation of MRP1 was particularly evident in the 
progenitor cell compartment (29). This observation points towards a possible role for 
MRP1 in hepatic progenitor cell activation and/or function. 
4.3 MRP1 transcriptional regulation 
Chemotherapeutic drugs such as Vinca-alkaloids (68), anthracyclines, etoposide 
(66,69), platinum based drugs (68) and epipodophyllotoxines may lead to induced 
expression of MRP1 in cancer cells and cause multidrug resistance. Detailed 
knowledge about the transcriptional regulation of MRP1 is required to understand 
the underlying mechanisms that could be used to limit MRP1 expression and thereby 
prevent the problem of drug resistance. Unfortunately, relatively little is known of 
transcriptional regulation of MRP1. The human MRP1 promoter has been cloned 
and putative binding sites have been identified for Activator Protein 1 (AP-1 , a 
complex of the proteins c-jun and c-fos) and Sp1 transcription factor (70). In addition, 
responsive elements have been identified, including a cyclic AMP response element 
(CRE), a glucocorticoid response element (GRE) and multiple estrogen response 
elements (ERE) (71 ). 
Although several binding sites were identified there is no direct evidence that the 
related transcription factors actually modulate MRP1 transcription. 
In addition, oxidative stress was shown to increase MRP1 expression in rat hepatoma 
cells (72), but there is no information yet about the factors or regulatory mechanisms 
involved. 
Besides chemotherapeutic drugs, numerous endogenous compounds have been 
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identified that are able to regulate MRP1 expression. The human tumor suppressor 
protein p53 (70,73), Sp1 transcription factor (73,74) as well as the growth factor 
epidermal growth factor (EGF) (75) are able to modulate the expression of MRP1 
in human cancer cells. Sp1 is a strong activator of MRP1 expression. Sp1 is able to 
induce MRP1 expression up to 200-fold (74,76). In the presence of p53, transcription 
activators are not able to bind to Sp1 sites of the MRP1 promoter. It is hypothesized 
that p53 directly binds Sp1, thereby suppressing its activity (77). Treatment of MCF-
7 breast cancer cells with EGF shows an increased expression of the MRP1, 3, 5 
and 7 genes and increased MRP1 promoter activity (75). Furthermore, treatment of 
mice with peroxisome proliferator-activated receptor (Ppar)-alpha agonists showed 
reduced intestinal expression of Mrp1, indicating a possible role for Ppar-alpha in 
Mrp1 regulation (78). PPARs are involved in the regulation of fatty acid metabolism. 
PPAR-alpha is the most dominant PPAR in the liver, regulating transcription of genes 
involved in fatty acid-induced catabolism. However, no direct evidence is available for 
the involvement of these transcription factors in the regulation of MRP1 transcription. 
The mechanism by which MRP1 is regulated in physiological conditions is therefore 
still obscure. 
4.4 MRP1 function during (smoke-induced) inflammation 
Recently, extensive evidence has been obtained for a role of MRP1 in cytoprotection 
in physiologically relevant conditions. Van der Deen et al., demonstrated that MRP1 
protects against negative effects of smoking. They show that MRP1 inhibition 
aggravates cigarette smoke-induced cell death in human lung epithelial cells (79). In 
addition, Mrp1 /Mdr1 a/Mdr1 b triple knockout mice showed a reduced inflammatory 
response to cigarette smoke (79,80). 
Taken together, these observations indicate that MRP1 may have an important 
function during inflammation. MRP1 absence leads to reduced export of leukotriene 
C4, which is involved in maintaining the inflammatory response as part of the so 
called slow reaction substance of anaphylaxis. By blocking MRP1 mediated export, 
L TC4 is retained in the cells and leads to the formation and secretion of L TB4, which 
is a chemotactic factor for neutrophils. Inhibition of MRP1 may therefore change 
the inflammatory cascade from a T cell-mediated reaction to a neutrophil-mediated 
reaction. 
5. Scope of the thesis 
The aim of this thesis is to determine the function and regulation of the multidrug 
resistance-associated protein 1 (MRP1) in diseases of the intestine and the liver. In 
chapter 2, we compared the expression of mucosal MRP1 in uninflamed and inflamed 
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regions of the terminal ileum and colon of patients with inflammatory bowel disease 
(IBD). As MRP1 is significantly induced by inflammation, we analyzed its protective 
role in intestinal epithelial cells exposed to various inflammatory signals. In chapter 
3, we extended our analysis to the function of MRP1 in T-lymphocytes in patients 
with IBD. T-lymphocytes are overactivated in IBD and often resistant to drug-induced 
cell death. Therefore, we compared the expression of MRP1 in T-lymphocytes from 
healthy volunteers and IBD patients and analyzed its role in protecting these cells 
against apoptotic cell death. In chapter 4, we changed our focus to the liver and 
determined the function of Mrp1 in stem cell-driven liver regeneration in mice. Liver 
regeneration was induced by removing 70 % liver mass from wild type and Mrp1-
knock out mice that were simultaneously treated with 2-acetylaminofluorene to 
block hepatocyte proliferation. Liver regeneration than depends on proliferation and 
differentiation of stem cells. Finally, in chapter 5, we studied the putative involvement 
of PPAR-alpha in the transcriptional regulation of human MRP1 colon and hepatic 
cell lines. PPAR-alpha is present in the liver and intestine and its activity can be 
manipulated by various pharmaceutical agonists and antagonists. It is therefore an 
interesting target to regulate MRP1 expression in liver and intestinal diseases. 
Taken together, this thesis aims to increase our understanding of the role and 
regulation of MRP1 in intestinal and hepatic diseases to help develop and/or improve 
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ABSTRACT 
The multidrug resistance-associated protein 1 (MRP1) is well known for its role 
in providing multidrug resistance to cancer cells. In addition, MRP1 has been 
associated with both pro- and anti-inflammatory functions in non-malignant cells. 
The pro-inflammatory function is evident from the fact that MRP1 is a high-affinity 
transporter for cysteinyl-leukotriene C 4 (L TC 4) ,  a lipid mediator of inflammation. 
It remains unexplained, however, why the absence of Mrp1 leads to increased 
intestinal epithelial damage in mice treated with dextrane-sodium sulphate, a model 
for inflammatory bowel disease (IBD). We found that MRP1 expression is induced 
in the inflamed intestine of IBD patients, e.g. Crohn's disease and ulcerative colitis. 
Increased MRP1 expression was detected at the basolateral membrane of intestinal 
epithelial cells. To study a putative role for MRP1 in protecting epithelial cells 
against inflammatory cues, we manipulated MRP1 levels in human epithelial DLD-
1 cells and exposed these cells to cytokines and anti-Fas. Inhibition of MRP1 (by 
MK571 or RNA interference) resulted in increased cytokine- and anti-Fas-induced 
apoptosis of DLD-1 cells. Opposite effects, e.g. protection of DLD-1 cells against 
cytokine- and anti-Fas-induced apoptosis, were observed after recombinant MRP1 
overexpression. Inhibition of LTC4 synthesis reduced anti-Fas-induced apoptosis 
when MRP1 function was blocked, suggesting that LTC4 is the pro-apoptotic 
compound exported by epithelial MRP1 during inflammation. These data show that 
MRP1 protects intestinal epithelial cells against inflammation-induced apoptotic cell 
death and provides a functional role for MRP1 in the inflamed intestinal epithelium 




Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the 
gastrointestinal tract and manifests as ulcerative colitis (UC) or Crohn's disease 
(CD) (1 ). The pathophysiology of IBD is characterized by a highly activated state of 
the mucosal immune system and excessive mucosal damage (2). In recent years, 
important progress has been made in identifying and characterizing susceptibility 
genes for IBD (3). The (putative) functions of the proteins they encode corroborate 
the notion that the primary cause for the development of IBD originates from a 
dysregulated immune response to commensal intestinal bacteria, defects in mucosal 
barrier function and/or bacterial clearance. 
Irrespective of the genetic cause, severe and continuous inflammation causes 
damage to the intestinal epithelium that may strongly affect its absorptive and 
secretory functions as well as its protective role against toxic compounds. 
Cytoprotection is provided by ATP-binding cassette (ABC) transporters that are 
specialized in exporting toxic compounds of foreign or endogenous origin (4). P-gp/ 
MDR1 (ABCB1 ), well-known for its adverse role in protecting cancer cells against 
anti-cancer drugs (5), is also expressed in the healthy intestinal epithelium (6). 
Absence of Mdr1 a in transgenic mice results in the spontaneous development of 
colitis (7). In line with this observation, specific single nucleotide polymorphisms 
(SNPs) in the ABCB1 gene have been reported to be associated with CD (8-10). 
Moreover, we recently showed that MDR1 expression is strongly reduced in the 
inflamed intestine of IBD patients, which may further aggravate the disease (11 ). 
The multidrug resistance-associated protein 1 (MRP1, encoded by the ABCC1 gene) 
also plays a role in inflammatory responses. It transports glutathione and substrates 
that are conjugated to reduced glutathione, glucuronide or sulphate as part of 
the detoxification machinery of (cancer) cells (12;13). The glutathione conjugate 
leukotriene C 4 (L TC 4) has been identified as an endogenous, high affinity substrate 
for MRP1 (14;15). Leukotrienes are important lipid mediators of inflammatory 
responses and have been implicated in the pathophysiology of both acute and 
chronic inflammatory diseases, including IBD (14;16;17). The role of Mrp1 in the 
inflammatory signalling pathway is evident from studies with Mrp1-1- knockout mice 
that show a strongly reduced response to arachidonic acid-induced inflammatory 
stimuli as measured by decreased ear oedema and vascular permeability (18). 
Relevant for IBD, however, it was shown that intestinal damage was significantly 
aggravated in Mrp1-1- knock-out mice exposed to dextrane sulfate sodium (DSS)­
induced colitis (19). These animal studies suggest that Mrp1 serves a dual role 
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during inflammation, both sending out inflammatory signals as well as protecting the 
intestinal epithelium. The mechanism of the latter and the relevance for IBD patients 
is unknown to date. 
In this study, we show that MRP1 expression is increased in the inflamed epithelium 
of patients with IBD, in particular in the intestinal crypts. We demonstrate that MRP1 
protects intestinal epithelial cells against cytokine-induced cell death by exporting 
pro-apoptotic compounds from the cysteinyl leukotriene biosynthesis pathway. 
MATERIALS AND METHODS 
Patient characteristics 
Intestinal mucosal biopsy specimens were obtained during endoscopy following 
informed consent from patients with IBD. Diagnosis of IBD was established by 
endoscopic and histopathological examination. The Ethics Committee of the 
University Hospital Groningen approved the protocol (METc 2002/177c). Intestinal 
biopsies were obtained from macroscopically inflamed and non-inflamed mucosa 
from 35 patients with IBD using a standard biopsy forceps. Intestinal specimens 
were immediately snap-frozen in liquid nitrogen for mRNA and protein analysis or 
liquid nitrogen-cooled isopentane for immunohistochemical staining, and stored at 
-80 °C until further processing. 
lmmunohistochemistry 
lmmunohistochemistry was performed with the mouse monoclonal antibody QCRL-
3 against MRP1 on frozen sections according to the protocol described (dilution 
1: 10, Santa Cruz Biotechnology, Heidelberg, Germany) (20). The sections were 
counterstained with hematoxylin. Negative controls consisted of omission of the 
primary antibody and were consistently negative. 
Cell culture 
The human colon carcinoma cell line DLD-1 was cultured as previously described 
(21 ). DLD-1 cells were treated with anti-Fas (lmmunotech, Marseille, France) or 
human tumor necrosis factor-a (TNF-a, R&D Systems Europe, Abingdon, UK). The 
LTD 4 receptor antagonist MK571 (3-([[3-{2-[7-chloro-2-quinolinyl]ethenyl) phenyl}-({3-
(dimethylamino-3-oxopropyl)-thio )-methyl]thio) propanoic acid; Alexis Biochemicals, 
Lausen, Switzerland) was used to inhibit MRP function. The 5-lipoxygenase inhibitor 
AA861 (2-(12-hydroxydodeca-5, 1 0-diynyl)-3,5,6-trimethyl-p-benzoquinone; Sigma, 




siRNA-mediated reduction of MRP1 expression 
DLD-1 cells were seeded in 6 well plates at a density of 400.000 cells per well in 
RPMI 1640 with glutamax supplemented with 1 % fetal bovine serum (FBS). After 
4 hours, medium was replaced by serum free medium. DLD1 cells were transiently 
transfected with siRNA-MRP1 duplexes using oligofectamine (lnvitrogen, Breda, The 
Netherlands) according to the manufacturers instructions. SiRNA-MRP1 primers 
were obtained from lnvitrogen (sense 5'-GGA GUG GAA CCC CUC UCU GdTdT-3' 
and antisense 5'-CAG AGA GGG GUU CCA CUC CdTdT-3'; kindly provided by Dr. 
D.J. de Groot, University Medical Center Groningen, Groningen, The Netherlands). 
Control cells were treated with only oligofectamine. Four hours after transfection, 
medium was supplemented with RPMl-1640 with 30 % FBS to adjust the serum 
concentration to 10 %. Subsequently, the cells were cultured in an incubator at 37 °C 
and 5 % CO2 for 48 hours. MRP1 RNA and protein expression was then analyzed by 
real time PCR and Western blot analysis. 
MRP1 overexpressing cell line 
DLD-1 cells were seeded in 6-well plates at 300.000 cells per well. The cells were 
transfected with plasmid pcDNA3.1 (-)-MRP1-GFP (22). Transfection was performed 
using the BIO-RAD Transfectin™ Lipid reagent protocol (Bio-Rad laboratories B.V., 
Veenendaal, The Netherlands). Transfected cells were grown to 70 % confluence 
before adding 0.625 mg/ml geneticine to the medium. After three days colonies were 
selected and expanded in medium containing 0.625 mg/ml geneticine. Two clones 
were further purified by fluorescence activated cell sorting (FACS) based on the GFP 
signal to obtain homogenous MRP1-expressing cell lines. 
RNA isolation and quantitative PCR 
Total RNA was isolated as described (23). RNA integrity was confirmed by agarose 
gel electrophoresis and RNA concentration was measured using a Ribogreen RNA 
quantitation kit (Molecular Probes, Leiden, The Netherlands). Complementary DNA 
( cDNA) synthesis was performed on 2.5 µg of total RNA using random primers in a 
final volume of 50 µI (Reverse Transcription System, Promega, Madison, WI, USA). 
For real-time PCR, 4 µI of 20-fold diluted cDNA was used for every PCR reaction in a 
final volume of 20 µI, containing 900 nmol/L sense and antisense primers, 200 nmol/L 
fluorogenic probe, 5 mmol/1 MgCl2 , 0.2 mmol/1 deoxynucleoside triphosphate mix, 2 
µI real-time PCR buffer (1 Ox), and 0.5 U Hot Goldstar DNA Polymerase (Eurogentec, 
35 
Seraing, Belium). Details about primers and probes are described in Table S1. Real­
time PCR was performed with an ABI Prism 7700 Sequence Detector version 1.6 
software (Perkin Elmer Life Sciences, Foster City, CA, USA). The expression of 
genes was normalized to the endogenous control (18S). 
Western blot 
Total cell lysates of DLD-1 cells were separated by 10 % sodium dodecyl sulfate­
polyacrylamide gel electrophoresis (SOS-PAGE) and analyzed by Western blotting. 
Protein concentrations were determined using the Bio-Rad DC Protein Assay 





































5'-CCA ATT ACA GGG CCT CGA AA-3' 
5' FAM-CGC GCA AAT TAC CCA CTC CCG A-TAMRA 3' 
5'-GGC TCA AAT CTC GGC AGA ATC-3' 
5'-GGC CAT CCT CAC AGG AGA GTT-3' 
5' FAM-TCC GAC ATC CAG CCG TGC CAC-TAMRA 3' 
5'-GGC AAA GAA ATA AAG CGA CTG AA-3' 
5'-GGC TGT TGT CTC CAT AGG CAA T-3' 
5' FAM-CGT GTC CCA GGA GCC CAT CCT GT-TAMRA 3' 
5'-CTT CTG GAG GAA TTG GTT GTA TAG AAG-3' 
5'-GGT AGA CCC AGA CAA GGA TGT TAG A-3' 
5' FAM-TCT TTG AGA TGC TTC TGG CTC CCA TCA C-TAMRA 3' 
5'-TGC AGC CTC CAT AAC CAT GAG-3' 
5'-CTT CGT CTT CCT TCA GGC TAT TCA-3' 
5' FAM-CAG CTT TCG TCG AAC ACT TAG CCG CA-TAMRA 3' 
5'-GCC ATC GAC CTG GAG ACT GA-3' 
5'-GAC CCT GGT GTA GTC CAT GAT AGT G-3' 
5' FAM-CAT CCG CAC CCA GTT TGA TAC CTG CAC-TAMRA 3' 
5'-AAG TGA ACAACC TCC AGT TCC AG-3' 
5'-GGC TCT CCA GAG CAC CAT CT-3' 
5' FAM-CAA ACC GAA GAC TCT GAG AAG GTA CGA TTC CT-TAMRA 3' 
5'-TGA AAG CCA TTC CAG TTG-3' 
5'-CGG AAA AGC TCG TCA TGC A-3' 
5' FAM-CTC GCA GCG TGC CCT TGA CAA AG-TAMRA 3' 
5'-AGA CAC GGT TGA CGT GGA CAT-3' 
5'-GCT GAC CTC CAG GAG TCC AA-3' 
probe 5' FAM-CCA GAC AAA CTC CGG TCC CTG CTG AT-TAMRA 3' 
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system (Bio-Rad GmbH) using bovine serum albumin as standard. Rabbit polyclonal 
antibody against human PARP (dilution 1 : 1000, Cell Signaling Technology, Beverly, 
Massachusetts, USA), mouse monoclonal antibody GAPDH (dilution 1 :5000, 
Calbiochem, Darmstadt, Germany) and rat monoclonal antibody MRPr1 were 
used (dilution 1 :500) (24). Horse radish peroxidase-labeled swine anti-rabbit and 
rabbit anti-mouse lgG were used as secondary antibodies (dilutions 1 :2500; DAKO, 
Heverlee, Belgium). 
The blots were exposed in a ChemiDoc XRS system (Bio-Rad, Hercules, CA). The 
intensity of the protein bands were quantified using Quantity One software. 
Caspase-3 assay 
Caspase-3 enzyme activity was determined according to the manufacturer's 
instructions using a caspase-3 activity kit with fluorimetric detection (Promega, 
Leiden, The Netherlands). 
Data analysis 
Statistical analyses were performed using SPSS version 12.0 for Windows (SPSS 
Inc. ,  Chicago, USA). Data obtained from the different groups are expressed as mean 
values ± standard deviation (SD). Different groups were compared using Mann­
Whitney U-tests and Kruskal-Wallis tests. A p-value of <0.05 was considered as 
statistically significant. 
RESULTS 
Expression of MRP1 in inflamed and uninflamed intestinal tissue. 
To study the effect of inflammation on ABC-transporter expression in the intestinal 
epithelium, we analyzed bordering mucosal biopsies from uninflamed and inflamed 
tissue from patients with IBD. In an initial screening, expression of MRP1-6 and 
MDR1 was analyzed in biopsies from 5 IBD patients (3 x UC and 2 x CD). M RP1 
mRNA levels were significantly increased in inflamed intestinal mucosa, while M DR1 
expression was down-regulated (Fig. 1A), as described earlier (11 ). The mRNA levels 
of MRP2-6 were similar in uninflamed and inflamed intestinal tissue of IBD patients 
(Fig. 1A). Subsequently, biopsies from 15 UC patients and 20 CD patients were 
analyzed. Inducible nitric oxide synthase (iNOS) expression was determined as a 
measure of inflammation in the biopsies (Fig. 1 B). Also in this larger cohort of IBD 
patients, MRP1 expression was significantly increased in inflamed intestinal mucosa 
in both UC and CD (Fig. 1 C) and M DR1 expression was decreased in both IBD 
subgroups (Fig. 1 D). lmmunohistochemistry for MRP1 on colonic biopsy material 
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with high grade inflammation showed a clear basolateral staining of intestinal 
epithelial cells as well as MRP1-positive mononuclear cells. Notably, MRP1 staining 
intensity was homogeneous in the epithelial cells lining the whole crypt, while the 
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uninflamed inflamed uninflamed inflamed 
Figure 1.  Increased MRP1 mRNA and protein expression in inflamed intestinal tissue of CD and 
UC patients. (A) mRNA levels of MDR1 and MRP1-6 in uninflamed (normal) and inflamed tissue of 5 180 
patients (CD n=2; UC n=3) were determined by real time RT-PCR. Only for MRP1, a significant increase 
in inflamed intestinal tissue was detected. (B-0) mRNA levels of iNOS (8), MRP1 (C) and MDR1 (D) in 
uninflamed and inflamed tissue of 20 CD and 15  UC patients. MRP1 levels are increased in inflamed in­
testinal tissue of both patient groups. mRNA levels from uninflamed tissue was set to 1 and relative mRNA 
expression levels were normalized to 1 BS. Data are expressed as means ± SD. * p<0. 05 compared with 
non-inflamed samples. (E) lmmunohistochemical localisation of MRP1 expression in inflamed colonic tis­
sue of a patient with ulcerative colitis. MRP1-dependent staining is indicated by arrowheads. The original 
magnification is 200x. 
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experiments, the uninflamed tissue from these patients remained unstained for 
MRP1 (data not shown). 
The effect of MK571-mediated inhibition of MRPs on anti-Fas- and TNF-a-induced 
apoptosis. 
Increased MRP1 levels may aid to cell protection during gastrointestinal inflammatory 
diseases. Cell damage/death may be induced through receptor-mediated apoptosis 
in response to Fasl or TNF-a, as previously shown in the intestinal mucosa of IBD 
patients (25-27). To study this putative function, we performed in vitro experiments 
using the human colon epithelial cell line DLD-1. Both human colon biopsies and 
DLD-1 cells show significant expression of MDR1 and various MRPs, including 
MRP1 (Fig 2). This makes DLD-1 cells a useful model for MRP1 inhibition and 
overexpression studies. First, we tested whether chemical inhibition of MRP-function 
by MK571 affected DLD-1 cell survival during exposure to anti-Fas or TNF-a. As 
reported by others (28-31 ), anti-Fas and TNF-a induce apoptosis in DLD-1 cells in 
a time-dependent manner with caspase-3 activities peaking at 16 and 12 hours for 
TNF-a and anti-Fas, respectively (Fig. 3A, D). Concurrently, significant amounts of 
activated (cleaved) PARP were detected after 16 hours TNF-a (Fig. 3B) or 8 hours 
anti-Fas (Fig. 3E) treatment. Adding MK571 strongly increased caspase-3 activities 
in both TNF-a- and anti-Fas-treated cells (Fig. 3A, D), which was accompanied 
by a further increase in the amount of cleaved PARP (Fig. 3B, E). The increase 
of TNF-a- or anti-Fas-induced apoptosis was dependent on the concentration of 
MK571 causing a significant increase of TNF-a- and anti-Fas-induced apoptosis at 
MDR1 MRP1 MRP2 MRP3 MRP4 MRP5 MRP6 MDR1 MRP1 MRP2 MRP3 MRP4 MRPS MRP6 
colon biopties DLD-1 cells 
Figure 2. MDR1 and MRP1-6 mRNA expression in human colon biopsies and DLD-1 cells. Relative 
mRNA levels of indicated genes were determined by real time RT-PCR and are corrected for 18S expres­
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Figure 3. Effect of MK-571 on anti-Fas- and TNF-a-induced apoptosis of DLD-1 cells. (A, D) 
Caspase-3 activity in DLD-1 cells treated for 4 to 24 hours with 10 nglml TNF-a (A) or 0.25 µglml anti­
Fas (D) in the absence or presence of 50 µM MK571. (B, E) Cleavage (activation) of PARP in DLD-1 cells 
treated for 16 hours with TNF-a (B) or 8 hours with anti-Fas (E) with and without MK571 (C, F). Duplicate 
experiments for each condition are shown. Caspase-3 activity in DLD-1 cells treated with TNF-a (C) or 
anti-Fas (F) in combination with different concentrations of MK571. Data are expressed as means ± SD. 
concentrations as low as 6.25 µM (Fig. 3C, F). M K571 (up to 50 µM tested) itself did 
not induce caspase-3 activity in DLD-1 cells. Taken together, these results show that 
inhibition of MRP function strongly sensitizes DLD-1 cells for TNF-a- or anti-Fas­
induced apoptosis. 
Inhibition of MRP1 expression by RNA-interference. 
MK571 is a non-specific MRP inhibitor and the different MRPs expressed in DLD-
1 cells (Fig. 2B) may contribute to variable extends to cytoprotection. To study the 
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Figure 4. Effect of stable overexpression of MRP1 on a-Fas- or TNF-a-induced apoptosis. DLD-1 
cells were stably transfected with a plasmid producing MRP1-GFP. Total mRNA was isolated from 2 
clones and the native DLD-1 cells. MRP1 mRNA levels were quantified by real time RT-PCR. Compared 
to DLD-1 cells, MRP1 mRNA levels were increased 1 7- and 35-fold in DLD1-GFP1 and DLD1-GFP2, 
respectively (A). MRP1 protein expression was determined by Western blotting using specific antibodies 
against MRP1 (B) and confocal laser scanning microscopy by detecting GFP fluorescence (C). A strong 
MRP1-specific signal was obtained when analyzing 10 µg of total protein from the recombinant clones. 
Endogenous MRP1 in DLD-1 cells was only detected when at least 40 µg of total protein extract was 
analyzed (B). The recombinant MRP1-GFP protein was predominantly present on the plasmamembrane 
(C, left panel DLD1-GFP1 and right panel DLD1-GFP2). MRP1 overexpression resulted in reduced 
a-Fas-induced caspase-3 activities (D) and PARP-cleavage (E), as well as reduced TNF-a-induced PARP 
cleavage (F). Caspase-3 activity and PARP-cleavage were determined in total protein extracts of cells 
exposed for 8 or 16 hours to 1 µg/ml a-Fas and 10 ng/ml TNF-a, respectively. Western blot detection of 
GAPDH was used as protein loading control. 
interference. DLD-1 cells were transiently transfected with MRP1-specific siRNA 
duplexes and after 48 hours, MRP1 mRNA (Fig. 4A) and protein (Fig. 4B, C) levels 
were significantly reduced to approximately 40 % of control cells. Exposure of the 
siRNA-MRP1 treated DLD-1 cells to anti-Fas led to significantly increased caspase-3 
levels (2.0-fold, Fig. 4D). These data show that specific inhibition of MRP1 sensitizes 
DLD-1 cells to anti-Fas-induced apoptosis and that other MRPs expressed in DLD-1 
cells are not able to fully compensate for the loss of MRP1 function. 
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Stable overexpression of MRP1 in DLD-1 cells. 
Next, we generated DLD-1 cell lines that overexpress MRP1 to examine whether this 
would increase the resistance of these cells against anti-Fas- and TNF-a-induced 
apoptosis. DLD-1-derivative cell lines, DLD-MRP1-GFP#1 and DLD-MRP1-GFP#2 , 
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Figure 5. Effect of stable overexpression of MRP1 on anti-Fas- or TNF-a-induced apoptosis. MRP1 
mRNA (A) and protein (B) expression in DLD-1 cells and two DLD-1-derived cell lines stably transfected 
with a plasmid producing MRP 1-GFP. Western blot analysis revealed the presence of a protein of 220 
kDa in both MRP1-GFP-transfected DLD-1-clones, which was detected with the MRP1-specific antibody 
and had the expected size of GFP-tagged MRP1.  Endogenous MRP1 in DLD-1 cells was only detected 
when at least 40 µg of total protein extract was analyzed. (C) Duplicate experiments for each condition are 
shown. The recombinant MRP 1-GFP protein was predominantly present on the plasmamembrane (DLD1-
MRP 1-GFP1 left panel; DLD1-MRP 1-GFP2 right panel). Caspase-3 activity (D) and PARP-cleavage (E, 
F) in DLD-1 cells and the two DLD-1-MRP1-GFP clones exposed for 8 or 16  hours to 1 µg/ml anti-Fas 
and 1 O nglml TNF-a, respectively. Western blot detection of GAPDH was used as protein loading control. 
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(MRP1-GFP). Previously, it has been shown that this MRP1-GFP hybrid protein 
retains its substrate transport activity (32). DLD-MRP1-GFP#1 and DLD-MRP1-GFP#2 
contained 17-fold and 35-fold increased MRP1 mRNA levels, respectively (Fig. SA). 
Western blot analysis revealed a strong MRP1-specific signal at approximately 220 
kDa, the expected size of the hybrid protein consisting of MRP1 (190 kDa) and 
GFP (30 kDa) (Fig. 58). In normal DLD-1 cells, only the endogenous MRP1 protein 
of approximately 190 kDa was detected. Fluorescence microscopical analysis to 
determine the subcellular location of the GFP signal revealed a predominant plasma 
membrane staining in the DLD-MRP1-GFP clones (Fig. SC), which was not detected 
in the native DLD-1 cells (data not shown). Exposure of the MRP1 overproducing 
cell lines to anti-Fas or TNF-a resulted in significantly lower caspase-3 activities and 
PARP-cleavage compared to the native DLD-1 cells (Fig. 5D, E and F). Notably, we 
observed an inverse correlation between the MRP1-GFP expression level and the 
level of anti-Fas- or TNF-a-induced apoptosis in these cells. These data imply that 
MRP1 is able to protect cells from anti-Fas- or TNF-a-induced apoptosis. 
Inhibition of cysteinyl leukotriene biosynthesis. 
Inflammation induces the conversion of arachidonic acid into cysteinyl leukotrienes. 
LTC4 is a high-affinity substrate for MRP1 that is converted to the anti-apoptotic 
LTD 4 after cellular export. We studied whether blocking MRP function results in the 
accumulation of a pro-apoptotic compound or, alternatively, prevents the extracellular 
formation of an anti-apoptotic compound. The lipoxygenase inhibitor AA861 was 
used to prevent leukotriene synthesis from arachidonic acid. AA861 alone does not 
induce caspase-3 activity in DLD-1 cells (Fig. 6A). Co-treatment of DLD-1 cells with 
anti-Fas and increasing amounts of AA861, however, results in a dose-dependent 
increase in caspase-3 activity. This is probably due to the accumulation of pro­
apoptotic arachidonic acid (33;34 ). Crucial is the observation that the caspase-3 
activity in anti-Fas/AA861-treated cells is significantly lower than that in anti-Fas/ 
MK571-treated cells (Fig. 6A). When DLD-1 cells were then co-treated with anti­
Fas, MK571 and increasing amounts of AA861, a dose-dependent decrease in 
caspase-3 activity was observed (Fig. 6A). At the highest concentration AA861 (20 
µM), caspase-3 activity in the anti-Fas/MK571/AA861-treated cells was reduced to 
levels comparable to anti-Fas/AA861-treated DLD-1 cells (Fig. 6A). These data imply 
that blocking leukotriene synthesis by AA861 results in the accumulation of a pro­
apoptotic compound (arachidonic acid) in anti-Fas treated DLD-1 cells. However, 
M861 prevents the intracellular accumulation of an even more potent pro-apoptotic 
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Figure 6. Inhibition of leukotriene synthesis in MK-571-treated DLD-1 cells that are exposed to anti­
Fas- or TNF-a-induced apoptosis. (A) Caspase-3 activity in DLD-1 cells exposed for 8 hours to 0. 25 
µg/ml anti-Fas and co-treated with 50 µM MK571 (MRP1 inhibitor) and/or increasing amounts (1, 5 or 20 
µM) of AA861 (5-/ipoxygenase inhibitor). Data are expressed as means ± SD, * p<0.05. (B) Schematic 
representation of the relationship between MRP1,  the leukotriene synthesis pathway and apoptosis. An 
inflammatory stimulus leads to receptor-mediated intracellular influx of calcium ions. As a consequence, 
cytosolic phospho/ipase A2 (cPLA) translocates from the cytosol to the nuclear membrane. cPLA2 cleaves 
arachidonic acid (AA) from the membrane phospholipids. Then, AA is converted by 5-/ipoxygenase to 
leukotriene A4 (LTA), which is converted to LTC4 through the sequential action of LTB4 hydrolase and 
LTC4 synthase. LTC4 is exported by MRP 1.  Inhibition of 5-/ipoxygenase leads to the accumulation of pro­
apoptotic AA, but the inhibition of MRP1 leads to the accumulation of an even more potent pro-apoptotic 
agent, LTC4 (8). 
(Fig. 6B shows a schematic representation of LTC4 biosynthesis and export and the 
position and effect of the inhibitors used in this study). 
DISCUSSION 
In this study, we show that the ABC-transporter MRP1 is induced in inflamed intestinal 
epithelial cells of patients with inflammatory bowel disease (IBD). Pharmacological 
inhibition of MRP function increased anti-Fas- and TNF-a-induced apoptosis of 
DLD-1 cells. Specific reduction of MRP1 expression by RNA interference sensitizes 
DLD-1 cells for anti-Fas-induced apoptosis. Anti-Fas- and TNF-a-induced apoptosis 
was reduced in DLD-1 cells stably overexpressing MRP1 or when the intracellular 




MRP1 is best known for its ability to protect tumor cells by stimulating efflux of 
drugs that will otherwise induce apoptosis or necrosis of these cells (35). However, 
MRP1 is also expressed in normal (non-malignant) tissues such as the colon where 
it is specifically present in crypt cells that form the proliferative cell compartment 
of the gut (32;36;37). It has been suggested that this may protect these cells 
against damage induced by xenobiotics (38). We observed that during intestinal 
inflammation, MRP1 levels were significantly induced. Using immunohistochemistry, 
we detected a clear basolateral staining for MRP1 of the crypt cells of the inflamed 
intestine. The increase in MRP1 expression was not part of a general induction of 
cytoprotective efflux systems, since the expression of another ABC-transporter MDR1 
was decreased under these conditions (11 ). Therefore, MRP1 may have a specific 
role in protecting crypt intestinal epithelial cells during inflammation. We provide 4 
lines of evidence for such a function of MRP1. Firstly, pharmacological inhibition 
(by MK571) of MRPs strongly increases cytokine- {TNF-a) and anti-Fas-induced 
apoptosis in DLD-1 cells. Many earlier studies reported that cytokines or anti-Fas 
induce apoptosis in intestinal and other cell types/lines (28;29;39;40), but this is the 
first time that a protective role for an MRP transporter in this process is described. 
Apparently, exposure to anti-Fas or TNF-a leads to intracellular processes that give 
rise to apoptotic compounds that are substrates for MRPs. Others have shown that 
anti-Fas-induced apoptosis is associated with rapid extrusion of reduced glutathione 
(GSH), which precedes apoptotic cell death (41 ;42). MRP1 has been suggested to 
be the transporter responsible for glutathione export under these conditions (43). 
Blocking MRP1-dependent export of glutathione in anti-Fas treated Jurkat cells led 
to a decrease in apoptosis, the exact opposite of what we detected for DLD-1 cells. 
It is relevant to note that controversy exist in recent literature which transporter(s) 
are responsible for glutathione export in apoptotic cells. Others have suggested that 
not MRPs, but rather OATPs in jurkat cells are responsible for this effect (44 ). We 
further studied the opposite effect of MRP inhibition on anti-Fas-induced apoptosis 
of T lymphocyte cell lines (Jurkat and MOLT-4) and DLD-1 (Van Steenpaal et al., 
submitted). We show that cellular glutathione levels are only marginally affected 
under our experimental conditions and that glutathione depletion is unlikely to be the 
primary inducting condition for apoptosis in Jurkat and DLD-1 cells. 
Secondly, specific repression of MRP1 expression (by RNA interference) sensitizes 
DLD-1 cells for anti-Fas induced apoptosis. The increased level of apoptosis when 
expression of specifically MRP1 is reduced shows that, of the MRPs present in 
DLD-1 cells, MRP1 plays the predominant role in cytoprotection against anti-Fas-
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induced apoptosis. Thirdly and in line with the previous observation, recombinant 
overexpression of MRP1 in DLD-1 cells dose-dependently reduced apoptosis 
induced by anti-Fas or TNF-a. These data suggest that these compounds induce 
the intracellular production of an apoptotic compound for which MRP1 is the most 
important efflux pump. TNF-a and anti-Fas are known to induce apoptosis by 
activation of membrane receptors (TNF-receptor, Fas) (45). Once activated, these 
receptors recruit adaptor proteins that initiate a signaling pathway, which ultimately 
leads to activation of effector caspases that mediate apoptosis. No obvious 
substrate is present in this signaling pathway that may be exported by MRP1 thereby 
preventing apoptosis. However, TNF-a or anti-Fas may also induce apoptosis 
through the release of arachidonic acid from the membrane after activation of Ca2+ -
dependent cytosolic phospholipases (46). Arachidonic acid stimulates apoptosis 
through activation of sphingomyelinase and through its downstream metabolites, 
prostaglandins and leukotrienes. Gastrointestinal epithelial cells have been shown to 
be able to produce these compounds (47). Indeed and as the fourth line of evidence, 
we found that blocking the biosynthesis of leukotrienes leads to a reduction in 
TNF-a- or anti-Fas-induced apoptosis in DLD-1 cells with an inhibited MRP function. 
Since leukotriene C4 (LTC4) is a high affinity substrate of MRP1, we suggest that 
this is the pro-apoptotic compound during inflammatory conditions (15). MRP4 
and MRP6 have also been shown to be able to transport LTC4 with relatively high 
affinity(48;49) and both transporters are expressed in human intestinal tissue and 
DLD-1 cells. However, even a partial reduction of MRP1 in DLD-1 cells already leads 
to sensitization of these cells for anti-Fas-induced apoptosis. Apparently, MRP4 and/ 
or MRP6 cannot fully compensate for the loss of MRP1 expression. 
Collectively, these data show that MRP1 has an important role in protecting the 
intestinal epithelium during inflammation. Our data correlate well with observations 
by Nishikawa et al. who observed that inhibition of LTC4 synthesis is associated 
with decreased intestinal damage induced by trinitrobenzene sulfonic acid-induced 
colitis (50). In addition, Mrp1 -1- mice have been shown to develop more severe colitis 
after administration of dextran sulfate sodium (19;50). A cytoprotective role of MRP1 
against inflammation-induced cell death may not be restricted to intestinal epithelial 
cells. Previously, we found that in livers of patients with severe hepatitis, hepatic 
progenitor cells contain high levels of MRP1 (51 ). Similar to the intestinal crypt 
cells, hepatic progenitor cells are involved in regeneration of damaged tissue during 
pathophysiological conditions. They need to survive in conditions when they are 
exposed to cytokines, toxic metabolites and xenobiotics. MRP1 may be an important 
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component of cellular cytoprotection during inflammation. 
In conclusion, our data show a novel function of MRP1, that is protection of intestinal 
epithelial cells against inflammation-induced apoptosis. MRP1 expression is 
increased in intestinal epithelial cells, in particular those lining the crypt, that may 
serve to preserve the intestinal regenerative capacity. 
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Abstract 
Immune responses are tightly controlled by balancing activation and apoptotic cell 
death of T-lymphocytes. This process is disturbed in inflammatory bowel diseases 
(IBD), e.g. Crohn's disease and ulcerative colitis. In particular the resistance of 
T-lymphocytes to apoptosis poses serious limitations for effective treatment of 
Crohn's disease. Recently, we found that the Multidrug Resistance-associated 
Protein 1 (MRP1/ABCC1) protects intestinal epithelial cells against inflammation­
induced apoptosis. Here, we studied the role of MRP1 in protecting T-lymphocytes 
against apoptosis. 
MRP1 is highly expressed in peripheral T-lymphocytes and T-lymphocyte cell lines 
(Jurkat, MOLT-4) compared to monocytes and MRP2, MRP3 and MRP4. MRP1 
expression is highly variable (5-fold) in peripheral blood mononuclear cells (PMBCs) 
of IBD patients compared to PBMCs from healthy volunteers. Pharmacological 
inhibition of MRP1 decreased anti-FAS-induced apoptosis in Jurkat and MOLT-4 
cells, opposite to the effect in intestinal epithelial cells. Modulation of apoptosis in 
Jurkat and DLD-1 was independent of cellular glutathione levels, which is a substrate 
of MRP1 and previously implicated in T-cell apoptosis. 
These data show that low MRP1 levels in T-lymphocytes lead to resistance to 
apoptosis through a glutathione-independent mechanism. Induction of MRP1 
could therefore be benificial for IBD patients as it protects intestinal epithelium and 




Inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis 
(UC), are chronic inflammatory disorders of the gastrointestinal tract without an 
identifiable pathogenic cause (1 ). Both diseases are characterized by an exaggerated 
inflammatory response to the endogenous gut flora (2). This leads to increased 
levels of cytotoxic cytokines in the gastrointestinal tract and eventually to lesions and 
ulcerations of the intestinal mucosa. Activated T-lymphocytes produce Fas-ligand 
that, in a feedback mechanism, induces T-lymphocyte apoptosis, thereby controlling 
immune system homeostasis. In IBD patients, this feedback apoptotic mechanism 
is disturbed (reviewed in (3)). The hallmark of immunomodulatory drugs used for 
the treatment of IBD is that they induce apoptosis of T-cells thereby terminating 
the ongoing inflammation. Unfortunately, this therapy is unsuccessful in a significant 
number of IBD patients, where T-lymphocytes appear to resist drug-induced 
apoptosis (4-6). Recent data suggest that ATP-Binding Cassette (ABC)-transporters, 
and in particular the Multidrug Resistance-associated Protein 1 (MRP1/ ABCC1 ), 
play a role in modulating anti-Fas- and cytokine-induced cell death (7,8) In addition, 
MRP1 is able to export numerous cytotoxic drugs or their metabolites to prevent cell 
death (9-11 ). 
MRP1 is ubiquitously expressed throughout the body with high expression levels in 
the brain, kidney, heart, lung and testis. Lower, but considerable expression levels are 
observed in the intestine and peripheral mononuclear cells (PBMCs) (12-14). MRP1 
has a broad substrate specificity, but its function depends strongly on the presence 
of glutathione (reviewed in (15)). High-affinity endogenous substrates are the pro­
inflammatory compound Leukotriene C4 (LTC4) (16), compounds conjugated to 
glutathione, sulphate or glucuronide and glutathione itself. Although MRP1-mediated 
multidrug resistance against chemo-therapeutics has been described extensively 
(reviewed in (78)), the (patho )physiological function of MRP1 is not well understood. 
There is increasing evidence that MRP1 has an important function in inflammation 
and immune responses. Previous studies of our group have shown induction of 
MRP1 in several inflammatory conditions (18, 19). In addition, several mouse studies 
have shown that absence of Mrp1 result in altered immune responses (20,21 ). 
Furthermore, MRP1 induction has recently been identified as an activation marker 
for human and murine Th-lymphocytes (22-24 ) .  
As part of the feedback mechanism to maintain immune system homeostasis, MRP1 
has been proposed to sensitize T-cells to anti-Fas induced apoptosis (7,25). Anti-Fas 
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treatment of Jurkat T-cells was shown to lead to rapid release of reduced glutathione 
(GSH) via MRP1, which precedes apoptosis. Inhibition of MRP1-mediated GSH 
export reduced anti-Fas-induced apoptosis. 
In a previous study (8), we found increased expression of MRP1 in the inflamed 
mucosa of IBD patients. Two cell types contained detectable levels of MRP1: 
intestinal epithelial cells and lamina propria mononuclear cells. This prompted us 
to study the role of MRP1 in anti-Fas-induced apoptosis in both cell types, since 
intestinal epithelial cells form the crucial barrier between the antigen-rich gut lumen 
and the host immune system and mononuclear cells are the target cells for therapy. 
In contrast to what has been described for Jurkat T-cells ,  MRP1 protects intestinal 
epithelial cells from anti-Fas and cytokine-induced apoptosis (Blokzijl et al, JBC 
published) by exporting pro-apoptotic compounds from the leukotriene biosynthetic 
pathway. Since the role of MRP1 in anti-Fas-induced apoptosis of T-cells is currently 
a matter of debate (7 ,26 ,27), we aimed to establish the role of MRP1 in T-cells. 
In this study we investigated the MRP1 expression in human T-lymphocytes of 
healthy volunteers and IBD patients_ Next, we compared the MRP expression profile 
of human T-cells to T-cell lines Jurkat and MOLT-4, as well as the colon carcinoma 
cell line DLD-1. After establishing the MRP1 transport activity in these cell lines, 
we determined the effect of several pharmacological inhibitors on anti-Fas induced 
apoptosis. Finally, we studied whether MRP1-mediated GSH efflux is involved in 
modulation of apoptosis in these cells. 
Materials and methods 
Materials 
RPE-labeled mouse antibodies to human CD4 and CD8 were obtained from IQP 
products (Groningen, Netherlands). The monoclonal rat antibody MRPr1 was from 
Sanbio BV (Uden, Netherlands). Mouse monoclonal antibody GAPDH was from 
Calbiochem (Darmstadt, Germany). Donkey-anti-rat Alexa 488, culture media, 
fetal bovine serum, TRlzol reagent and 5-CFDA (5-carboxyfluorescein diacetate) 
were obtained from lnvitrogen Life technologies (Breda, Netherlands). MK571 was 
purchased from Tebu Bio B.V. (Heerhugowaard, The Netherlands) and oleanolic 
acid, paraformaldehyde and Triton X-100 were obtained from Sigma-Aldrich chemie 
B.V. (Zwijndrecht, The Netherlands). 
For PBMC isolation, Lymphoprep® was used from Axis-shield (Rodel0kka, Norway). 
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Penicillin, streptomycin, amphotericin B were from Biowhittaker (Verviers, Belgium) 
Fluorescent mounting medium was used from DAKO cytomations (Glostrup, 
Denmark) 
For cell death assays the Annexin apopkit was purchased from Nexins research 
(Kattedijke, The Netherlands). 
Patient characteristics 
Blood samples were obtained from healthy controls (n=8), CD patients (n=5) and 
UC patients (n=4) after informed consent. Disease activity was scored according 
to Harvey-Bradshaw for CD (29) and a similar index for UC and verified by routine 
blood values (BSE, Hb, CRP, albumine) 
The simplified index for UC is based on 8 variables: 
Rectal blood loss: none (0), sometimes (1 ), frequently (2) 
Rectal mucus loss: none (0), sometimes ( 1 ), frequently (2) 
Stool frequency: <3 per day (0), 3-6 per day (1 ), >6 per day (2) 
Stool consistency: normal (0), semi liquid (1 ), liquid (2) 
Painful! instigation: none (0), mild (1 ), severe (2) 
Abdominal pain: none (0), mild (1 ), severe (2) 
Anal pain: none (0), mild (1 ), severe (2) 
Nausea, vomitting: none (0), sometimes ( 1 ), frequently (2) 
Points for all variables are added and resulting scores is defined as: 
0-4 remission, > 4 relapse 
The protocol was approved by the Ethics Committee of the University Medical Center 
Groningen (METc 2002/177c). 
Cell culture 
The colon carcinoma cell line DLD-1 (DZSM, Braunschweig, Germany) was 
maintained in RPM 1-1640 medium with glutamax supplemented with 10% fetal bovine 
serum, penicillin, streptomycin and amphotericin B. Cells were passaged twice a 
55 
week. Cells were grown to 90% confluency prior to stimulation or RNA isolation. The 
human leukemia derived T-cell lines Jurkat and MOLT-4 were a kind gift from Dr. L. 
Visser (dept. Pathology, UMCG). Jurkat and MOLT-4 cells were maintained in RPMl-
1640 with glutamax supplemented with 10% FBS, penicillin (100 U/ml), streptomycin 
(100 µg/ml) and amphotericin B (fungizone, 25 ng/ml)(psf). Cells were passaged 
twice a week. For experiments 500,000 cells were used per condition. 
Human peripheral blood mononuclear cells were maintained in RPMl-1640 
supplemented with FBS and psf. 
Isolation and culture of peripheral blood mononuclear cells 
Heparinized blood was diluted one-to-one in sterile PBS after wich it was brought 
onto a Lymphoprep® density gradient and centrifuged for 20 minutes at 800xg. The 
mononuclear cell fraction was transferred into a clean tube and washed three times 
with culture medium. Lymphocytes were purified by attachment of monocytes during 
two hour culture in a culture flask. Enrichment was checked by quantitative real-time 
PCR for CD3 expression. 
Isolation and quantitative PCR 
Total RNA was isolated using the TRl-zol isolation method according to the 
manufacturers instructions (lnVitrogen Life technologies, Breda, Netherlands) 
Reverse transcription was performed in a final volume of 50 µI. Messenger RNA 
(mRNA) levels of 18S and MRP1 to MRP4 were quantified using the ABI PRISM 
7700 (Applied Biosystems, Calfornia, USA). Real-time PCR conditions were as 
described previously (19). For quantification of mRNA levels, the CT-value difference 
was calculated between the gene of interest and the housekeeping gene 18S. This 
delta Ct was corrected to a linear scale (2-b.Ct) to obtain a relative amount of mRNA 
compared to 18S. Primer and probe sequences are shown in the supplementary 
figures. 
Western blotting 
Total cell lysates were prepared by freeze-thawing cells 4 times in lysis buffer 
containing DTT, Hepes, PMSF and proteinase inhibitors. Protein concentrations 
were determined using the Bio-Rad Protein Assay system (Bio-Rad GmbH, Munich, 
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Germany) using bovine serum albumin as a standard. For MRP1 detection 20 
µg of protein was loaded on a 7,5% SOS-PAGE gel . For GAPDH, 5 µg of protein 
was separated on a 10% SOS-PAGE gel. Protein was transferred by tank blotting. 
Detection of MRP1 was performed using the primary rat monoclonal antibody Mrpr1 
(dilution 1 :500) and rabbit-anti-rat peroxidase secondary antibody. GAPDH was 
detected using mouse monoclonal antibody (dilution 1 :5000) antibody and rabbit­
anti-mouse peroxidase secondary antibody. The blots were exposed in a ChemiDoc 
XRS system (Bio-Rad, Hercules, CA) and the intensity of the protein bands were 
quantified using Quantity One software. 
lmmunofluorescence microscopy 
Cytospins were prepared from Jurkat cells and peripheral blood mononuclear cells 
(PBMCs ). Cytospins were dried overnight at room temperature. The cells were fixed 
with 4% paraformaldehyde for 20 minutes and subsequently permeabilized using 
1 % Triton X-100 for 5 minutes. Cytospins were then incubated with the primary 
antibody overnight at 4 °C. Secondary antibodies were incubated for 1 hour at room 
temperature. Finally, the cytospins were incubated with RPE-labeled antibodies for 
CD4 or CD8 for 30 minutes at room temperature. Cytospins were then mounted on 
fluorescence mounting medium and analyzed by confocal microscopy (Leica TCS 
SP2/AOBS, Rijswijk, Netherland). 
5-Carboxyf/uorescein (5-CF) efflux assay 
MRP1 activity was determined by analyzing the efflux of the fluorescent MRP 
substrate 5-CF as described by Laupeze et al (12). The cells were loaded for 30 
minutes with 1 µM 5-CFDA. Subsequently, cells were washed twice with ice-cold 
PBS and were resuspended in pre-warmed (37oC) RPMl-1640 (10% FBS, psf) with 
or without inhibitor. The percentage of 5-CF retained in the cells was determined by 
flow cytometric analysis on a FACScalibur (BD bioscience) (average fluorescence 
intensity, AV I). Flow cytometry data was analyzed using Winlist 6.0 software. 
The level of MK571- or oleanolic acid-dependent MRP1 inhibition was calculated 
using the following formulas: 
% 5-CF retained= ((AVI t=2o - AVI bland / (AVI t=O - AVI blanc)) *100. 
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% MRP1 inhibition = %5-CF retained MK571 /0A - % 5-CF retained control 
Detection of cell death 
To quantify apoptosis of DLD-1 cells, caspase-3 enzyme activity was determined 8 
hours after stimulation with anti-Fas using a caspase-3 activity kit with fluorimetric 
detection according to the manufacturer's instructions. (Promega, Leiden, The 
Netherlands). In Jurkat cells, the percentage of apoptotic cells was determined by 
flow cytometric detection of Annexin-V and propidium iodide staining after 3 hours 
of stimulation according to manufacturer's instructions (Annexin apopkit, Nexins 
research, Kattedijke, The Netherlands). Flow cytometry data was analysed using 
Winlist 6.0 software. Results are represented as the fold change vs anti-Fas­
induced apoptosis. Overlay histograms for illustration were created using WinMDI 
2.8 software. 
Determination of glutathione concentration 
Glutathione concentrations were determined using a spectrophotometric 
determination as described previously (29). Glutathione concentrations were 
corrected for protein concentrations. 
Statistical analysis 
Experiments were performed in triplicate and analyzed by Student's t-test or Kruskall-
Table 1. Patient characteristics. Included patients were all in clinical remission as determined by 
the Harvey-Bradshaw score for Crohn s disease and the index for ulcerative colitis as described in 



























acid , corticosteroids 
Azathioprine, 5-aminosalicylic 
acid 
CD score (Harvey-Bradshaw): remission 0-3; relapse >3 UC score: remission 0-4; relapse >4 
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Wallis and Mann-Whitney tests. All statistical tests were performed in SPSS v12.0 
for windows. Significance was defined as p<0.05. 
Results 
MRP1 expression is high in CD4+ Th lymphocytes, with strong variability in /BO 
patients. 
MRP1 expression was detected in epithelial and lamina propria mononuclear cells 
in the inflamed intestine of 18D  patients (9). First, to determine whether MRP1 is 
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Figure 1. MRP1 expression in peripheral blood mononuclear cells in healthy control and IBD patients. 
(A) Peripheral blood mononuclear cells (PBMCs) from healthy controls were subfractionationed into 
T-lymphocyte- and monocytes/granulocyte-enriched fractions, followed by quantitative PCR to deter­
mine MRP1 mRNA levels. * p < 0. 05 (B) MRP1 mRNA levels in T-/ymphocytes from healthy control 
and IBD patients. Diamonds represent healthy controls, squares represent Crohn 's disease and tri­
angles represent ulcerative colitis patients. Real time data are represented as the relative expression 
versus 18S. (C) lmmunonuorescent detection of MRP1 in peripheral blood mononuclear cells and 
co-staining with CD4 (left panels) or CDB antibodies (right panels). 
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in subfractions of PBMCs. PMBCs were isolated from healthy volunteers and 
separated into T-lymphocyte- and monocyte/granulocyte-enriched fractions as 
described in Experimental procedures. RNA was isolated and MRP1 mRNA levels 
were determined by quantitative RT-PCR fraction (Figure 1A). CD3 mRNA levels 
were used as marker to determine the enrichment of T-lymphocytes over monocytes/ 
granulocytes. 
Samples in which a 5-fold increase of CD3 expression was found were used for MRP1 
detection. MRP1 expression was detected in both T-lymphocytes and monocyte/ 
granulocyte-enriched fractions with a 1, 7-fold higher level in T-lymphocytes. Next, 
the expression level of MRP1 in lymphocytes from IBD patients in clinical remission 
were compared to healthy controls. The characteristics of the patients are reported 
in table 1 .  A remarkable observation here was the high interindividual variability of 
lymphocyte MRP1 expression in IBD patients, both in CD and UC, whereas this was 
not observed for healthy controls. Significantly higher and lower MRP1 levels were 






1 .4 D Molt-4 
en [;I DLD-1 
T- 1 .2 
1/) 
> 










� 1 ,2 �---� 
� 1 ,0 
> 
5 0,8 
"iii E o.s 
� 0,4 
a: 




MRP1 I 1:�� 
GAPDH I- - - - - - - - -1 .... 37 
Jurkat MOL T-4 DLD-1 
Figure 2. Expression of MRP1-4 in human lymphocytes, Jurkat, MOL T-4 and DLD- 1 cells (A) Ex­
pression profile of MRP1-4 in human lymphocytes, Jurkat, MOL T-4 and DLD- 1 cells. MRP mRNA 
expression is correlated to 18S. MRP1 expression in the different cell lines is set to 1. (Inset A) 
relative MRP1 expression in human lymphocytes, Jurkat, MOL T-4 and DLD- 1 cells. MRP1 mRNA 
expression in Jurkat cells is set to 1 (B) Relative MRP1 protein expression in Jurkat, MOL T-4 and 
DLD- 1 cells. MRP1 protein levels were visualized by Western blotting and protein band intensities 
were quantified by the Quantity One software and normalized to GAPDH protein levels. Data are 
expressed as means ± SD 
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group, no significant difference was observed in MRP1 expression levels between 
IBD patients and healthy controls. The MRP1 expression in IBD patients does not 
correlate to medication or disease score (data not shown). 
To determine whether MRP1 expression is present in a subpopulation of lymphocytes, 
cytospins were prepared from PBMCs isolated from blood from healthy volunteers 
and co-stained for MRP1 and CD4 {T-helper cells) or CD8 (cytotoxic effector T-cells) 
(Figure 1 C). Confocal laser scanning microscopical analysis revealed that MRP1 
shows strong colocalization with CD4. In contrast, no significant colocalisation was 
detected for MRP1 and CD8 (Figure 1 C). 
MRP1 is the predominant MRP in primary human T-lymphocytes and human T-ce/1 
lines. 
To determine whether MRP1 is co-expressed with other MRP family members with 
overlapping substrate specificity (31 ,32), we determined the relative mRNA levels 
of MRP1-4 in human T-lymphocytes (Figure 2A). MRP1 is the most dominant MRP 
member expressed in these cells. MRP4 expression is at least 5-fold lower compared 
to MRP1 and MRP2 and MRP3 are almost undetectable in human T-lymphocytes. 
The MRP expression pattern in human T-lymphocytes is very similar to that observed 
in Jurkat and MOL T-4 cells, two routinely used model cell lines for T-cells (Figure 2A 
and (8)). To study the role of MRP1 in T-cells in vitro, we performed experiments with 
Jurkat cells in a direct comparison to the intestinal epithelial cell line DLD-1. MRP1 
mRNA levels are approximately 4-fold lower in DLD-1 cell compared to Jurkat cells. 
DLD-1 cells further express MRP2-4 in a similar pattern compared to Jurkat cells 
with MRP1 being the most dominant MRP (Figure 2A). 
MRP1 protein expression is subject to post-translational regulation and especially 
cell-cell contact stabilizes MRP1 protein at the plasma membrane (33,34 ). We 
therefore also determined the MRP1 protein levels in Jurkat, MOLT-4 and DLD-1 
cells (Figure 2B). MRP1 protein was readily detectable in total protein extracts of 
these cell types. MRP1 levels were the highest in Jurkat cells with slightly lower 
levels in MOLT-4 cells mirroring the mRNA levels in these cells. MRP1 protein in 
DLD-1 and MOLT-4 cells was comparable, even though MRP1 mRNA levels were 
approximately 3-fold lower in DLD-1 cells. This further substantiates the existence of 
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Figure 3. MRP1 activity in Jurkat and MOL T-4 cells. Cells are loaded with 5-CFDA. (A) Internally, 
5-CFDA is converted to the nuorescent MRP1 substrate 5-CF, wich is detected by now cytometry. 
Jurkat cells loaded with 5-CFDA (open histogram) and untreated Jurkat cells (filled histogram) are 
shown. (B) 5-CFDA is washed away and 5-CF efflux is determined in time. The 5-CF nuorescence at 
t=0 is set to 100%. Triangles represent Jurkat cells, squares represent MOL T-4 cells. MK571 (C, D) 
and OA (E,F) inhibit 5-CF efflux in Jurkat cells. After 20 minutes of efflux with or without 50 µM MK571 
(C) or OA (E), the 5-CF nuorescence is determined Filled histogram, nuorescence at t=0, open his­
togram thick line represents nuorescence after 20 minutes of efflux, the open histogram with thin line 
represents nuorescence after 20 minutes of efflux in the prescence of MK571 or OA. MK571 (D) and 
OA (F) dose-dependently inhibit 5-CF efflux from Jurkat cells. 5-CF from Jurkat cells was determined 
in the presence of 0, 50, 100 and 250 µM MK571 (D) or 0, 1 ,  10 and 20 µg/ml OA (F). 
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MRP function in T lymphocyte and epithelial cell lines 
In order to investigate whether MRP1 is located to the plasma membrane and is 
active in all model cell lines, the export of the MRP substrate 5-carboxyfluorescein 
(5-CF) was measured. Cells were loaded with 5-CFDA. This compound is taken 
up by the cells and metabolized intracellularly into the fluorescent MRP substrate 
5-CF (figure 3A). Jurkat cells, MOLT-4 (Figure 3D) and DLD-1 cells (data not shown) 
export 5-CF efficiently. After 20 minutes of export the percentage of 5-CF retained 
in the cells is 15, 7 +/- 4,4 % in Jurkat cells, 23,2 +/- 9,0 % in MOL T-4 cells and 11,2 
+/- 0,3 % in DLD-1 cells. Two unrelated pharmacological inhibitors of MRP transport, 
MK571 and oleanolic acid (OA), were used to inhibit 5-CF export from Jurkat cells 
(Figure 3 B,C, E and F). MK571 is routinely used at a concentration of 50 µmol/L to 
block MRP1 dependent export and also in our assay this was sufficient to effectively 
block export of 5-CF from Jurkat cells (Figure B and E). OA has only recently been 
identified as an inhibitor of MRP1 transport activity (35,36). We observed a dose­
dependent effect of OA and the amount of 5-CF retained in Jurkat cells (Figure 3C 
and E). At 10 µg/ml a maximal inhibitory effect on the 5-CF efflux was detected. 
MK571 is a stronger inhibitor of MRP-mediated efflux of 5-carboxyfluorescein 
Next, we determined to what extent these inhibitors inhibit MRP1 in DLD-1, Jurkat 
and MOL T-4 cells. All cell lines were treated with different concentrations of both 
MK571 or OA. The highest non-toxic concentrations were used to study the maximal 
MRP1-inhibition. Both inhibitors (MK571 50 µM; OA 10 µg/ml) increased the amount 
of 5-CF retained in both Jurkat cells (from 15,7 +/- 4,5% to 50, 1 +/- 5,2% and 49,7 
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Figure 4. Inhibition of MRP mediated 5-CF efflux 
by MK571 or Oleanolic acid in Jurkat, MOL T-4 and 
DLD- 1 cells. 5-CF efflux assays were performed 
with Jurkat, MOL!-4 and DLD- 1 cells in the presen­
ce or absence of 50 µM MK571 or 10 µg/ml OA. 
The % MRP1 inhibition was determined as descri­
bed in experimental procedures. Data are obtained 
from 3 individual experiments and are expressed 
as means ± SD 
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+/- 20,9% resp.). The amount of 5-CF retained in DLD-1 cells increased from 11,2 +/-
0,3% in control cells to 86,7 +/- 0,0% and 43, 1 +/- 7, 1 % in cells treated with MK571 
or OA, respectively (Figure 4 ). 
MRP inhibition decreases apoptosis in Jurkat cells and increases apoptosis in DLD-
1 cells 
MRP1 is localized at the plasma membrane and active in all cell lines. Next, to 
determine the possible role of MRP1 in cell survival, we determined the effect of 
MRP1 inhibition on anti-Fas-induced apoptosis. Apoptosis was induced in Jurkat 
and DLD-1 cells by exposure to 1 µg/ml or 0.25 µg/ml anti-Fas, respectively, in the 
presence or absence of the MRP inhibitors MK571 (50 µmol/L) or OA (1 O µg/ml) 
(Figure 5). Anti-Fas induces apoptosis in both Jurkat (3.3-fold induction vs control) 
and DLD-1 cells (12.3-fold induction vs control). Co-treatment of Jurkat cells with 
anti-Fas and 50 µmol/L MK571 or 1 O µg/ml OA resulted in a significant reduction of 
the percentage of apoptotic cells (-45% and -55%, respectively) compared to anti­
Fas treatment alone (Figure SA). In contrast, co-treatment of DLD-1 cells with anti­
Fas and MK571 or OA significantly induced the caspase-3 activity 2.3- or 2.4-fold, 
respectively, compared to anti-Fas treatment alone (Figure 5B). Treatment of Jurkat 
or DLD-1 cells with only MK571 or OA did not induce apoptosis. 
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Figure 5. MRP inhibition differentially modulates apoptosis in Jurkat and DLD- 1 cells. Apoptosis 
was induced by stimulation with 1 µg/ml anti-FAS for 3 hours in Jurkat cells (A) and 0.25 µglml for 8 
hours in DLD- 1 cells (8). (A) Inhibition with both 50 µM MK571 or 10 µglml OA reduces the number of 
anti-FAS-induced apoptotic Jurkat cells determined by Annexin- V/propidium iodide staining. (8) Tre­
atment of MK571 or OA induces anti-FAS-induced apoptosis in DLD- 1 cells determined by caspase-3 
activity. MK571 and Oleanolic acid alone do not induce apoptosis. Anti-FAS-induced apoptosis is set 
to 1. Data are obtained from 3 individual experiments and are expressed as means ± SD (* p < O. 05 
vs anti-FAS) 
64 




i 1 50 








Figure 6. Glutathione concentration in 
Jurkat and DLD- 1 cells after anti-FAS-indu­
ced apoptosis . .  Jurkat and DLD- 1 cells were 
treated with 50 µM MK571, 10 µg/ml OA, 
anti-FAS (0.25 µglml for Jurkat,· 1 µg/ml for 
DLD- 1) and combinations, followed by deter­
mination of the total intracellular glutathione 
concentrations. 
Increased survival of T cells by MRP1 inhibition is not a result of inhibition of 
glutathione export. 
MRP1-dependent export of reduced glutathione (GSH) has previously been 
proposed to aid to anti-Fas induced apoptosis of Jurkat cells (8) We determined 
the cellular GSH concentrations at the peak of apoptosis in anti-Fas-treated Jurkat 
(3 h) and DLD-1 cells (8 h). Untreated Jurkat and DLD-1 cells contain cellular GSH 
concentrations of 190 +/-78 and 114 +/-39 nM/µg protein, respectively. In Jurkat cells, 
anti-Fas alone, or in combination with MK571 or OA, did not significantly change 
the cellular GSH concentration (Figure 6A). Similarly, GSH levels in anti-Fas- or 
MK571-treated DLD-1 cells were comparable to untreated control. Remarkably, OA 
treatment alone leads to a decrease in cellular GSH content (-25% versus control), 
but did not induce apoptosis. DLD-1 cells co-treated with anti-Fas and OA or MK571 
show strongly increased caspase-3 activities (Figure 5), but cellular GSH levels 
were comparable to anti-Fas-treated DLD-1 cells. These data show that anti-Fas­
dependent modulation of apoptosis in Jurkat and DLD-1 cells is independent of 
cellular GSH levels. 
Discussion 
The multidrug resistance-associated protein 1 (MRP1) is strongly expressed in 1) 
mononuclear cells and 2) epithelial cells in the inflamed intestine of patients with I8D. 
We show that MRP1 has opposite roles in modulating anti-Fas-induced apoptosis 
in mononuclear cells and epithelial cells (chapter2 MRP1 sensitizes Jurkat cells for 
anti-Fas-induced apoptosis, while protecting intestinal epithelial DLD-1 cells. This 
opposite effect is particularly relevant for IBD, since currrent therapies are aimed at 
inducing apoptosis in T-cells and recovery of the intestinal epithelium. 
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Apoptosis resistance of T-lymphocytes is a common phenomenon in 180 patients, 
in particular in Crohn's disease patients, as it contributes to the development of the 
disease and negatively affects medical treatment. 
To investigate the function of MRP1 in the apoptotic response of human T-lymphocytes 
we used Jurkat cells as a model cell type. The expression profile of MRPs with an 
overlapping substrate specificity (MRP1 to MRP4) is comparable between human 
T-lymphocytes and Jurkat cells, with MRP1 being the most dominantly expressed. 
This validates the choice of Jurkat cells as a model T-cell line for studying the role of 
T-cell MRPs, and MRP1 in particular. 
We found that pharmacological inhibition of MRP function using several MRP1 
inhibitors strongly decreased anti-Fas-induced apoptosis in Jurkat cells, whereas 
it increased anti-Fas induced apoptosis in DLD-1 cells. The latter observation 
correlates to the results from our previous study (6). MRP1-mediated protection in 
DLD-1 cells was shown to be due to the export of a pro-apoptotic component from 
the leukotriene biosynthesis pathway. In the present study, we also tested whether 
MRP1-dependent export of leukotriene (metabolite )s may be involved in sensitizing 
Jurkat cells to apoptosis. Inhibition of leukotriene synthesis by AA861, either in the 
presence or absence of MRP1-inhibition, did not affect the level of apoptosis (data not 
shown). Therefore, we conclude that such leukotriene(metabolite)s are not involved 
in the MRP1-mediated sensitization of Jurkat cells to anti-Fas induced apoptosis. 
Recently, controversial observations were made regarding the possible role of MRP1 
in anti-Fas-induced glutathione efflux from Jurkat cells, which may be directly linked 
to induction of apoptosis. Franco et al. and Hammond et al. both showed that anti­
Fas treatment of Jurkat cells leads to cellular glutathione efflux (7 ,26). However, 
opposite effects of MK571 treatment were observed. Hammond et al. showed that 
MK571 treatment inhibited the glutathione efflux and decreased anti-Fas induced 
apoptosis. Specific inhibition of MRP1 by RNA interference also reduced the anti­
Fas induced glutathione efflux. They therefore suggested that MRP1 inhibition 
protects Jurkat cells by reducing glutathione efflux. In contrast, Franco et al 
observed that MK571 actually increased anti-Fas-induced glutathione efflux from 
Jurkat cells, leading to a further increase in apoptosis (36). As a consequence, 
they propose that glutathione efflux is not mediated by MRP1, but rather by SLC0/ 
OATP-type transporters. To complicate matters even further, Hentze et al. found that 
glutathione depletion in fact inhibits anti-Fas-induced apoptosis in several 8- and 
T-lymphoblastoid cell lines including Jurkat cells (37). These contradictory results 
may, in part, be a result of different experimental approaches used. Hammond et al 
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present the relative distribution of GSH between cells and the medium after anti-Fas 
treatment. While the relative amount of extracellular GSH increases after anti-Fas 
treatment, the absolute amount of cellular GSH remained unclear. In addition, all 
measurements by Hammond et al were performed in glucose-depleted conditions, 
which might influence the apoptotic response or even induce cell death. Franco 
et al. only determined the intracellular pools of GSH by flow cytometry. In these 
studies, monochlorobimane is added to the cells, that after diffusion into the cells, 
is conjugated to GSH to form fluorescent bimane-glutathione. This conjugate, 
however, is a substrate for MRP1 (38). This complicates the interpretation of these 
results as the cellular levels of bimane-glutathione depend on 1) monochlorobimane 
diffusion rate, 2) GSH conjugation rate by gluthation-S-transferases and 3) MRP­
dependent export of bimane-glutathione. In our studies, we maintained the Jurkat 
and DLD-1 cells in normal growth conditions to observe the most natural reaction to 
anti-Fas treatment. In addition, we measured the absolute intracellular glutathione 
concentration after cell lysis using a spectrophotometric assay. We found no decrease 
in intracellular glutathione concentration during anti-Fas-induced apoptosis in Jurkat 
cells. Glutathione concentrations were also not significantly altered when cells were 
co-treated with anti-Fas and MK571 or oleanolic acid. Oleanolic acid treatment 
alone, however, did show a trend towards decreasing intracellular glutathione 
concentrations which correlates to the transactivation of GSH efflux by MK571 
treatment, as observed by Franco et al. 
Since apoptosis is an essential process in the removal of activated T-cells and 
therefore important in the regulation of the immune response (reviewed in (3)), 
failure to express MRP1 or low MRP1 expression could lead to apoptosis-resistant 
T-lymphocytes. In this respect, it is relevant to note that MRP1 expression in 
lymphocytes from I8D patients in clinically non-active disease showed strong 
variation. In contrast, MRP1 levels in T-lymphocytes from healthy controls were 
highly comparable between individuals. However, for the I8D patients included in 
this study, MRP1 expression levels did not correlated to either the disease score or 
specific medication. 
In this study, we show that MRP1 is expressed exclusively in CD4-positive T cells 
compared to CDS-positive T cells. Previous studies have indicated that MRP1 
expression in CD4 positive T-cells is increased during activation and in addition, 
that MRP1 inhibition alters the cytokine profile. Since CD4-positive T-cells produce 
(apoptotic) cytokines during inflammation, the MRP1 expression could have several 
functions. It might be involved in the export of the cytokines from the cell and/or it 
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provides a mechanism for apoptosis to regulate the inflammatory response. 
Our previous studies indicate a cytoprotective function of MRP1 in intestinal epithelial 
cells. These two studies combined indicate a dual role for MRP1 in modulating 
apoptosis, which is particularly relevant during intestinal inflammation. Increased 
levels of MRP1 in the intestinal epihelium reduces tissue damage via anti-Fas­
induced apoptosis, whereas the important target of ! BO-therapy, the T-lymphocytes, 
become more sensitive to apoptosis. Upregulation of intestinal MRP1 expression 
could therefore, be considered as a treatment option for patients with active 
inflammatory bowel disease. However, further studies to investigate the clinical 
application are necessary. 
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Mrp 1 is not required for hepatocyte- and hepatic progenitor 
cell-dependent liver regeneration in mice. 
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gen, University of Groningen, Groningen, The Netherlands. 
Abstract 
Hepatic progenitor cells (HPCs) and bone marrow stem cells contribute to liver 
regeneration when hepatocyte proliferation is compromised, e.g. during severe liver 
injury. The multidrug resistance-associated protein 1 (MRP1) is expressed in HPCs 
as well as in bone marrow nuclear cells (BMNCs). Recently, we found that MRP1 
provides cellular protection against cytokine-induced apoptosis. Induced expression 
of MRP1 was observed in the regenerative compartment of both the intestinal 
epithelium in the inflamed mucosa of patients with inflammatory bowel disease and 
the liver of patients with diseases associated with hepatic inflammation. Thus, MRP1 
may protect stem cells to allow tissue regeneration in pathophysiological conditions. 
The aim of this study was to determine whether Mrp1 is required for stem cell­
dependent liver regeneration in mice. 
Mrp1-/- mice and wild type control mice were subjected to 70% partial hepatectomy 
(pHx) in the presence or absence of 2-acetylaminofluorene (2-AAF) to block 
hepatocyte proliferation. Liver regeneration was monitored by liver weight recovery. 
Hepatic expression of genes encoding Mrp's and stem cell markers (alpha­
fetoprotein-AFP) was determined by quantitative PCR. Cell proliferation was 
analyzed by immunohistochemical microscopy after Ki-67 staining. 
Three days after 70% pHx, liver weight in wild type and Mrp1-/- mice was 85% of the 
pre-operative liver mass, independent of the 2-AAF treatment. 2-AAF treatment lead 
to a strongly increased AFP expression in PHx-treated wild type mice, which was not 
observed in Mrp1-/- mice. 2-AAF treatment increased the number of Ki-67 positive 
cells to a similar level in the livers of pHx-treated wild type and Mrp1-/- mice. Mrp3 
expression was significantly increased in untreated Mrp1-/- mice compared to wild 
type controls. ,  but was comparable in the 2-AAF/pHx-treated groups. 
Stem cell activation is compromised in Mrp1-/- mice, but does not affect liver 




The liver plays an important role in glucose, fat and vitamin metabolism as well as in 
detoxification and in immune responses. Liver diseases are therefore associated with 
a variety of symptoms. For most functions, the liver has a significant overcapacity. 
Symptoms demonstrate only when the liver suffers from major injury. Liver disease is 
potentially reversible as the liver has the capacity to regenerate after loss of functional 
tissue. This maintains liver function and repair during diseases such as liver fibrosis, 
viral hepatitis or alcohol and drug toxicity (1 ). Moreover, it allows the regrowth of the 
liver after surgical procedures such as tumor resection or liver transplantation. 
Cell renewal in the healthy liver is very limited. Hepatocytes are the functional liver 
cells and make up over 80% of the liver. Under normal conditions, only 1 in 20.000-
40.000 hepatocytes divides. However, when liver mass is lost, hepatocytes re-enter 
the cell cycle and start to proliferate until the liver is restored to its original size. 
This is a very efficient and fast process when no complicating factors are present. 
Removal of 70% of the liver in mice or rats is fully compensated in 7-10 days in which 
the liver regrows to its original size (2). In many liver diseases, however, hepatocyte 
proliferation is compromised due to the increased levels of cytotoxic factors, such as 
cytokines, bile salts and reactive oxygen species (ROS). Liver regeneration can still 
occur under such conditions through the activation, proliferation and differentiation 
of liver- and/or bone marrow-derived stem cells. Liver-specific stem cells, also 
called hepatic progenitor cells (HPCs) or oval cells, are bipotent cells that can 
differentiate into functional hepatocytes and cholangiocytes (bile canaliculi epithelial 
cells) (3,4) and are located in the canals of Hering where the bile canaliculi merge 
into interlobular bile ducts. Activation of HPCs/oval cells is morphologically detected 
as ductular reactions. Liver damage has also been shown to induce hepatic gene 
expression profiles in bone marrow cells (5) and mesenchymal stem cells (MSCs) 
and hematopoietic stem cells can transdifferentiate to hepatic cell lineages in vitro 
and repopulate the damaged liver in vivo (recent reviews by (6-8)) 
Our earlier studies have shown the induction of specific multidrug resistance-type 
ATP-binding cassette (ABC) transporters in HPCs in regenerating rat liver, as well 
as in livers from patients with primary biliary cirrhosis and chronic viral hepatitis C 
(9, 10). Specifically, multidrug resistance protein 1 (MDR1/P-glycoprotein), multidrug 
resistance-associated protein 1 (MRP1) and MRP3 were strongly induced. These 
proteins have been shown to protect ( cancer) cells against a wide variety of 
structurally unrelated drugs and endogenous metabolites. Of particular interest is the 
induction of MRP1, which transports phase-2 metabolites (glutathione-, sulphate-
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and glucuronide-conjugates)(11 ), glutathione (12) and the pro-inflammatory cytokine 
leukotriene C4 (LTC4) (13). In the injured liver, MRP1 is expressed in HPCs as well 
as in activated hepatic stellate cells that cause fibrosis (14) The level of MRP1 in 
hepatocytes is low. Notably, MRP1 is also significantly expressed in Sea+ and/ 
or c-kit+ mouse HSCs (15). The presence of MRP1 in stem cells and its induction 
in liver disease suggest that this protein may have additional functions, besides 
its well-known drug transporting activity. Recently, we found that MRP1 provides 
cytoprotection to intestinal epithelial cells against cytokine-induced apoptosis (16). 
MRP1 expression was specifically detected in the regenerative compartment of the 
intestinal epithelium. Similarly, MRP1 may protect HSCs and HPCs against cytotoxic 
factors that accumulate during liver disease so that the liver can regenerate from 
these cells. 
In this study, we analyzed the functional relevance of Mrp1 during liver regeneration 
in mice, specifically under conditions where hepatocyte proliferation is blocked. Wild 
type and Mrp1-/- mice were subjected to 70% partial hepatectomy in the absence and 
presence of 2-acetylaminofluorene (2-AAF), which selectively inhibits hepatocyte 
proliferation (5, 17) 
Materials and methods 
Animals 
Five to eight week-old Mrp1-/- (FVB.129P2-Abcc1atm1Bor N1) mice and their wild­
type counterparts (FVB/Ntac) were obtained from Taconic farms (Denmark). Animals 
were kept in a 12 hour light/dark regime and were fed standard chow and water 
ad libitum. The animal experiments were approved by the ethics committee of the 
medical faculty of the University of Groningen (D4757). 
2-MF treatment and partial hepatectomy 
2-Acetylaminofluorene (2-AAF, Sigma-Aldrich Chemie B.V., Zwijndrecht, The 
Netherlands) was dissolved in DMSO (200 mg/ml, Sigma-Aldrich Chemie B.V., 
Zwijndrecht, The Netherlands). Mice were injected with 30 mg/kg 2-AAF (WT, n=10; 
Mrp1-/-, n=10) or vehicle (corn oil/5% DMSO, Sigma-Aldrich Chemie B.V.) (WT, 
n=1 O; Mrp1-/-, n=10) daily for 7 days. Subsequently, sham or partial hepatectomy 
(pHx) was performed as described (18), generating 8 treatment groups of n=5. 
Briefly, animals were anaesthetized using isoflurane. The abdomen was opened and 
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a suture was applied proximal to the liver lobe. The lobe was removed as close as 
possible to the suture. This process was performed for all anterior lobes, resulting 
in ± 70% pHx. A final dose of 2-MF or vehicle was administered into the peritoneal 
cavity, followed by closure of peritoneum and skin. 2,5 ml of saline (37°C), was 
injected subcutaneously to compensate for fluid loss during the surgery. Animals 
were kept in a recovery incubator during the first night after pHx or sham operation. 
Buprenorphine (0,05 mg/kg) was administered subcutaneously 12 h and 24 h after 
surgery. The animals were sacrificed 72 hours after surgery. The liver was removed, 
weighted and samples were stored in liquid nitrogen or fixed in 4% formaldehyde. 
AST/ALT determination in blood 
Blood was stored in EDTA-containing tubes (Greiner Bio-one, Kremsmunster, 
Austria). Plasma was obtained by centrifugating the blood samples for 15 minutes 
at 10,000 rpm. AST and ALT enzyme concentrations were determined using the 
Spinreact GOT and spinreact GPT kit according to the manufacturer's instructions 
(Spinreact, Girona, Spain). 
RNA isolation and quantitative PCR 
Total RNA was isolated using the TRlzol isolation method (lnVitrogen Life 
Technologies, Breda, The Netherlands) according to the manufacturers instructions. 
cDNA was synthesized in a final volume of 50 µI as described before (16). Messenger 
RNA (mRNA) levels of 18S, Mrp1 to Mrp7 and alpha-fetoprotein (AFP) were 
quantified using the ABI PRISM 7700 (Applied Biosystems, California, USA). Real­
time conditions were as previously described (10). For quantification of mRNA levels, 
the difference was calculated between the gene of interest and the housekeeping 
gene 18S. This delta Ct was corrected to a linear scale (2-b.Ct) to obtain a relative 
amount of mRNA compared to 18S. Real time primers and probe sequences are 
shown in Table 1. 
lmmunohistochemistry 
lmmunohistochemistry for Ki-67 was performed on 4 µm-thick slices of paraffin 
embedded tissues. Antigen retrieval was performed using 1 OmM citrate buffer (pH 6,0). 
Slides were stained with the rat anti-mouse Ki-67 monoclonal antibody (dilution1 : 50; 
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Table 1: realtime Primers and probes 
Gene Primer/Probe 



























Mdr1 a Forward 
Reverse 
Probe 









5' FAM-CGCGCAAATTACCCACTCCCGA-TAMRA 3' 
5'-TGAAACAGAGAAGGAGGCTCCT'-3' 
5'-AGGCAGTAATCCCGGAACTCTA-3' 






5' FAM-CACCAGTGTCATTCGGGCCTATGG C-TAMRA 3' 
5'-GCCGACATCTACCTCCTTGAT G-3' 
5'-CGTGCAACGCCTGACAGA-3' 
5' FAM-CCCACTTCTGCATCGACAGCGCT-TAMRA 3' 
5'-CGGAGAACAAGATCGTTGGAAT-3' 
5'-CAGGGAAAGCCCCTCAACTC-3' 
5' FAM-CCAAGATGCTCTCGAAACAGCAGCCC-TAMRA 3' 
5'-CCACAGGATTGACAGCAGAAGA-3' 
5'-CGCAGGTAGCTCAGGTATATGGT-3' 
5' FAM-TCTTCACCCGGCCATATCGCACAC-TAMRA 3' 
5'-GGGGCCACTTACAGGTTTGA-3' 
5'-ATCGTGGCATAGGAAGCAAACT-3' 
5' FAM-AACCAGCGACTCTTGGAGCTGAACCA-TAMRA 3' 
5'-GCTCAGTACGACAAGGTCGTTCT-3' 
5'-TGGATGCTCTCTTTGTCTGGAA-3' 
5' FAM-TCCTCCTTGTTGTCAGCTTTGCAGCA-TAMRA 3' 
5'-GCAGGTTGGCTAGACAGGTTGT-3' 
5'-GAGCGCCACTCCATGGATAA-3' 
5' FAM-AGCAGCCAGAGTTCCCACCAGCATG-TAMRA 3' 
5'-GCTGGACAAGCTGTGCATGA-3' 
5'-TGGCAGAATACTGGCTTCTGCT-3' 
5' FAM-CTTCCCCTCTTGATGCTGGTGTTTGGAAAC-TAMRA 3' 
5'-GCAGCGAGAAACGGAACAG-3' 
5'-GGTTGCTGATGCTGCCTAGTT-3' 
5' FAM-AAAGTCGCCGTCTAGGCGGCGCCGT-TAMRA 3' 
Dako Cytomation, Denmark A/S Glostrup ), the secondary antibody polyclonal 
rabbit anti-rat immunoglobulin/HRP (dilution 1 :50; Dako Cytomation, Denmark A/S 
Glostrup) and tertiary antibody polyclonal goat anti-rabbit immunoglobulins/HRP 
(dilution 1 :50; Dako Cytomation, Denmark A/S Glostrup ), followed by 10 minute 





Experiments were performed in triplicate and analyzed by Student's t-test or Kruskall­
Wallis and Mann-Whitney tests. All statistical tests were performed in SPSS v14.0 
for Windows. Significance was defined as p<0,05. 
Results 
Compensatory Mrp expression profile in Mrp 1 knockout mice 
We first determined the relative mRNA levels of Mdr1 a, 1 b, 2 and Mrp1-7 in the livers 
of wild type and Mrp1-/- mice to identify putative compensatory mechanisms induced 
by the absence of Mrp1 (Figure 1 ). Mrp2 is the most dominantly expressed Mrp in 
the liver of wild-type mice. Significant levels of Mdr2, Mrp3, 6 and 7 mRNAs are 
also detected, but are substantially lower than Mrp2. Mrp1, Mrp4, Mrp5, Mdr1 a and 
Mdr1 b expression is low. The absence of Mrp1 does not result in strong changes 
in the hepatic Mdr/Mrp expression profile, except for Mrp3, which is significantly 
increased (1.9-fold) compared to wild type mice. In addition, the low levels of Mdr1 b 
in wild type mice are further decreased in Mrp1-/- mice. 
















Mrp1 Mrp3 Mrp4 Mrp5 Mrp6 Mrp7 l'v'dr1 a l'v'dr1b l'v'dr2 Mrp2 
• wild type o Mrp1 _,_ 
Figure 1. Mrp expression profile in wild type and Mrp 1-knockout mice. Relative mRNA 
expression was determined by Q-RT PCR in liver of vehicle/sham treated mice (both wild 
type and Mrp 1-/-). Expression was normalized to 1 BS expression and represented as the 
relative mRNA expression (2'1-.tJCt). Data represent means + SD (n=5). * p < 0,05 vs 
wild type. # p < 0, 01  vs. wild type. Significance was determined by Mann-Whitney test 
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Bodyweight recovery after partial hepatectomy is not influenced by 2-AAF treatment 
or the absence of Mrp 1 .  
The dynamics of liver regeneration in the presence of 2-MF (hepatocyte proliferation 
blocker) and/or the absence of Mrp1 has not been studied before in mice. Therefore, 
we next determined whether mice survived 70% pHx in combination with 2-MF 
treatment and/or Mrp1-deficiency. Bodyweight of the animals was monitored after 
surgery. Both wild type and Mrp1-/- mice survived combined 2-MF/pHx-treatment 
at least up to day 3 after surgery. Sham operation caused a comparable weight 
loss in wild type and Mrp1-/- mice of approximately 5% at day one, after which the 
body weight stabilized (Figure 2A and B). Wild-type mice that underwent pHx lost 
more weight (corrected for explant weight) compared to sham operated mice. This 
difference was significant at day two after surgery both for vehicle-treated (sham 
93.4% +/- 1.9 and pHx 87.5% +/- 2.3) as well as 2-MF-treated mice (sham 92.2% 
+/- 2.3 and pHx 88. 7% +/- 1.4 ). At day 3, pHx-treated wild-type mice had regained 
weight and the bodyweight was similar to sham-operated animals, both in the 
vehicle- and 2-MF-treated group. 
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Figure 2. Body weight of mice aher sham or hepatectomy operation. Mice were weighed 
before and daily aher sham operation or hepatectomy. Body weight before partial hepa­
tectomy was set to 100%. The weight was corrected for the mass of the removed liver 
tissue. The relative body weight was determined daily for both wild type (A) and Mrp 1-l­
(B) mice. Data represent means +/- sd (n=S). # p<0, 05 vehicle/sham vs. vehiclelpHx,· t 
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Figure 3. AST and AL T concentrations in blood 3 days after pHx. To analyze liver dama­
ge, AL T and AST levels in blood were determined Data show means + sd (n=S, except 
WT 2-AAF/sham n=4). # p < 0, 05 vs. sham treated group. t p < 0,01  vs. sham treated 
group. Statistics determined by T-test 
bodyweight loss at day 2, however, the difference to sham-operated Mrp1-/- mice 
was not significant (p=0.70) (Figure 2B). In contrast, 2-MF/pHx-treated Mrp1-/­
mice lost significantly more body weight compared to sham- (p=0.001 at day 2) or 
2-MF- (p=0.01 at day 2) treated animals. In contrast to 2-MF/pHx-treated wild type 
mice, the body weight of the 2-MF/pHx-treated Mrp1-/- mice did not recover at day 
3. These data suggest that Mrp1 is required for post-pHx recovery of mice when 
hepatocyte proliferation is blocked. 
The absence of Mrp 1 does not increase liver damage after pHx. 
Serum aspartate transferase (AST) and alanine transferase (ALT) levels were 
analyzed at 3 days after pHx to determine whether the absence of weight gain in 
the 2-MF/pHx-treated Mrp1-/- mice was associated with increased liver damage 
(Figure 3). A minor, but significant increase in AST levels was detected in pHx-treated 
mice, which was similar for WT and Mrp1-/- mice (Figure 3A). 2-MF co-treatment 
did not further increase the AST levels in either group. A similar trend was observed 
for ALT (Figure 3B ). Thus, the absence of body weight gain in the 2-MF/pHx-treated 
Mrp1-/- mice is not associated with increased liver damage at day 3. 
The absence of Mrp 1 does not reduce liver regrowth after pHx 
To establish whether Mrp1 is directly involved in HPC-mediated recovery of liver 
mass, we determined the liver weight:body weight ratios of all 8 groups (+/- Mrp1; 
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Figure 4. Liver weight recovery after partial hepatectomy. Mice were weighed directly 
before surgery. The removed liver mass was weighed directly after removal. The liver 
to body weight ratio was calculated to determine the relative amount of liver removed 
during surgery (A). This procedure was repeated at the time of sacrifice to determine the 
normal liver to weight ratio in sham operated animals and the liver to weight ratio after 
3 days of liver regeneration (B). # p < 0, 05 versus sham treated animals, t p < 0. 0 1  vs. 
sham treated animals. Significance was determined by Mann-Whitney test 
+/- 2-MF; +/- 70% pHx) of mice at day 3 after surgery (Figure 4 ). As a result of 
70% pHx, both wild type and Mrp1-/- mice lost 3.5% of the total body weight (Figure 
4A). At day 3 after surgery, vehicle/sham- and 2-MF/sham-treated wild-type mice 
had similar liver to bodyweight ratios (5.42 +/- 0.13 and 5.38 +/- 0.12, respectively) 
(Figure 48). Comparable liver to bodyweight ratios were detected for the sham­
operated Mrp1-/- mice (vehicle/sham: 5.44 +/- 0.24 and 2-MF/sham: 5.47 +/- 0.37). 
Animals that had undergone 70% pHx had significantly reduced liver tissue at day 3 
post-pHx compared to sham-treated animals. However, no difference was observed 
between pHx-treated wild type and Mrp1-/- mice with or without 2-MF cotreatment 
(WT: vehicle/pHx 4.72 +/- 0.26 and 2-MF/pHx 4.49 +/- 0.28; Mrp1-/-: vehicle/pHx 
4.66 +/- 0.42 and 2-MF/pHx 4.60 +/- 0.46). In all 4 pHx-treated groups, the liver 
weight at day 3 after surgery was restored to approximately 85% of the original 
liver weight (WT: vehicle/pHx 87.2 +/- 4.7% and 2-MF/pHx 83.4 +/- 5.2%; Mrp1-/-: 
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Figure 5. Hepatic progenitor cell 
activation is negatively affected in 
Mrp 1-knockout mice. To analyze 
progenitor cell activation the alpha 
fetoprotein (AFP) mRNA expressi­
on was determined by Q-RT PCR. 
Expression was normalized to 18S 
expression and represented as re­
lative mRNA expression (2A-L'.J Ct). 
Data show means + sd (n=5). # 
p < 0, 05 vs. sham treated group. 
t p < 0, 05 vs. vehicle/pHx treated 
group. Statistics determined by 
Mann-Whitney test. 
Mrp 1 deficiency blocks alpha-fetoprotein induction in pHx/2-AAF-treated mice. 
Messenger RNA levels of alpha fetoprotein (AFP) were determined as a marker for 
stem cell activation/differentiation in the livers of all 8 treatment groups (Figure 5) 
(19). As expected, AFP expression was low in sham operated wild-type and Mrp1-
/- mice and 2-MF treatment did not affect its expression. AFP expression was 
significantly increased in livers at day 3 in PHx-treated animals and to a similar level 
in wild type and Mrp1-/- mice. Combined treatment of 2-MF and pHx resulted in a 
strong 3.8-fold increase in AFP expression in wild type mice compared to pHx alone. 
In contrast, 2-MF treatment did not increase AFP expression in pHx-treated Mrp1-
/- mice, indicating a lack of HPC activation in these mice. 
Increased numbers of Ki-67 positive cells in wild type and Mrp 1 -/- livers 3 days after 
2-AAF/pHx-treatment 
Surprisingly, neither 2-MF nor the absence of Mrp1 resulted in decreased liver 
regrowth at day 3 after pHx, even though AFP expression was clearly affected. To 
determine whether the number of proliferating cells at that time point is different in 
one or more of the 8 treatment groups, Ki-67 immunohistochemistry was performed 
on liver sections. The Ki-67 antigen is present in all stages of the cell cycle except 
for the GO phase. As expected, no Ki-67 positive cells were detected in livers from 







Figure 6. Proliferation is increased after combined 2-MF treatment and partial hepatecto­
my. To determine which cells were proliferating in regenerating liver, Ki-67 staining was per­
formed liver slices from partial hepatectomy (A, C, E, G) or sham (B, D,F,H) operated animals. 
Staining was performed on liver slices obtained from both wild type animals (A-D) as well as 
Mrp 1-1- (E-H) animals treated with vehicle (A-8, E-F) or 2-MF (C-D, G-H). Representative 
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Figure 7. Proliferation is not af­
fected by Mrp 1 knockout To de­
termine the number of proliferating 
cells in regenerating liver, the Ki-
67 staining were quantified. Ki-67-
-positive and -negative cells were 
counted in 3 representative fields 
per stained slide, correlating with 
+/- 570 counted cells per slide. # p 
< 0, 001,· N S.  not significant Signi­
ficance was determined by Mann­
Whitney test (n=5 per condition). 
6A, C, E, G). In contrast, Ki-67 positive cells were readily detectable in vehicle/pHx­
treated mice, both wild type and Mrp1-/-, indicating that the regenerative process 
was ongoing. Ki-67 positive cells were detected throughout the liver parenchyma 
(Figure 68, F). The number of Ki-67 positive cells was more pronounced in livers 
from 2-AAF/pHx wild type and Mrp1-/- mice (Figure 6D, H). Ki-67 positive cells were 
detected throughout the liver but appeared slightly concentrated in the pericentral and 
periportal regions. The number of Ki-67 positive cells were quantified in representative 
fields (Figure 7). The percentage of Ki-67 positive cells was comparable in pHx­
treated wild type and Mrp1-/-mice (16.6 +/- 5.7% and 20.1 +/- 5.5%, respectively). 
2-AAF treatment strongly increased the number of Ki-67 cells in pHx-treated wild 
type and Mrp1-/- mice, but no significant difference was detected between these 
groups (wild-type 33.5 +/- 3.3% and Mrp1-/- 31.1 +/- 7.6%). lmmunohistochemical 
staining for active caspase-3 was negative in all groups, to exclude the possibility 
that the 2-AAF-induced proliferation was due to increased apoptotic cell death (data 
not shown). 
MRP expression during liver regeneration. 
Basal Mrp3 expression is increased in the livers of Mrp1-/- mice (Figure 1 ). As 
Mrp1 and Mrp3 transport similar substrates, they may compensate for each other. 
Therefore, we next determined whether pHx, either alone or in combination with 
2-AAF treatment, affects hepatic expression of Mrp's and Mdr's in wild type and Mrp1-
/- mice, as described before in rats (10). Quantitative real-time PCR was performed 
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Figure 8. Hepatic Mdr and 
Mrp expression profiles during 
liver regeneration. To deter­
mine the expression profiles 
of Mdr 1 ,  Mdr2 and Mrp 1 to 
Mrp 7 during liver regenera­
tion, mRNA expression was 
determined by Q-RT PCR. 
Expression was normalized to 
18S expression and represen­
ted as the relative mRNA ex­
pression (21\-LlCt). Data show 
means + sd (n=5). * p < 0,05 
vs. sham treated group. t p < 
0, 05 vs. vehicle/pHx treated 
group. Significance was deter­
mined by Mann-Whitney test. 
Mdr1 b expression is increased after pHx compared to sham-treated animals, both 
in the vehicle- as well as in the 2-AAF-treated group. In addition, Mdr1 b expression 
was significantly increased after combined 2-AAF/pHx-treatment compared to pHx­
treated animals. Surprisingly and in contrast to rats, Mrp3 expression was decreased 
in 2-AAF/pHx-treated wild-type mice compared to sham-operated and pHx-treated 
wild type mice. Moreover, expression of Mrp1 was relatively low in all treatment 




In Mrp1-/- mice, expression of all investigated genes remained the same in the 4 
treatment groups, except for Mrp3. pHx reduced Mrp3 expression compared to 
sham operated animals and 2-MF treatment did not affect Mrp3 expression. 
When wild type and Mrp1-/- mice are compared, differential regulation of Mdr1 a, 
Mdr1 b and Mrp3 is observed. Mdr1 a and Mdr1 b expression is induced in pHx-treated 
wild type mice, but not in Mrp1-/- mice. Mrp3 expression remains unchanged in 
pHx-treated wild type mice, but is reduced in pHx-treated Mrp1-/- mice. In contrast, 
Mrp3 is reduced in 2-MF/pHx-treated wild type mice and is unchanged 2-MF/PHx­
treated Mrp1-/- mice. 
Discussion 
In this study, we show that in mice Mrp1 is required for the induction of alpha­
fetoprotein during liver regeneration when hepatocyte proliferation is blocked by 
2-MF. This suggests that Mrp1 is required for activation of stem cells to regenerate 
liver mass. However, 3 days after pHx, liver mass recovery was similar in pHx/2-
MF-treated wild type and Mrp1-/- mice. This implies the existence of hepatocyte­
and alpha-fetoprotein-independent mechanisms that contribute to liver regeneration 
in mice. 
MRP1 was previously shown to be highly expressed in the hepatic stem cell 
compartment in human liver disease (9), which is morphologically detected as a 
ductular reaction. Similarly, high levels of Mrp1 were observed in the hepatic stem 
cell compartment in hepatectomized rats exposed to 2-MF (10), which blocks 
hepatocyte proliferation. Following our observation that MRP1 expression is also 
increased in the regenerative compartment of the inflamed intestine and that it 
provides protection against cytokine-induced cell death (16), we aimed to determine 
here its role in stem cell-dependent liver regeneration. 
First, we compared the hepatic Mrp/Mdr expression profile in wild type and Mrp1-/­
mice to assess possible compensatory regulatory mechanisms due to the absence 
of Mrp1. The "basal" Mrp/Mdr-expression profile was similar in wild-type and Mrp1-
/- mice. Significant differences were only observed for Mrp3 and Mdr1 b. Absence 
of Mrp1 leads to an increased expression of Mrp3. Structurally, Mrp3 is the closest 
homolog of Mrp1, which is reflected in an overlapping substrate specificity (e.g. LTC4, 
glutathione) (20). It is therefore likely that increased Mrp3 expression compensates 
for the absence of Mrp1 under normal conditions. The expression of hepatic Mdr1 b 
is significantly lower in Mrp1-/- mice compared to wild-type animals. However, the 
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levels of Mdr1 b in wild type murine liver are already very low. Therefore, the relevance 
of the decrease in Mdr1 b expression is questionable, although it could represent 
effects in a low-abundant cell type in the liver. This needs further investigation. 
Next, we exposed wild type mice to 70% hepatectomy in the absence and presence 
of 2-MF. On average, the remaining liver mass was reduced to 35% during partial 
hepatectomy. 3 Days after surgery, the livers had regrown to approximately 85% of 
normal liver weight (e.g. sham-operated animals), which correlates well with previous 
studies (2,2) Notably, regain of liver mass was similar in the presence of 2-AAF. 
2-MF is metabolized by hepatocytes and sulphate-conjugated metabolites block 
hepatocyte proliferation at the G 1 /S phase transition (21-23 ). Liver regeneration then 
depends on activation and differentiation of stem cells. However, strong ductular 
reactions were not detected in pHx/2-MF treated mice in our study. This is in line 
with recent data reported by Jelnes et al (24 ). A side-by-side comparison of the 
pHx/2-MF model in rats and mice revealed a lack of ductular reactions in mice, 
whereas it was strongly induced in rats. Still, it has been shown by others that 2-MF 
inhibits hepatocyte proliferation in hepatectomized mice also (5). Approximately 70% 
of the hepatocytes were Ki-67 positive 2 days after pHx, while only 15% were Ki-67 
positive in the pHx/2-MF livers. Three days after pHx, we detected the opposite 
balance of Ki-67 positive cells comparing pHx- (17% Ki-67 positive cells) and pHx/2-
MF-(34% Ki-67 positive cells) treated wild type mice. Peak hepatocyte proliferation 
is normally detected 1-2 days after pHx (25,26) and this may explain the relatively 
low number of Ki-67 positive cells 3 days post pHx. The increased number of Ki-67 
positive cells in pHx/2-MF treated mice may arise from stem cells (from hepatic or 
extrahepatic origin) that start to proliferate in response to the block of hepatocyte 
proliferation. However, the interpretation of the Ki-67 staining may also be troubled 
by the fact that 2-MF causes a block of cell division in the G1/S phase. Such cells 
may also appear as Ki-67 positive cells. Still, 3 days after pHx, the number of Ki-
67 positive cells is significantly higher in 2-MF treated mice, either indicating a 
delayed peak of liver regeneration or an effective block of hepatocyte proliferation. 
Irrespective of the cellular effect, liver mass recovery at day 3 was similar in pHx and 
pHx/2-MF treated wild type mice. 
The observation that AFP expression is strongly increased in pHx/2-MF treated 
mice suggests the participation of stem cells in the regeneration process. Jelnes 
et al. suggested that also proliferating mouse hepatocytes may express low levels 
of AFP (24). Indeed, we observed increased AFP expression in regenerating livers 
in the absence of 2-MF. However, the AFP was significantly super-induced (4-
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fold) in pHx/2-MF treated mice, strongly suggesting the involvement of stem cells. 
Remarkably, the 2-MF-mediated super-induction was completely absent in Mrp1-/­
mice. Thus, Mrp1 is required for induced AFP expression in the liver when hepatocyte 
proliferation is blocked. The question remains, what is the origin of the cells that 
are responsible for liver regeneration in pHx-2-MF treated Mrp1-/- mice. Ductular 
reactions are not evident in Mrp1-/- or wild type mice. Stem cells may be recruited 
from the bone marrow to the liver to aid to liver regeneration. Bone marrow cells 
have been shown to obtain a hepatic gene expression profile in pHx/2-MF treated 
mice (5) and Mrp1 activity has been detected in mouse bone marrow stem cells (15). 
However, AFP was clearly induced in these bone marrow cells (5), which was not 
detected in the pHx/2-MF treated Mrp1-/- mice in our study. As the liver regrowth is 
not significantly reduced in these mice, the AFP-negative cells responsible for this 
phenomenon remain to be identified. The pHx/2-MF-treated Mrp1/- mice recover 
badly from pHx, as shown by the lack of body weight gain between day 2 and 3. Still 
expression of typical hepatocyte markers genes (Mrp2, Mdr2, HNF4a-not shown) 
was similar in all 8 animal/treatment groups, indicating the presence of similar 
numbers of functional hepatocytes at day 3 after pHx. It is remarkable, though, that 
no induction of Mrp1 mRNA was observed in pHx/2-MF treated wild type mice. 
This is in contrast to earlier observations of increased levels of Mrp1 and Mrp3 in 
stem cell-based liver regeneration in rats and humans (9, 10). For Mrp3, we even 
detected lower expression levels in pHx/2-MF-treated wild type mice compared 
to pHx-treated animal. This suggests that regulation of Mrp expression during liver 
regeneration is species specific and/or time dependent. 
Taken together, this study suggests that there are several redundant mechanisms 
involved in the regeneration of liver mass, including one in mice that is independent 
of hepatocyte proliferation and induction of the stem cell marker alpha fetoprotein. 
Footnotes 
The authors would like to thank Andre Zandvoort, Michel Weij and Annemiek Smit­
Van Oosten for performing the partial hepatectomy. 
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MRP1 expression in human intestinal and hepatic epithelial 
cells is not suppressed by PPARa 
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Abstract 
The multidrug resistance-associated protein 1 (MRP1) is an important drug target to 
treat cancer, but also for inflammatory bowel disease and liver fibrosis. Therefore, 
it is important to understand the mechanisms that regulate MRP1 expression to 
explore possibilities for MRP1-directed therapy. Until now, very little is known about 
the transcriptional regulation of human MRP1. Recent data indicate that intestinal 
expression of mouse Mrp1 is suppressed by the peroxisome proliferator-activated 
receptor alpha (PPARa). PPARa acts in concert with the Retinoid X receptor-alpha 
(RXRa) to regulate fatty acid metabolism. The activity of PPARa and RXRa is 
controlled by selective ligands. Several pharmaceutical compounds activate PPARa 
and are used in the treatment of hypercholesteremia. 
In this study, we aimed to determine whether PPARa regulates human MRP1 
expression in intestinal and liver epithelial cells. 
The human colon carcinoma cell lines DLD-1 and Caco-2 and the human hepatoma 
cell line HepG2 were exposed to PPARa (WY14,643 and GW7647) and/or RXRa 
agonists (9-cis retinoic acid; 9cRA), in the absence and presence of transiently­
transfected PPARa /RXRa. MRP1 expression was determined by quantitative PCR, 
western blot analysis and immunofluorescence microscopy. 
Significant expression of PPARa and MRP1 is detected in DLD-1, Caco-2 and HepG2 
cells. WY14,643 and GW7647 induced expression of well-established PPARa target 
genes (CPT1A and HMG-CoA), but did not change MRP1 mRNA levels. MRP1 
expression was not affected by PPARa overexpression, 9cRA treatment significantly 
reduced MRP1 expression in HepG2 (-77%) and DLD-1 (-57%) cells. The 9cRA­
mediated suppression of MRP1 was attenuated by WY14,643 and GW7647. 
Our results show that human MRP1 is not regulated by PPARa. In contrast, MRP1 




The multidrug resistance-associated protein 1 (MRP1 /ABCC1) is a 190 kDa 
membrane-bound protein. It is a member of the ATP-binding cassette (ABC) 
transporter superfamily and exports a wide range of endo- and exogenous 
compounds out of cells . 
MRP1 was discovered in 1992, when its corresponding gene (now called ABCC1) 
was cloned and shown to confer resistance to the lung cancer cell line H69AR against 
doxorubicin (1 ). Further characterization of MRP1 revealed that it belongs to the 
same family of proteins as the multidrug resistance protein 1 (MDR1/ABCB1/Pgp), 
a protein that is absent in highly drug resistant H69AR cells. MRP1 is a genuine 
multidrug transporter as it has been shown to confer resistance to a wide variety 
of anti-cancer drugs, including Vinca-alkaloids (2), anthracyclines, etoposide (3,4 ), 
platinum based drugs (2) and epipodophyllotoxines (reviewed in 2,6) 
In addition to its function in drug resistance, substantial evidence demonstrate an 
important physiological function of MRP1 as well. MRP1 transports endogenous 
compounds like the pro-inflammatory molecule leukotriene C4 (5), glutathione-, 
sulphate- (6) and glucuronide- (7) conjugates and (oxidized) glutathione (GSSG + 
GSH). It is present in specific cell types throughout the body. MRP1 is present in 
epithelial cells of the blood brain barrier, kidney and testis. Furthermore, relatively 
high MRP1 levels are found in (activated) murine and human T-helper cells (8,9), 
in organ-specific stem cells in the intestine (10) and liver (11, 12) and in activated 
hepatic stellate cells that cause liver fibrosis (13). Recent data suggest an important, 
but paradoxal function for MRP1 in controlling cell survival during inflammatory 
conditions. MRP1 was shown to sensitize T lymphocytes for anti-Fas-induced 
apoptosis (14-16), while it protects intestinal epithelial cells under these conditions 
(10). The dichotomal effect may be a direct effect of cell type-specific production of 
compounds that are transported by MRP1. The regulation of MRP1 transcription 
and/or function is therefore of significant therapeutic value as it may dampen an 
overactive immune system and at the same time prevent excessive organ damage. 
Unfortunately, very little information is available about the transcriptional and post­
translational regulatory mechanism that control MRP1. Most data are obtained by 
analyzing the regulation of MRP1 by anti-cancer drugs in cancer cell lines (17-20). 
In line with this, significant induction of MRP1 expression was observed in vivo in 
bladder cancer cells after i.v. treatment with doxorubicin (21 ). In addition, high MRP1 
expression was found in human glioma compared to normal brain tissue (22). 
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In an attempt to identify the regulatory mechanism of M RP1 expression, the human 
and rodent MRP1 promoter have been cloned. Conserved regions were detected and 
several potential binding sites for transcription factors have been identified, including 
those for activator protein 1 (AP-1) and Sp-1 (23). However, the c-jun/fos complex 
that binds to the AP-1 site and is involved in several signal transduction routes related 
to inflammation and cell cycle, appears not to be involved in the regulation of MRP1 
transcription (24 ). p53, a key protein in the development of tumor cells, was shown 
to inhibit expression of MRP1, but the molecular mechanism remains unclear (25). 
Wang&Beck and Sullivan et al found that binding of transcription factors to the Sp-1 
site in the M RP1 promoter was blocked by p53 (25,26). In contrast, Muredda et al. 
showed that the p53-dependent inhibition of M RP1 is independent of Sp-1 sites (23). 
Of considerable pharmacological interest is the observation by Hirai et al. who 
detected reduced Mrp1 mRNA levels in the intestine of mice treated with synthetic 
agonists for the peroxisome proliferator-activated receptor alpha (PPARa) (27). 
PPARa is a ligand-activated transcription factor that belongs to the nuclear hormone 
receptor superfamily. PPARa is expressed predominantly in tissues that have a 
high level of fatty acid catabolism, such as liver, heart, and muscle, but lower levels 
are also detected in the intestine PPARa regulates the expression of a number of 
genes critical for lipid and lipoprotein metabolism and PPARa agonists are used 
for the treatment of dyslipidemia. Remarkably, the PPARa-mediated suppression of 
Mrp1 appeared organ-specific as hepatic Mrp1 expression was not affected in mice 
treated with PPARa agonists (28). 
To evaluate the potential of PPARa as a therapeutic target to manipulate MRP1 
levels in human disease, we analyzed the putative involvement of PPARa in the 
regulation of human MRP1 in intestinal and hepatic cell lines. 
Materials and methods 
Cell culture 
The human hepatoma cell line HepG2 was maintained in DMEM supplemented 
with 10% FBS, penicillin (100 U/ml), streptomycin (100 µg/ml) and amphotericin B 
(fungizone, 25 ng/ml) (psf). 
The colon carcinoma cell line DLD-1 (DZSM, Braunschweig, Germany) was 
maintained in RPMl-1640 medium with Glutamax, supplemented with 10% FBS 
(lnvitrogen, Breda, The Netherlands) and psf. Cells were passaged twice a week. 
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The colon carcinoma cell line Caco-2 was maintained in DMEM (lnvitrogen, 
Breda, The Netherlands) supplemented with 10% FBS, non-essential amino acids 
(lnvitrogen, Breda, The Netherlands) and psf (Biowhittaker, Verviers, Belgium). Cells 
were passaged twice a week. 
For PPARa stimulation, cells were incubated with indicated concentrations of 
synthetic PPARa agonists GW764 7 (Sigma, Zwijndrecht, The Netherlands) or 
WY14,643 (Sigma) or DMSO (Sigma) as a control. For RXRa stimulation, cells were 
incubated with 9-cis retinoic acid (Sigma). 
PPARa and RXRa transfections 
DLD-1 cells were seeded in 6-well plates at 300.000 cells per well. The cells were 
transfected with plasmid pSG5-PPARa, which was kindly provided by the laboratory 
of pediatrics (University Medical Center Groningen, Groningen, The Netherlands). 
Transfection was performed using the Bio-Rad TransfectinTM Lipid reagent 
protocol (Bio-Rad laboratories B.V. ,  Veenendaal, The Netherlands) according to the 
manufacturer's instructions. A Transfectin to DNA ratio of 3:1 was used. 
HepG2 cells were seeded at 400.000 cells per well. Cells were grown to 70-80% 
confluency before transfection. HepG2 cells were transfected using the calcium 
phosphate coprecipitation method (29). Transfections were performed using 100 ng 
of pSG5-PPARa 100 ng of pSG5-h RXRa (30) and 800 ng pCMV, or with 10 µg of 
pSG5-PPARa. 
Isolation and quantitative RT-PCR 
Total RNA was isolated using the TRlzol isolation method according to the 
manufacturers instructions (lnvitrogen Life technologies, Breda, Netherlands) 
Reverse transcription was performed in a final volume of 50 µI. Messenger RNA 
(mRNA) levels of 18S, PPARa, MRP1, CPT1A and HMG-CoA-synthase were 
quantified using the ABI PRISM 7700 (Applied Biosystems, California, USA). Real­
time PCR conditions were as described previously (12). For quantification of mRNA 
levels, the Ct-value difference was calculated between the gene of interest and the 
housekeeping gene 18S. This delta Ct was corrected to a linear scale (2-LiCt) to 
obtain a relative amount of mRNA compared to 18S. 
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Protein isolation and western blot analysis 
Total cell lysates were prepared. Protein concentrations were determined using the 
Bio-Rad Protein Assay system (Bio-Rad GmbH, Munich, Germany) using bovine 
serum albumin as a standard. 
For western blot analysis of MRP1 protein expression, 15 µg of protein was loaded 
and separated on 7,5% SOS-PM gels. Proteins were transferred to a nitrocellulose 
membrane using tank blotting. Membranes were blocked using 2% milk and 0,5% 
BSA in PBS/Tween (0,05%). MRP1 was detected using the rat monoclonal antibody 
Mrpr1 (1 :500, Signet, TEBU-Bio) followed by horseradish peroxidase-labeled rabbit 
anti-rat antibody (1 :2000, DAKO). Development of the blot was performed using 
Supersignal West dura extended Supersignal kit (Perbio Science, Etten Leur, the 
Netherlands) and signal detection was documented using a Biorad Photodoc system 
(Biorad, Veenendaal, The Netherlands). Finally, Quantity One software (Biorad, 
Veenendaal, the Netherlands) was used for to quantify protein levels. 
Luciferase assay 
The luciferase construct with a PPRE site in its promoter region was a generous gift 
of Nicolette Huijkman (Dept. of Pediatrics, UMCG, the Netherlands). The luciferase 
system was provided by Promega. Luciferase activity was determined according 
to the manufacturers protocol (Promega). Measurements were performed using a 
microplate luminometer (Berthold detection systems). 
lmmunof/uorescence microscopy 
Cells grown on coverslips were washed three times with PBS and fixed with 4% 
paraformaldehyde (Sigma) for 20 minutes. Permeabilization was achieved using 
1 % Triton X-100 (Sigma) for 5 minutes. Cells were then incubated with the primary 
antibody (Mrpr1 (Signet) or PPARa (Santa cruz)) overnight at 4°C. Directly RPE­
or Alexa 488-labeled secondary antibodies were incubated for 1 hour at room 
temperature. Cells were then mounted on fluorescence mounting medium (Dako 
cytomation, Heverlee, Belgium) analyzed by confocal microscopy (Leica TCS SP2/ 




Experiments were performed in triplicate and analyzed by Student's t-test All 
statistical tests were performed in SPSS v14.0 for Windows. Significance was 
defined as p<0,05. 
Results 
Expression of MRP1, PPARa and PPARa target genes in human intestinal and 
hepatic epithelial cell lines. 
First, the endogenous expression levels of PPARa, MRP1 and known PPARa target 
genes were analyzed in various human intestinal en hepatic cell lines. RNA was 
isolated from the human colon carcinoma cell line DLD-1, the human colon adenoma 
cell line Caco-2 and the human hepatoma cell line HepG2. Using quantitative real-time 
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Figure 1. Expression of PPARa, PPARa target genes and MRP1 in colon and hepatic 
epithelial cell lines. RNA was isolated from HepG2, DLD- 1 and Caco-2 cells. Relative 
mRNA expression of PPARa (A), MRP1 (B), CPT1A (C), HMGCoAS (D) were determined 
by Q-RTPCR. Expression was corrected for 18S. Results are represented as means 
+/- SD. 
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PCR, PPARa, MRP1, Carnitin Palmitoyl Transferase I A (CPT1A) and mitochondrial 
Hydroxymethyl Glucoronide CoA-synthase (HMGCoAS) mRNA expression levels 
were determined (Figure 1 ). 
PPARa mRNA was present at detectable levels in all cell lines. HepG2 and Caco-2 
express similar levels of PPARa mRNA, with approximately 2-fold lower levels in DLD-
1 cells. MRP1 mRNA was also readily detectable in all three cell lines. Expression 
was comparable in HepG2 and DLD-1 cells. Caco-2 cells express approximately 
2-fold lower levels of MRP1 compared to HepG2 and DLD-1 cells. Expression of the 
PPARa target gene CPT1A is highest in HepG2 cells. DLD-1 cells express 2-fold 
lower, but still significant levels of CPT1 A. CPT1 A levels in are much lower in Caco-
2 cells (> 10-fold) compared to HepG2 and DLD-1 cells. In contrast, HMGCoAS 
expression was high in Caco-2 cells and undetectable in HepG2 and DLD-1 cells. In 
following experiments, CPT1A was used as marker for PPARa activation in DLD-1 
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Figure 2. PPARa stimulation results 
in upregulation of CPT1A and HM­
GCoAS. DLD- 1, HepG2 and Caco-2 
cells were treated for 24 hours with 
PPARa agonists WY14, 643 (100 or 
200 µM) or GW7647 (15 or 60 µM). 
mRNA expression levels of CPT1A in 
DLD- 1 (A) and HepG2 (B) and HMG­
CoAS in Caco-2 (C) cells were deter­
mined by Q-RTPCR. Expression was 
corrected for 18S. Results are repre­
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Figure 3. PPARa stimulation with WY-
14, 643 or GW7647 does not affect MRP1 
expression. DLD- 1, HepG2 and Caco-2 cells 
were treated for 24 hours with PPARa ago-
nists 200 µM WY14, 643 or 15 µM GW7647. 
mRNA expression levels of CPT1A (DLD-
1, HepG2), HMGCoA (Caco-2), MRP1 and 
PPARa were determined by Q-RTPCR in 
DLD- 1 (A), HepG2 (B) and Caco-2 (C) cells. 
Expression was corrected for 18S. Results 
GW7647 are represented as means +/- SD. 
Determination of optimal concentrations of PPARa agonists WY 14, 643 and GW764 7. 
Next, we determined the optimal concentration for analyzing the effect of the PPARa 
agonists WY14,643 and GW7647 on target gene expression in DLD-1, HepG2 and 
Caco-2 cells (Figure 2). The induction of PPARa target genes by WY14,643 was 
dose-dependent and showed strongest effects at 200 uM in all 3 cell lines, leading 
to 5.3-fold, 7.8-fold and 3.6-fold increases in DLD-1 (CPT1A), HepG2 (CPT1A) 
and Caco2 (HMGCoAS), respectively. In addition, treatment of all cell lines with 
15 µM GW7647 lead to the maximal induction of PPARa target genes. Increasing 
the concentration of GW7647 to 60 µM did not further increase the expression of 
the marker genes in DLD-1 and Caco-2 cells. In HepG2 it actually lead to a lower 
induction of CPT1 A. The mRNA levels of the PPARa target genes was not further 
increased after prolonged (36 h) treatment with PPARa agonists (data not shown). 
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Figure 4. PPARa overexpression in DLD- 1 
and HepG2 cells. DLD- 1 and HepG2 cells 
were transfected with pSG5-PPARa leading 
to a >200-fold increase in PPARa mRNA le­
vels (A). Western blot was performed to ana­
lyze PPARa protein expression in untrans­
fected cells and cells transfected with 100 
ng, 10 µg pSG5-PPARa or 1 µg pCMV (B). 
lmmunolluorescence microscopy was per­
formed for PPARa to determine transfection 
efficiency and subcellular location of PPARa 
after transfection with 10 µg pSG5-PPARa 
(C). mRNA expression levels of CPT1A (D) 
and MRP1 (E) were determined in cells 
transfected with 1 µg pCMV (control) and 
cells transfected with 10 µg pSG5-PPARa. 
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MRP1 mRNA levels are not changed by PPARa stimulation 
Next, HepG2, DLD-1 and Caco-2 cells were incubated for 24 h with 200 µM WY14,643 
or 15 µM GW7647 and analyzed for transcriptional regulation of MRP1 by Q-PCR 
(Figure 3). PPARa activation did not result in a change of MRP1 transcript levels 
(neither induced nor reduced) in any of the human cell lines tested. As established 
before, CPT1 A or HMGCoAS expression was induced in all cases, while PPARa 
expression itself was not affected by WY14,643 or GW7647 treatment. 
Transient PPARa overexpression does not affect PPARa target gene or MRP1 
expression 
The data presented above suggest that PPARa does not regulate MRP1 expression 
in human cell lines. However, the absence of a regulatory response towards PPARa 
ligands may also be due to the presence of limited amounts of PPARa in these cells, 
which may favour induction (CPT1A, HMGCoAS) rather than repression (MRP1) 
of specific target genes. To maximize the effects of PPARa stimulation, HepG2 
and DLD-1 cells were transiently transfected with expression plasmids for PPARa 
(pSG5-PPARa ) and RXRa (pSG5-h RXRa). PPARa mRNA levels were increased 
over 200-fold in DLD-1 and HepG2 cells transfected with pSG5-PPARa compared 
to control (Figure 4A), which was accompanied by a significant overproduction 
of PPARa protein in both cell types (Figure 48). The amount of PPARa protein 
produced appeared significantly higher in DLD-1 cells compared to HepG2 cells. 
lmmunofluorescence microscopy showed that approximately 50% of the DLD-1 cells 
showed clear PPARa positive nuclei after transfection. In case of HepG2 cells, this 
was observed for only approximately 10% of the cells (Figure 4C). Endogenous 
levels of PPARa in both cell lines were hardly detectable by immunofluorescence 
microscopy (see Figure 4C, pCMV-tranfected cells). Unexpectedly, the increased 
PPARa levels did not affect the GW7647 induced expression of CPT1A (Figure 4D), 
nor the mRNA levels of MRP1 (Figure 4E). GW7647 lead to a 3-fold increase of 
CPT1A in untransfected HepG2 cells (2.7-fold) as well as in PPARa/RXRa- (2.9-fold), 
or pCMV-control transfected cells (2.8-fold) (data not shown). MRP1 mRNA levels 
were unchanged in all conditions (+/- transfection; +/- GW7647 treatment). Also 
when analyzed at the cellular level by immunofluoresence microscopy, expression 
of MRP1 appeared the same in cells with strong PPARa-positive nuclei and cells 
without increased PPARa expression (Figure 5, shown for HepG2 cells) 
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PPARa MRP1 overlay 
Figure 5. PPARa overexpression does not affect MRP1 protein expression at the 
cellular level. HepG2 cells were transfected with 100 ng pSG5-h RXRa and 10 µg 
pSG5-PPARa. Subsequently, cells were stimulated for 24 hours with 15 µM GW7647. 
Cells were stained for MRP1 and PPARa and analyzed by confocal microscopy. Clear 
cellular staining of PPARa was detected in transfected cells (left panel). MRP1 staining 
located at cellular membranes was readily detected in cells with high and low (/no) 
PPARa expression (middle panel and overlay in right panel). The inset in the righ panel 
shows a HepG2 cell with clear nuclear PPARa staining together with MRP1 staining at 
the cellular membrane. The intensity of the MRP1 staining is, however, comparable to 
the surrounding non-transfected cells. 
Transfection of pSGS-PPARa results in expression of functional PPARa 
To confirm that the artificially produced PPARa is functional, DLD-1 cells were co­
transfected with pSG5-PPARa, pSG5-h RXRa and a luciferase reporter construct 
containing three PPRE's in front of the luciferase gene (pPPRE-luciferase ). After 
an additional 24 h treatment with GW764 7, cell were harvested and analyzed for 
luciferase activity. Transfected DLD-1 cells with only the pPPRE-luciferase construct 
contained low luciferase activity (400 AFU), which was not induced by GW7647 
(Figure 6). Cotransfection with pSG5-h RXRa resulted in a minor increase in 
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Figure 6. Heterologously expressed 
PPARa is active and ligand-inducible. 
DLD- 1 cells were transiently transfec­
ted with a luciferase reporter plasmid 
containing 3 PPARa responsive ele­
ment (control), combined with 100 ng 
pSG5-PPARa and 100 ng pSG5� RXRa 
(PPARa I RXRa) or only 100 ng pSG5-h 
RXRa (RXRa). Twenty four (24) h after 
transfection, cells were treated for an ad­
ditional 24 h with DMSO (control) or 15 
µM GW7647, followed by determination 
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Figure 7. The RXRa-ligand 9cRA decreases MRP1 expression in DLD- 1 and HepG2 
cells. DLD- 1 cells and HepG2 cells were transiently transfected with 100 ng pSGS-PPARa 
and 100 ng pSG5-h RXRa. Subsequently, cells were treated for 24 hours with 1 µM 9-cis 
retinoic acid (9cRA), 200 µM WY14, 643, 15 µM GW7647 or a combination. mRNA expres­
sion levels of CPT1A, MRP1 and PPARa were determined in DLD- 1 (A) and HepG2 (B) 
cells by Q-RTPCR. Expression was corrected for 18S. Results are represented as means 
+I- SD. 
co-transfection of DLD-1 cells with pSG5-PPARa, pSG5-h RXRa and pPPRE­
luciferase strongly induced luciferase activity (42*103 AFU). Moreover, GW7647 
further increased the luciferase activity 2-fold in these cells (73*1 Q3 AFU). These 
data show that the artificially produced PPARa is functional. 
9-cis retinoic acid downregulates MRP1 in DLD- 1 and HepG2 cells and increases 
PPARa mRNA expression in DLD-1 cells 
Finally, we investigated whether RXRa may independently influence the activation 
of PPARa-regulated gene transcription and/or MRP1. DLD-1 and HepG2 cells were 
co-transfected with pSG5-PPARa and pSG5-h RXRa to allow maximum activation 
of PPARa, followed by selective activation by WY14,643, GW7647 and/or the RXRa 
ligand 9-cis retinoic acid (9c-RA). WY14,643- and GW7647-induced expression 
of CPT1 A was even further increased by 9cRA in both cell types (Figure 7). No 
change in expression was observed for PPARa and MRP1 in any condition where 
a PPARa ligand was present. However, when cells were treated with 9cRA alone, a 
significant reduction in MRP1 mRNA levels was detected in both DLD-1 and HepG2 
cells. Remarkably, 9cRA treatment causes a strong induction (2.6-fold) of the PPARa 
mRNA levels in DLD-1 cells. This was not observed in HepG2 cells. 
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Discussion 
In this study, we show that human MRP1 expression is not suppressed by PPARa 
in hepatic HepG2 and colonic DLD-1 and Caco-2 cells. Neither PPARa agonist 
nor PPARa overexpression did affect MRP1 transcription. In contrast, MRP1 mRNA 
levels were significantly reduced by the RXRa ligand 9-cis retinoic acid. Remarkably, 
the 9cRA-mediated repression of MRP1 was attenuated by PPARa agonists. 
MRP1 is an important drug target. MRP1 levels are increased in many types of cancer 
and protect malignant cells against cytostatic drugs (2-4 ). Moreover, increased levels 
of MRP1 were detected in activated hepatic stellate cells that cause liver fibrosis 
(13). The other side of the coin is that MRP1 levels are also increased in regenerative 
tissue in the intestine and liver (10-12) and MRP1 was shown to protect against 
cytokine-induced cell death (10). Finally, Mrp1 is required for the activation of the 
adaptive immune response (31 ). These studies show that there is not one straight 
approach for MRP1-targeted therapy; for some diseases MRP1 should be inhibited 
(cancer, liver fibrosis), for others it should be induced (IBD, liver regeneration). 
Pharmaceutical inhibitors of MRP1 transport activity are known, like MK571 and 
oleanolic acid, but these compounds are not very selective and are prone to give side 
effects when used for therapy. Manipulation of the transcriptional regulation of MRP1 
would be alternative approach to change MRP1 activity. Unfortunately, to date, little 
is known about the molecular mechanisms involved in the transcriptional regulation 
of human MRP1. The recent discovery that PPARa may repress Mrp1 expression 
in mice opened new possibilities to therapeutically modulate MRP1 expression. 
PPARa is a ligand-activated transcription factor. Agonists and antagonists are 
available that allows modulation of Ppara target gene expression depending on 
the desired therapeutic effect Mrp1 expression is reduced in the intestines of mice 
that are treated with Ppara agonists (Wy14643 and GW7647) (27). Notably, Mrp1 
levels were not changes in the livers of these Wy14643- or GW7647-treated mice. 
Following these observations, we studied the possible PPARa-mediated regulation 
of human MRP1 in intestinal and hepatic cell lines. However, we did not detect any 
significant effect of PPARa agonist on the transcriptional levels of MRP1 in these 
cell lines. Our experimental conditions showed robust induction of known PPARa 
target genes by the PPARa agonists Wy14643 and GW7647 in DLD-1, Caco-2 and 
HepG2 cells. Transient transfection of functional PPARa did not result in changed 
levels of MRP1 even though transfection efficiencies of 50% were obtained. Also in 
individual cells with clearly increased levels of PPARa, MRP1 expression appeared 
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unchanged and was detected in the cellular membrane. These data fail to indicate 
any role for PPARa in human MRP1 regulation. A possible explanation for these 
observations is that PPARa is already (partly) activated by endogenous ligands in 
these cell lines resulting in full repression of MRP1. PPARa agonists may still be 
able to induce expression of positively regulated target genes, but may not exert an 
additional effect on suppressed target genes, like MRP1. To explore this possibility, 
we exposed DLD-1 and HepG2 cells to the PPARa antagonist MK866. Preliminary 
data reveal that also MK866 does not change MRP1 expression, arguing against a 
high basal level of PPARa activation in these cells. Taken together, these results do 
not support a possible role of PPARa in the regulation of human MRP1. 
The question remains whether the change in intestinal MRP1 expression in 
Wy14643- or GW764 ?-treated mice is a direct effect of PPARa-mediated regulation. 
The fact that the repression of MRP1 was not observed in Ppara -ko mice seems to 
support this possibility. However, these results have not been confirmed by a detailed 
Mrp1 promoter analysis and/or chromatin immune precipitation experiments. Also 
no putative PPARA response elements (PPREs) have been studied in the Mrp1 
promoter element. Therefore, it cannot be ruled out that the observed suppression of 
Mrp1 in intestines of Wy14643- or GW7647-treated mice is in fact and indirect effect. 
The only factor that significantly affected MRP1 transcription in our study was the 
RXRa ligand, 9-cis retinoic acid (9cRA) leading to a 77% reduction in DLD-1 cells 
and a 57% reduction in HepG2 cells. Remarkably, this repression was attenuated 
by PPARa agonists. It remains to be determined whether 9cRA acts through RXRa. 
It has been reported that high levels of 9cRA may reduce RXRa protein levels 
(30) thereby reducing the expression of its target genes. However, such a strong 
reduction in RXRa protein was not detected when HepG2 cells were treated with 
1 µM 9cRA (30). Thus, our observations suggest that there is a complex interplay 
between RXRa and PPARa ligands in relation to MRP1 transcription. In access 
9cRA, PPARa agonists induce MRP1 expression. This is opposite to the Ppara­
dependent regulation of mouse Mrp1 in the intestine. 
In conclusion, our data do not support a role of PPARa in suppressing human MRP1 
expression. In contrast, the RXRa ligand was identified as an inhibitor of human 
MRP1 expression. PPARa agonists attenuate the 9cRA-mediated suppression of 
MRP1. These data warrant a further analysis of the interplay of PPARa, RXRa and 
their ligands in the regulation of human MRP1. 
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General discussion and summary 
A. van Steenpaal 
The Multidrug Resistance-associated Protein 1 (MRP1) has been a major subject 
of scientific and clinical interest ever since its first characterisation in 1992 (1 ). 
Its role in the development of multidrug resistance has turned it into an important 
diagnostic marker and a therapeutic target to increase the efficacy of a variety of 
drugs, including ones to treat cancer and HIV. However, MRP1 also serves important 
(patho) physiological functions that are unrelated to drug therapy (reviewed in 
Chapter 1 ). These functions are only now being discovered. In this thesis, we studied 
the (patho) physiological function of MRP1 in intestinal and liver diseases. Specific 
focus was put on its function and regulation in inflammatory bowel disease ( 180) and 
liver during regeneration. 
The role of MRP1 during inflammation 
In chapter 2 of this thesis, we show that the expression of MRP1 is increased in 
the inflamed intestinal mucosa of 180 patients when compared to the neighbouring 
uninflamed tissue. High MRP1 expression is observed in two cellular compartments 
of the inflamed mucosa, the intestinal epithelial cell layer (predominantly in the crypt 
region) and lamina propria mononuclear cells. 
In order to investigate the functions of MRP1 in inflamed intestine, we subjected 
cells from the human intestinal epithelial cell line 0LD-1 and human T-lymphocytes 
to inflammation factors, e.g. tumor necrosis factor-a (TNF-a) and anti-Fas, in 
combination with manipulation of the level or activity of MRP1 (Chapter 2 and 3). We 
found that MRP1 protects intestinal epithelial cells from cytokine-induced apoptosis, 
whi le the exact opposite, MRP1 promotes cytokine-induced apoptosis, was observed 
for T-lymphocytes. This indicates that the effect of MRP1 function differs between 
cell types, most likely depending on external conditions that affect the cellular status 
and the production of specific substrates that are transported by MRP1. 
The protective effect of MRP1 in 0L0-1 cells is related to the MRP1-mediated export 
of a pro-apoptotic compound from the leukotriene biosynthesis pathway, which is 
most likely the high affinity substrate of MRP1 leukotriene C4 (LTC4) (Chapter 2). 
Apoptotic cell death of 0L0-1 cells is prevented when the intracellular generation of 
LTC4 is blocked in combination with cytokine-exposure and MRP1 inhibition. MRP1 
blockade has also been shown to prevent angiotensin II-mediated endothelial cell 
apoptosis thereby confirming a role for MRP1 and intracellular LTC4 generation in 
modulating cell survival during inflammation (2). 
In contrast to its role in epithelial cells, MRP1 expression sensitized T-lymphocytes 
110 
Chapter 6 
for apoptosis (Chapter 3). Two other independent studies have recently shown 
comparable effects of MRP1 inhibition on T-lymphocytes apoptosis (3,4 ). The 
exact mechanism of MRP1-dependent sensitization remains unclear, although we 
were able to exclude the involvement of the leukotriene biosynthetic pathway. In 
addition, we have shown that intracellular glutathione is not involved. Therefore, the 
involvement of MRP1-mediated glutathione export as a cause for T-cell apoptosis 
remains a subject of discussion (3-5). 
Since MRP1 expression increases upon T-lymphocyte activation (6) and is involved 
in cytokine release (5) a possible physiological function of MRP1 expression in 
T-lymphocytes could be self-regulation of the immune response. When T-cells are 
inactive, they express low MRP1 levels, therefore having a low(er) susceptibility 
to apoptosis and low production of cytokines. During an immune response, MRP1 
expression in T-lymphocytes is increased resulting in an increased sensitivity to 
cytokine-induced apoptosis, active T-lymphocytes are cleared by apoptosis more 
easily and subsequently the immune response is silenced. Derangements in 
this process could be important in patients with autoimmune diseases, including 
inflammatory bowel disease. Modulation of MRP1 levels or activity is therefore an 
interesting possibility to improve the balance of immune responses in these patients. 
The role of MRP1 in tissue regeneration 
Several organs are able to regenerate. The intestinal epithelium is continuously 
renewed by proliferation and differentiation of progenitor cells located at the base of 
the crypts (reviewed in (7)). During migration of newly formed epithelial cells to the top 
of the villus, these "na"ive" epithelial cells differentiate into fully committed intestinal 
epithelial cells (enterocytes). At the top of the villus, the "old" enterocytes die from 
apoptosis and are shed from the colon mucosa. This is a constitutive process that 
renews the entire epithelial cell layer every 2-5 days in the healthy intestine. 
A quite different situation is observed for the liver. Very little tissue regeneration is 
occurring in the healthy liver, where only 1 in 20.000-40.000 hepatocytes is dividing. 
Concurrently, the average life span of a hepatocyte is approximately 5 months, 
around 50-fold longer than an enterocyte. However, the hepatic regeneration 
machinery is strongly activated after injury that causes loss of functional liver mass 
(e.g. alcohol, surgical resection or (viral) infection) (reviewed in (8)). Under these 
conditions, hepatocytes enter cell division and proliferate until the original liver 
capacity is restored. The process of liver regeneration is initiated by the increased 
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production of several inflammatory cytokines, e.g. TNF-a and 1 1-6 . In response to 
the local increase of these cytokines, hepatocytes start to proliferate. During severe 
liver injury, when hepatocyte proliferation is inhibited (e.g. viral infections, chemical 
inhibition by drug abuse) the hepatic progenitor cells are activated (8). These cells 
proliferate and subsequently differentiate into mature hepatocytes or cholangiocytes. 
Interestingly, during inflammation in both liver (primary biliary cholestasis, chronic 
hepatitis C) and intestinal diseases (ulcerative colitis, Crohn's disease), M RP1 
expression was observed in the regenerative compartment containing the progenitor 
cells (9). In addition, an in vivo rat model for severe liver injury revealed MRP1 
induction in the progenitor cell compartment during liver regeneration (10). These 
observations combined suggest a functional role of MRP1 in progenitor cells. Based 
on the cytoprotective effects of MRP1 in epithelial cells (Chapter 2), we postulated 
that MRP1 also provides cytoprotection to progenitor cells, thereby ensuring the 
regenerative capacity of organs under toxic conditions. A common factor in hepatic 
or intestinal inflammatory disorders and liver regeneration is the increased presence 
of pro-apoptotic cytokines. 
Under normal conditions, MRP1 expression is very low in the liver which corresponds 
to the quiescent nature of the hepatocytes. In the intestine, where regeneration 
is continuous, M RP1 is present at much higher levels. In both organs, MRP1 is 
increased significantly in the progenitor cell compartment during severe inflammation, 
suggesting a functional role in ensuring tissue regeneration. 
To determine whether Mrp1 plays a crucial role in progenitor cell-mediated liver 
regeneration in vivo, we subjected wild type and Mrp1 knockout mice to partial 
hepatectomy (pHx) in the presence of the hepatocyte proliferation-blocker, 
2-acetylaminofluorene (2-MF) (Chapter 4 ). In contrast to our hypothesis, we did not 
detect a significant reduction in liver tissue recovery in 2-MF-treated Mrp1-1- and wild 
type mice 3 days after partial hepatectomy. However, our hypothesis was supported 
by the observation of a clear induction of the progenitor cell marker a-fetoprotein 
(AFP) in 2-MF/pHx-treated wild type, which was absent in 2-AAF/pHx-treated Mrp1-
,_ mice. The induction of AFP in 2-MF/pHx-treated wild type mice, however, did 
not coincide with induction of Mrp1 or any other ABC-transporter tested (Mrp2-7, 
Mdr1 a/b, Mdr2). In contrast, 2-MF treatment lead to a significant induction of Mrp1, 
Mrp3 and Mrp4 in partial hepatectomized rats (10). This was analyzed 9 days after 
pHx, while in our experiments transporter expression in mouse liver was analyzed 
3 days after pHx. It remains to be determined whether the discrepancy in Mrp1 
expression is species-specific and/or dependent on the exact time point after pHx. 
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A complicating factor in the analysis of the physiological functions of Mrp's in general 
is that a significant overlap in substrate specificity exist between the different Mrp's. 
Mrp3 is the closest structural homologe of Mrp1 with established substrate specificity 
overlap (11 ). Of all Mrp/Mdr's tested, actually only Mrp3 mRNA levels appear to 
be significantly increased in livers of Mrp1-1- mice compared to wild type controls 
(Chapter 4 ). This may suggest that compensatory mechanisms are induced in livers 
of Mrp1-1- to maintain the regenerative capacity under variable conditions. As also 
Mrp3 was strongly induced in livers of 2-AAF/pHx treated rats, it may be worthwhile 
to perform the 2-AAF/pHx experiments in Mrp1-1-/Mrp3-1- double knock-out animals 
to establish whether the combination of these two Mrps is required for optimal 
progenitor cell-mediated liver regeneration. 
Still, the absence of AFP induction in 2-AAF/pHx-treated Mrp1-1- is intriguing and 
suggest that Mrp1 specifically is required for progenitor activation. Ki-67 positive 
cells were detected throughout the liver parenchym which does not support a decent 
of the hepatic progenitor cell niche that is thought to reside in the canals of Hering. 
This may suggest that also bone marrow stem cells significantly contribute to liver 
regeneration in 2-AAF/pHx treated mice. Whether AFP levels remain low in the 
transition of these bone marrow stem cells to hepatocytes needs further investigation. 
Regulation of MRP1 expression 
lt is clear that MRP1 is an important therapeutic target in a variety of diseases, including 
cancer, HIV, autoimmune diseases -like the IBDs- and liver regeneration. However, 
inhibiting MRP1 is not the universal therapeutic approach for all these diseases. 
Especially for IBD and organ regeneration , stimulating MRP1 activity may aid to limit 
or reduce tissue damage. Early research has been especially focussed on identifying 
pharmacological inhibitors of the transport activity of MRP1. Most used is MK571, but 
several additional inhibitors have been identified and characterized in recent years 
(selective MRP1 inhibitors: (12, 13). The problem of these compounds is that they are 
not selective, even though they are often described as selective inhibitors of MRP1. 
An alternative approach to inhibit MRP1 function is to modulate the transcriptional 
regulation of the corresponding ABCC1 gene. Conditions are known in which MRP1/ 
ABCC1 expression is changed. For example, prolonged treatment of cancer cell lines 
with doxorubicin results in development of multidrug resistant clones overexpressing 
MRP1 (14). 
Although many putative regulatory sequences have been identified in the MRP1 
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promoter, none of them have been unequivocally shown to be involved in the 
transcriptional regulation of MRP1. One of the best described physiological 
compounds that regulates MRP1 expression is 1 1-6. 1 1-6 treatment has been shown 
to increase MRP1 expression and activity in human hepatoma cell lines as well 
as a human keratinocyte cell line (15, 16). 1 1-6 has been shown to reduce MOR 
expression levels in rat liver (17). Although contradictory effects are observed for 
the effect of 1 1-6 on ABC transporter expression, it is clear that 1 1-6 is involved in 
the transcription regulation of ABC transporters. It is hypothesized that, during the 
onset of inflammation, changes in expression levels of hepatic enzymes involved in 
metabolism are initiated by the release of 1 1-6. 
Recently, an interesting novel transcriptional regulator was identified that may be 
involved in tissue-specific regulation of Mrp1, namely the peroxisome proliferator­
activated receptor alpha (PPAR-a). Mrp1 expression was reduced in the intestines 
of wild type mice that were treated with synthetic PPAR-a agonists, while Mrp1 levels 
in the liver were unaffected. The Ppar-a agonist dependent repression of Mrp1 was 
not detected in Ppar-a knock mice. The tissue-selective mechanism involved in 
Ppar-a-mediated Mrp1 regulation may have value for therapeutic applications where 
highly tissue-selective manipulation of MRP1 is required. Since no data are available 
on the putative regulation of human MRP1 by PPAR-a, we studied this in Chapter 
5. Unfortunately, PPAR-a did not have any effect on human MRP1 expression in 
either hepatic or intestinal cell lines. It may be possible that there are many species­
specific differences in PPAR-a target gene expression, as already shown by the 
differences in expression level and location during embryonic development between 
rodents and humans (reviewed in (18)). However, our results might also indicate that 
the MRP1-reduction in the intestine does not take place in the intestinal epithelial 
cell compartment, but in an entirely different cell type. Remarkably, we found that 
activation of the binding partner of PPAR-a, RXR-a, by 9-cis retinoic acid leads to 
strong repression of MRP1 expression. In the presence of PPAR-a agonists, this 
repressive effect was absent. This indicates that there may be a complex interplay 
between PPAR-a, RXR-a and possibly additional factors that regulates MRP1 
expression. It is therefore relevant to further delineate the mechanisms that are 
involved in RXR-a/9 cis retinoic acid-mediated repression of MRP1. However, as 
RXR-a is an obligatory partner for many different members of the nuclear receptor 





Until recently, the focus of Mrp1 research was on the "negative" effects of MRP1 
expression, e.g. multidrug resistance in cancer tissue. Therefore, the use of MRP1 
inhibitors in the treatment of cancer has been the main therapeutic goal. Although 
this may be beneficial to sensitize multidrug resistant cancer cells to anticancer 
drugs, our research shows that in inflammatory conditions MRP1 inhibitors may 
potentially induce epithelial cell damage and T-cell resistance to apoptosis. It has 
already been demonstrated that adequate MRP1 function is required to prevent 
methotrexate-mediated intestinal cell damage (19) indicating that enhancing MRP1 
function can reduce intestinal toxicity of cytotoxic drugs. Our finding that MRP1 
expression sensitized T-lymphocytes to apoptosis is new. The physiological role of 
MRP1 in T-cells and other immune competent cells such as mast cells, monocytes, 
macrophages and antigen presenting cells is poorly addressed (20). For instance the 
lg- mediated release of cysteinyl leukotriene from mast cells is markedly impaired by 
MRP1 deficiency, indicating that MRP1 plays an important role in the development of 
allergic airway inflammation (21 ). In macrophages, the bacterial cell wall component 
lipopolysaccharide (LPS) can increase MRP1 expression and function (22). Generally, 
it is believed that the infection-driven upregulation of MRP1 is necessary to maintain 
the cellular redox status. As a consequence of increased MRP1 levels these immune 
competent cells are less susceptible for immunosuppressive drugs. However, in 
T-cells the opposite seems true, apart from the apparent function of MRP1 in cytokine 
release (5) its function in the T-cell life cycle needs further exploration. Considering 
the opposite effect of MRP1 inhibition on apoptosis of epithelial cells and T-cells, it 
is important to select the right disease and target the right cell for MRP1 inhibition 
or stimulation experiments. In Crohn's disease, resistance of T-cells to apoptotic cell 
death is an important negative factor so in this disease T-cells should be targeted for 
induction of MRP1 expression. In contrast, in ulcerative colitis epithelial cell damage 
is more prominent and local treatment (for instance via enemas) with enhancers of 
MRP1 function seems to be the best approach. We showed that MRP1 mediated 
intracellular LCT4 accumulation is involved in epithelial cell damage. LCT4 receptor 
inhibition has been explored in ulcerative colitis and indeed montelukast, a LCT4 
receptor inhibitor, showed beneficial effects on experimental colitis (23). In addition, 
it is known that smoking is beneficial for ulcerative colitis. It has already been shown 
that MRP1 protects airway epithelial cells against damage by cigarette smoking. 
Interestingly common anti-inflammatory drugs such as budesonide can decrease 
MRP1 function in pulmonary epithelial cells (24). Therefore, these drugs could be 
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detrimental for protection of epithelial cells in smoking patients. Since MRP1 function 
can also be inhibited by dietary components such as the phytochemical glycyrrhetinic 
acid (found in licorice) the effect of dietary components affecting drug transporters 
should be explored in IBD and intestinal cytotoxicity (25-28). 
In order to predict efficacy and potential side effects it is important to know the effects 
of MRP1 inhibition and/or overexpression on susceptibility to apoptosis in other 
diseases and cell types. For instance, Hannivoort et al. have shown that MRP1 
protects activated hepatic stellate cells from necrotic cell death (29). Therefore in 
liver inflammation, MRP1 upregulation could sustain the process of hepatic fibrosis. 
Secondly, there are many inducers of cell death for which the effect of MRP1 inhibition 
and/or overexpression has not been investigated yet. Therefore, it is still largely 
unclear whether MRP1 modulation can be successfully applied without strong side 
effects due to cytotoxic effects on selected cell types. 
Finally, a critical part of the potential use of modulators of MRP1 expression in 
clinical applications is the investigation of mechanisms that control the transcriptional 
regulation of human MRP1. Without knowledge of these processes safe manipulation 
of MRP1 function cannot be applied in either IBD or liver disease. 
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A. van Steenpaal 
Resistentie tegen geneesmiddelen is een onwenselijke complicatie bij de 
behandeling van ernstige, vaak chronische ziekten zoals auto-immuunziekten en 
kanker. Veel onderzoek heeft plaatsgevonden naar de mechanismen die leiden 
tot geneesmiddelresistentie, waardoor deze voor een gedeelte bekend zijn. Een 
van de oorzaken van resistentie is de verhoogde aanwezigheid of activiteit van 
specifieke transporteiwitten. Deze transporteiwitten pompen de geneesmiddelen 
de eel uit waardoor het zijn werk niet kan doen. Veel van deze transporteiwitten 
komen oak voor in gezonde/normale weefsels/organen, maar er is nag maar weinig 
bekend in welke cellen ze precies zitten en wat hun functie daarin is. Het onderzoek, 
beschreven in dit proefschrift, heeft zich gericht op de natuurlijke functie van een van 
deze eiwitten in de lever en de darmen. In deze samenvatting wordt een overzicht 
gegeven van de achtergrond en de, in dit proefschrift beschreven, resultaten. 
7.1.1 De darmen 
De darmen vormen een belangrijk deel van het verteringssysteem. Hier warden 
voedingsstoffen uit het voedsel opgenomen en een deel van de, in het lichaam 
aanwezige, schadelijke stoffen uitgescheiden. Het darmstelsel is opgebouwd uit 
een aantal verschillende delen. Wanneer voedsel de maag verlaat komt het in de 
twaalfvingerige darm. Hier wordt het voedsel gemengd met gal dat uit de galblaas 
de darmen in wordt geperst. De galzouten fungeren als een soort zeep, waardoor 
vetoplosbare stoffen in het voedsel "oplossen" en opgenomen kunnen warden via de 
darmwand. Het mengsel van voedsel en gal komt vervolgens in de dunne darm. Hier 
wordt het voedsel afgebroken door bacterien en lichaamseigen enzymen en warden 
essentiele voedingscomponenten opgenomen via de darmwand in het bloed. Via 
de dunne darm komt de massa in de dikke darm. In dit deel van de darmen warden 
water en zouten opgenomen uit de darminhoud om vochtverlies van het lichaam 
tegen te gaan. 
De darmwand is een essentieel onderdeel van de darmen. Het is in staat 
voedingsstoffen op te nemen uit de darminhoud. Daarnaast vormt het de eerste 
belangrijke barriere die ervoor zorgt dat bacterien de bloedbaan niet kunnen 
bereiken. De darmwand bestaat uit verschillende lagen, ieder met een eigen 
specifieke opbouw en functie. In dit proefschrift gaat het met name om de twee lagen 
die het dichtst bij de darminhoud zitten, namelijk de mucosa en de lamina propria. 
De mucosa bestaat uit een laag cellen welke verantwoordelijk is voor uitscheiding 
van enzymen, betrokken bij het vrijmaken van voedingsstoffen uit de darminhoud, 
en de daadwerkelijke opname van deze voedingsstoffen en vormt het directe 
contactoppervlak van de darmen. De oppervlakte cellen warden epitheelcellen 
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genoemd. De lamina propria is de laag direct onder de mucosa en bestaat voor een 
groat gedeelte uit bloed- en lymfevaten welke noodzakelijk zijn voor het aanvoeren 
van voedingsstoffen en een efficiente immuunreactie. 
7.1 .2 lnflammatoire darm ziekten 
lnflammatoire darm ziekten (IBD;  Inflammatory bowel disease) is de verzamelnaam 
voor chronische ontstekingsziekten van het darmstelsel. IBD kan onderverdeeld 
warden in de ziekte van Crahn (CD) en colitis ulcerasa (UC). Bij deze aandoeningen 
ontstaan zweren in de darm, welke lijden tot onder andere pijn, verminderde eetlust 
en (bloederige) diarree. De oorzaken van beide aandoeningen zijn nag grotendeels 
onbekend, maar warden in belangrijke mate bepaald door een "westerse" levensstijl. 
Met name raken heeft een grate invloed op de ernst van beide ziekten. Een 
belangrijke component in het ontstaan van IBD is een overmatige reactie van het 
immuunsysteem tegen de, natuurlijk aanwezige, darmflora. 
Zowel CD als UC kan nag niet genezen warden, maar wel met behu lp van 
ontstekingsremmende geneesmiddelen als 5-aminosalicylz�ur en corticostero'iden 
tot zekere hoogte onder controle gehouden warden. 
Naast de grate invloed van omgevingsfactoren is het voor zowel CD als UC duidelijk 
dat oak genetische factoren een belangrijke ral spelen. De afgelopen jaren zijn de 
genetische gegevens van zeer grate graepen CD en UC patienten en gezonde 
vrijwilligers geanalyseerd in zogenaamde "genome wide association studies". Deze 
studies hebben aangetoond dat mutaties in verschillende genen geassocieerd zijn 
met een dan wel beide aandoeningen. 
7.2.1 De lever 
De lever is een van de grootste organen in het menselijk lichaam en is in belangrijke 
mate betrakken bij het "zuiveren" van het bloed. 
De lever is opgebouwd uit verschillende typen cellen, waarvan de hepatocyten het 
graotste deel uitmaakt. Deze cellen zijn de functionele levercellen waarin schadelijke 
stoffen onschadelijk gemaakt warden. Daarnaast produceren hepatocyten galzouten 
die essentieel zijn bij de opname van bijvoorbeeld vetoplosbare vitaminen (A, D, E 
en K) uit de voeding. Hepatocyten liggen in strengen in de lever, omsloten door een 
bloedvat en een (kleine) galgang. De kleine galgangen komen samen in een grate 
galgang en deze mondt uit in de galblaas. 
Een belangrijke eigenschap van de lever is het vermogen om te regenereren. Dit 
wil zeggen dat, wanneer levercellen verloren zijn gegaan door ziekte, alcohol- of 
drugsmisbruik of bijvoorbeeld een operatie, er nieuwe levercellen aangemaakt 
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worden om de oude te vervangen. Dit proces is zo efficient dat in mensen, na het 
verlies van 50% van de lever massa, de lever binnen enkele maanden weer zijn 
oorspronkelijke grootte bereikt heeft. In ratten en muizen is na verwijdering van 70% 
van de lever deze zelfs na 7 tot 10 dagen al weer volledig hersteld. 
7.2.2. Leveraandoeningen 
Leverziekten komen veel voor en kunnen verschillende oorzaken hebben zoals 
virale infecties, auto-immuun afwijkingen of geneesmiddel- of alcohol misbruik. 
Leverziekten worden onderverdeeld in acute en chronische vormen, waarbij acute 
leverziekten zoals virale infecties of geneesmiddel intoxicatie leiden tot een snelle 
afname van gezond leverweefsel en medische behandeling nodig is om leverfalen 
te voorkomen. Chronische leverziekten ontstaan over periodes van jaren door 
aanhoudende infectie of auto-immuun afwijkingen. Door overactieve "stellaatcellen" 
wordt een rigide extracellulaire matrix geproduceerd (fib rose) die langzaam delen 
van de lever inkapselt en bloed en galkanalen afsluit ( cirrose ). Cirrose kan uiteindelijk 
leiden tot leverfalen waarna de enige behandeling bestaat uit levertransplantatie. 
7 .2.3 Leverregeneratie 
De lever bezit de bijzondere eigenschap dat deze zich herstelt na schade. Het proces 
is relatief snel, want na operatieve verwijdering van 70% van de lever in muizen is dit 
orgaan na 7-10 dagen volledig hersteld. Leverregeneratie is voor een groot gedeelte 
afhankelijk van deling en vermenigvuldiging (proliferatie) van hepatocyten. Daarnaast 
zijn er in de lever zones met specifieke leverstamcellen (progenitor cellen). Ook deze 
cellen vermenigvuldigen zich en kunnen zich gedurende dit proces specialiseren tot 
functionele levercellen (onder andere hepatocyten). Tot slot zijn ook stamcellen uit 
het beenmerg betrokken. Deze worden via het bloed in de lever "afgezet" waarna 
zij zich als de leverstamcellen ontwikkelen tot functionele levercellen. In de meeste 
leverziekten is de hepatocytproliferatie deels geblokkeerd waardoor activatie van de 
progenitor cellen een belangrijke rol speelt in het proces van leverregeneratie. 
7.3 ATP Binding Cassette (ABC) transporters 
De familie van ATP-bindingscassette (ABC) transporteiwitten is een grote familie van 
eiwitten, verantwoordelijk voor transport van stoffen de eel in en/of uit. De familie 
bestaat uit 49 leden, welke op basis van structuur en functie zijn onderverdeeld 
in 7 subfamilies (A Um G). Deze eiwitten zitten voornamelijk in de celmembraan 
waardoor ze stoffen van binnen naar buiten en vice versa kunnen verplaatsen. De 
overeenkomst tussen deze eiwitten is datze allemaal energie in de vorm van adenosine 
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trifosfaat (ATP) gebruiken om het substraat actief te verplaatsen. In het verleden is 
aangetoond dat enkele van deze ABC-transporter subfamilies in verhoogde mate 
betrokken zijn bij het veroorzaken van geneesmiddelresistentie van kankercellen. 
De best beschreven voorbeelden hiervan zijn het Multidrug Resistance protein 1 
(MDR1/ABCB1) en het Multidrug Resistance-associated Protein 1 (MRP1/ABCC1 ). 
Seide eiwitten transporteren de, voor de kankercel schadelijke, geneesmiddelen de 
eel uit voor ze het gewenste effect kunnen uitoefenen. Uit voorgaande onderzoeken 
is gebleken dat de expressie van verschillende ABC transporters verhoogd is in 
het leverstamcelcompartiment van ratten die onderworpen zijn aan modellen van 
leverziekten. Tevens vertonen de levers van mensen met verschillende ernstige 
leverziekten hetzelfde beeld. 
Het onderzoek in dit proefschrift richt zich met name op de MRPs en MRP1 in het 
specifiek. 
7.3.1 MRP1 
Hoewel sinds de ontdekking van MRP1 in 1992 veel gegevens verzameld zijn 
over het type geneesmiddelen dat MRP1 kan transporteren en in welke soorten 
kankercellen MRP1 een rol kan spelen in geneesmiddelresistentie, is nog relatief 
weinig onderzoek verricht naar de functie van MRP1 in zijn natuurlijke omgeving. 
Enkele belangrijke natuurlijke substraten zijn ge"identificeerd welke een tip van 
de sluier oplichten over de rol van MRP1. De belangrijkste substraten, voor zover 
bekend, zijn glutathion, een natuurlijke antioxidant; leukotrieen C4, een stof betrokken 
bij de immuunrespons en stoffen gebonden aan glutathion, sulfaat of glucuronide. 
Deze laatste groep stoffen ontstaat wanneer, veelal giftige, stoffen in een eel warden 
omgezet zodat ze beter uit te scheiden zijn via de urine of via de gal. Ook hieruit 
blijkt dat MRP1 een beschermende rol heeft tegen giftige stoffen. Tevens kan het 
transport van glutathion en leukotrieen C4 duiden op een functie tijdens ontsteking. 
7.3.2 MRP1 in de darmen 
Onder normale omstandigheden is MRP1 slechts in kleine hoeveelheden aanwezig 
in het darmweefsel. 
Uit het onderzoek, beschreven in hoofdstuk 2, is gebleken dat in ontstoken 
darmweefsel van patienten met CD of UC, de MRP1 expressie verhoogd is. Nader 
onderzoek heeft uitgewezen dat MRP1 aanwezig is in het epitheel van de darm 
mucosa en met name in een regio waar ook de darmstamcellen zich bevinden. Om 
uit te vinden wat de functie van MRP1 is tijdens dit ontstekingsproces is een cellijn 
van dikke darm epitheelcellen blootgesteld aan een mix van cytokines, die vrijkomen 
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tijdens ontsteking, al dan niet in combinatie met het remmen of tot overexpressie 
brengen van MRP1. Bij het remmen van MRP1 werden deze darmcellen gevoeliger 
voor celdood, terwijl het verhoogd tot expressie brengen van MRP1 de cellen 
beschermt tegen celdood. Hieruit blijkt dat MRP1 epitheelcellen beschermd tegen 
de schadelijke werking van deze cytokines. 
De verhoogde expressie van MRP1 in stamcellen van de darm tijdens ontsteking lijkt 
daarmee een natuurlijke reactie te zijn om het darmepitheel te beschermen. 
Tevens bevatten immuuncellen (T-lymfocyten/T-cellen) in de darm van patienten 
met UC of CD veel MRP1. Om uit te vinden of MRP1 een vergelijkbare functie heeft 
in T cellen als in epitheel cellen, zijn beide soorten cellen wederom blootgesteld aan 
cytokines. Uit dit vergelijkende onderzoek (beschreven in hoofdstuk 3) kwam naar 
voren dat MRP1 een tegengesteld effect heeft in T-cellen en epitheelcellen. Het 
rem men van MRP1 functie leidt tot minder celdood door cytokines in T-cellen. Wellicht 
is MRP1 daarom betrokken bij het in goede banen leiden van het ontstekingsproces. 
Epitheelcellen warden beschermd, terwijl de "schadelijke" T-cellen op den duur 
versneld opgeruimd warden. 
7.3.3 MRP1 in de lever 
Om alle functies van de lever goed en efficient te laten verlopen, moeten vele stoffen 
de levercellen in en uit getransporteerd warden. Dit transport wordt onder andere 
verzorgd door een groat aantal ABC transporters. MRP1 is aanwezig in verschillende 
celtypen van de lever welke allemaal verschillende functies vervullen. 
7.3.1 MRP1 tijdens leverregeneratie 
Uit eerder onderzoek naar leverregeneratie is aangetoont dat MRP1 expressie 
verhoogd is kart na het begin van dit proces. Dit effectis waargenomen in ratten 
na het uitvoeren van een proefdiermodel voor leverschade .. Opvallend is dat deze 
verhoogde expressie van MRP1 voornamelijk waar te nemen was in de stamcellen 
van de lever (progenitor cellen). Een vergelijkbare waarneming werd gedaan in de 
levers van menselijke patienten met enkele ernstige (chronische) leveraandoeningen 
zoals hepatitis C infectie en primaire billiaire cirrose. Ook hier werd meer MRP1 
gevonden in de stamcellen van de lever vergeleken met gezond leverweefsel. 
Om uit te vinden welke rol MRP1 speelt in het proces van leverregeneratie is in het 
onderzoek, beschreven in dit proefschrift, een vergelijkbare dierstudie uitgevoerd met 
muizen welke geen Mrp1 tot expressie brengen (Mrp1 knock-out of Mrp1-/-). In dit 
onderzoek is leverregeneratie in "normale" muizen vergeleken met leverregeneratie 
in Mrp1-/- muizen. Er zijn twee modellen van leverregeneratie toegepast. Het 
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"gewone" model, waarbij ongeveer 70% van de lever verwijderd wordt en een model 
waarbij stamcel activatie wordt gestimuleerd. Hierbij zijn de muizen eerst behandeld 
met een stof (2-AAF) die het vermenigvuldigen van hepatocyten blokkeert. Het 
tweede model is beter geschikt als model voor patienten met leverziekten omdat het 
complexe geheel beter wordt nagebootst. . 
Om te compenseren voor de afwezigheid van Mrp1 in de gezonde lever is de expressie 
van andere Mrp eiwitten verhoogd. Met name Multidrug resistance associated 
protein 3 (Mrp3/Abcc3), welke qua structuur het meeste lijkt op Mrp1, lijkt deze rol 
op zich te nemen. Het levergewicht van zowel de normale (wild type) muizen als 
de Mrp1 knock-out muizen verschilt niet. Slechts 3 dagen nadat 65% van de levers 
verwijderd is, is de lever geregenereerd tot 85% van het oorspronkelijke gewicht 
voor de operatie. In het diermodel voor stamcelactivatie tijdens leverregeneratie is 
eveneens geen verschil te zien in levergewicht tussen de wild type en de Mrp1 
knock-out muizen, zowel voor als 3 dagen na de operatie. Het lijkt er daarom op dat 
Mrp1 niet essentieel is voor leverregeneratie. Een belangrijke waarneming is dat de 
expressie van een merker voor stamcelactivatie niet verhoogd is in de levers Mrp1-
/- muizen, terwijl dit wel het geval is in de wild type muizen. Dit wijst erop dat de 
stamcellen in Mrp1-/- muizen anders reageren dan deze in wild type muizen. Om de 
exacte oorzaak en de eventuele gevolgen hiervan te bepalen zal verder onderzoek 
gedaan moeten warden. Deze studie is beschreven in hoofdstuk 4. 
7.4 Regulatie van MRP1 expressie 
Om therapeutisch gebruik te kunnen maken van de beschermende functie van 
MRP1 in bijvoorbeeld epitheelcellen is het belangrijk te weten hoe MRP1 expressie 
gereguleerd wordt. Hoewel vele studies de verhoogde expressie van MRP1 
beschrijven, gaat het hierbij met name over de geneesmiddel resistente kankercellen. 
De regulatie van expressie in de "normale" situatie is tot op heden onbekend. 
Recent is echter aangetoond dat de MRP1 expressie in de darmen van muizen 
verlaagd kan warden door PPAR-alpha, een nucleaire hormoon receptor betrokken 
bij het vetzuurmetabolisme. In hoofdstuk 5 hebben we onderzocht of dit mechanisme 
ook werkzaam is in menselijke darm en/of levercellen. Activatie van PPAR-alpha in 
zowel darm- als levercellen heeft geen effect op de expressie van MRP1 , zowel op 
RNA als op eiwitniveau. Op basis van deze resultaten kunnen we concluderen dat 
MRP1 in de humane lever en darm niet via dezelfde route gereguleerd wordt. Dit 
betekent dat PPAR-alpha niet gebruikt kan warden om MRP1 expressie in mensen 
te be"invloeden. 
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7 .5 Algemene conclusie en toekomstperspectieven 
Het in dit proefschrift beschreven onderzoek toont aan dat MRP1 een belangrijke 
functie heeft in de regulatie van celdood tijdens, of ten gevolge van, ontsteking. 
Epitheelcellen warden door MRP1 beschermd tegen cytokine ge"induceerde celdood, 
terwijl T-lymphocyten bij verhoogde MRP1 functie hiervoor juist gevoeliger warden. 
Hiermee wordt bevestigd dat de functie MRP1 niet beperkt is tot geneesmiddel­
resistentie in kankercellen, maar dat dit eiwit ook een belangrijke natuurlijke functie 
heeft in de bescherming van darmepitheelcellen en de regulatie van normale 
immuunreactie. 
In dit proefschrift hebben wij een beschermende functie van MRP1 laten zien in 
lever- en darmepitheel. Aanvullend onderzoek is echter noodzakelijk naar de 
mogelijke klinische toepassing van MRP1 regulatie in bijvoorbeeld de behandeling 
van "ontstekingsziekten" zoals de ziekte van Crohn en colitis ulcerosa. Tevens zou 
MRP1 regulatie gebruikt kunnen warden in het verhogen van de efficientie van 
regeneratieve processen zoals leverregeneratie na transplantatie of het verwijderen 
van tumoren. Gezien de relatief hoge expressie van MRP1 in stamcellen, is ook het 
gebruik van MRP1 regulatie in stamcelkweek en -therapie niet ondenkbaar. 
De moleculaire mechanismen van MRP1 regulatie zijn nog grotendeels onbekend. 
Dit vormt een van de belangrijkste hordes die genomen moet warden voordat er 
klinische toepassingen voor MRP1 regulatie mogelijk zullen warden. 
Gezien de associatie van MRP1 expressie met geneesmiddelresistentie is het 
daarnaast van het grootste belang dat uitgesloten wordt dat verhoogde expressie 




4 jaar onderzoek zijn omgevlogen en liggen momenteel zelfs alweer 2 jaar achter 
me. Mijn tijd op het lab MDL/kindergeneeskunde was leerzaam en bovenal 
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sessies kwamen steeds de wildste ideeen bij je naar boven. Jij ziet geen obstakels, 
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Beste Mariska, mijn steun en toeverlaat op het lab. lk heb met ontzettend veel 
plezier met je samengewerkt gedurende vier jaar. Bedankt voor je inzet, oak ( en 
misschien wel juist) toen het onderzoek even niet zo lekker liep. Voor mij ben jij het 
schoolvoorbeeld van groningse nuchterheid (nait souzen) en ik ben erg blij dat jij 
als paranimf wilt optreden tijdens mijn promotie. De volgende AIO die met je mag 
samenwerken mag in zijn of haar handen knijpen. 
Uiteraard zijn er meer mensen die ik wil bedanken. Zoals al eerder gezegd, heb 
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ik kunnen genieten van een geweldige groep collega's. Turbo-tweeling Hans 
en Tjasso, Lisette, Martijn, Kryszstof, Janette, Fiona, Laura, Antonella, Sandra, 
Rebecca, Manon, Atta, Golnar en Elise, bedankt voor de gezellige tijd, zowel op 
het lab als in de kroeg. Ook de "buren" van kindergeneeskunde hebben een grate 
bijdrage gehad in de goede werksfeer en graag wil ik ook hen hiervoor allemaal 
bedanken. 
Titia & Jannes, naast collega's ook vrienden. Bedankt voor de leuke avonden in 
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begeleiden tijdens hun afstudeerstages. Hier heb ik persoonlijk ontzettend veel 
plezier aan beleefd en wil Edmee, Marieke, Mark, Moniek en Jessica bedanken 
voor hun inzet. lk hoop dat jullie net zulke goede herinneringen bewaren aan jullie 
tijd bij MDL als ik. 
Michie!, alweer bijna 20 jaar mijn beste vriend. Onze regelmatige afspraken 
(kopje koffie, appelkoek, kip met prut en/of een avond achter de computer) zijn 
erg belangrijk voor mij geweest en vormen ook vandaag de dag een welkome 
onderbreking van de dagelijkse hectiek. lk ben blij dat ook jij mij bij wilt staan als 
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Lieve papa en mama, jullie bijdrage in het voltooien van dit proefschrift is met 
geen pen te beschrijven. Bedankt voor het vertrouwen dat jullie altijd in mij hebben 
gehad. Zander jullie steun was het nooit zover gekomen. 
Lieve Eefje, voor mij staat het afronden van dit proefschrift symbool voor het 
afsluiten van een hoofdstuk in ons leven. lk heb alleen maar goede herinneringen 
aan onze periode in Groningen, waar wij in 2004 zijn gaan samenwonen en we ons 
leven samen zijn gestart. lk wil je bedanken voor de steun die je me hebt gegeven 
en ben waanzinnig trots op je dat je "jouw" stad hebt verlaten nadat ik voor een 
andere richting had gekozen. Mij is de afgelopen jaren heel duidelijk geworden dat 
ons thuis is waar we samen zijn. lets dat we gelukkig hebben bezegeld met ons 
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